



**NOTE: Clicking on the 'Comments' tab to the left will display additional annotation information.**

Date: \_\_\_\_ / \_\_\_\_ / \_\_\_\_

## ENTRY PROCEDURES AND CRITERIA FOR ENROLLMENT

**Inclusion Criteria:** The answers for Items 1-8 must be YES to qualify for study.

**Yes No**

- 1. Males and postmenopausal females at least 50 years of age.
- 2. Diagnosis of probable AD as defined by National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA) guidelines (Protocol Attachment LZZT.7).
- 3. MMSE score of 10 to 23.
- 4. Modified Hachinski Ischemic Scale score of  $\leq 4$ . (Protocol Attachment LZZT.8).
- 5. CNS imaging (CT scan or MRI of brain) compatible with AD within past 1 year.

The following findings are incompatible with AD.

### 1. Large vessel strokes

- a. Any definite area of encephalomalacia consistent with ischemic necrosis in any cerebral artery territory.
- b. Large, confluent areas of encephalomalacia in parieto-occipital or frontal regions consistent with watershed infarcts.

The above are exclusionary. Exceptions are made for small areas of cortical asymmetry which may represent a small cortical stroke or a focal area of atrophy provided there is no abnormal signal intensity in the immediately underlying parenchyma. Only one such questionable area allowed per scan, and size is restricted to  $\leq 1$  cm in frontal/parietal/temporal cortices and  $\leq 2$  cm in occipital cortex.

### 2. Small vessel ischemia

- a. Lacunar infarct is defined as an area of abnormal intensity seen on CT scan or on both T1 and T2 weighted MRI images in the basal ganglia, thalamus or deep white matter which is  $\leq 1$  cm in maximal diameter. A maximum of one lacune is allowed per scan.
- b. Leukoariosis or leukoencephalopathy is regarded as an abnormality seen on T2 but not T1 weighted MRIs, or on CT. This is accepted if mild or moderate in extent, meaning involvement of less than 25% of cortical white matter.

### 3. Miscellaneous

- a. Benign small extra-axial tumors (ie, meningiomas) are accepted if they do not contact or indent the brain parenchyma.
- b. Small extra-axial arachnoid cysts are accepted if they do not indent or deform the brain parenchyma.



## ENTRY PROCEDURES AND CRITERIA FOR ENROLLMENT

**Inclusion Criteria:** The answers for Items 1-8 must be YES to qualify for study.

Yes No

- 6. Investigator has obtained informed consent signed by the patient (and/or legal representative) and by the caregiver.
- 7. Geographic proximity to investigator's site that allows adequate follow-up.
- 8. A reliable caregiver who is in frequent or daily contact with the patient and who will accompany the patient to the office and/or be available by telephone at designated times, will monitor administration of prescribed medications, and will be responsible for the overall care of the patient at home. The caregiver and the patient must be able to communicate in English and willing to comply with 26 weeks of transdermal therapy.

**Exclusion Criteria:** The answers for Items 9-31 must be NO to qualify for study.

Yes No

- 9. Persons who have previously completed or withdrawn from this study or any other investigating xanomeline TTS or the oral formulation of xanomeline.
- 10. Use of any investigational agent or approved Alzheimer's therapeutic medication within 30 days prior to enrollment into the study.
- 11. Serious illness which required hospitalization within 3 months of screening.
- 12. Diagnosis of serious neurological conditions, including
  - a) Stroke or vascular dementia documented by clinical history and/or radiographic findings interpretable by the investigator as indicative of these disorders
  - b) Seizure disorder other than simple childhood febrile seizures
  - c) Severe head trauma resulting in protracted loss of consciousness within the last 5 years, or multiple episodes of head trauma
  - d) Parkinson's disease
  - e) Multiple sclerosis
  - f) Amyotrophic lateral sclerosis
  - g) Myasthenia gravis.
- 13. Episode of depression meeting DSM-IV criteria within 3 months of screening.
- 14. A history within the last 5 years of the following:
  - a) Schizophrenia
  - b) Bipolar Disease
  - c) Ethanol or psychoactive drug abuse or dependence.



WORKSHEET (DNDE)  
H2Q-MC-LZZT

Yes No

**Exclusion Criteria:** The answers for Items 9-31 must be NO to qualify for study.

15. A history of syncope within the last 5 years.
16. Evidence from ECG recording at screening of any of the following conditions:
- a) Left bundle branch block
  - b) Bradycardia  $\leq$ 50 beats per minute
  - c) Sinus pauses  $>$ 2 seconds
  - d) Second or third degree heart block unless treated with a pacemaker
  - e) Wolff-Parkinson-White syndrome
  - f) Sustained supraventricular tachyarrhythmia
17. A history within the last 5 years of a serious cardiovascular disorder, including
- a) Clinically significant arrhythmia
  - b) Symptomatic sick sinus syndrome not treated with a pacemaker
  - c) Congestive heart failure refractory to treatment
  - d) Angina except angina controlled with PRN nitroglycerin
  - e) Resting heart rate  $<$ 50 or  $>$ 100 beats per minute, on physical exam
  - f) Uncontrolled hypertension
18. A history within the last 5 years of a serious gastrointestinal disorder, including
- a) Chronic peptic/duodenal/gastric/esophageal ulcer that are untreated or refractory to treatment
  - b) Symptomatic diverticular disease
  - c) Inflammatory bowel disease
  - d) Pancreatitis
  - e) Hepatitis
  - f) Cirrhosis of the liver



**Yes No      Exclusion Criteria:** The answers for Items 9-31 must be NO to qualify for study.

19. A history within the last 5 years of a serious endocrine disorder, including
- a) Uncontrolled Insulin Dependent Diabetes Mellitus (IDDM)
  - b) Diabetic ketoacidosis
  - c) Untreated hyperthyroidism
  - d) Untreated hypothyroidism
  - e) Other untreated endocrinological disorder
20. A history within the last 5 years of a serious respiratory disorder, including
- a) Asthma with bronchospasm refractory to treatment
  - b) Decompensated chronic obstructive pulmonary disease.
21. A history within the last 5 years of a serious genitourinary disorder, including
- a) Renal failure
  - b) Uncontrolled urinary retention
22. A history within the last 5 years of a serious rheumatologic disorder, including
- a) Lupus
  - b) Temporal arteritis
  - c) Severe rheumatoid arthritis
23. A known history of human immunodeficiency virus (HIV) within the last 5 years.
24. A history within the last 5 years of a serious infectious disease including
- a) Neurosyphilis
  - b) Meningitis
  - c) Encephalitis
25. A history within the last 5 years of a primary or recurrent malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal PSA postresection.
26. Visual, hearing, or communication disabilities impairing the ability to participate in the study; (for example, inability to speak or understand English, illiteracy).



Yes No

**Exclusion Criteria:** The answers for Items 9-31 must be NO to qualify for study.

27. Laboratory test values exceeding the Lilly Reference Range III for the patient's age in any of the following analytes: -creatinine, -total bilirubin, - SGOT, - SGPT, - alkaline phosphatase, - GGT, - hemoglobin, - white blood cell count, - platelet count, - serum sodium, potassium or calcium.

If values exceed these laboratory reference ranges, clinical significance will be judged by the monitoring physicians.

28. Central laboratory test values below reference range for folate, and vitamin B<sub>12</sub>, and outside reference range for thyroid function tests.

29. Positive syphilis screening with confirmatory testing.

30. Central laboratory test value above reference range for glycosylated hemoglobin (A<sub>1c</sub>) (insulin dependent diabetes mellitus patients only)

31. Treatment with the following medications within 1 month prior to enrollment

- a) Anticonvulsants including but not limited to

- Tegretolâ (carbamazepine)
- Depakoteâ (valproic acid)

- b) Alpha receptor blockers including but not limited to

- Catapresâ (clonidine)
- Aldometâ (methyldopa)

- c) Calcium channel blockers that are CNS active including but not limited to

- Nimotopâ (nimodipine)

- d) Beta blockers including but not limited to

- Inderalâ (propranolol)
- Tenorminâ (atenolol)

- e) Beta sympathomimetics (unless inhaled) including but not limited to

- Proventil Repetabsâ, Ventolinâ tablets (albuterol tablets)
- Dopamineâ

- f) Parasympathomimetics (cholinergics) (unless ophthalmic) including but not limited to

- Urecholineâ (bethanechol)
- Reglanâ (metoclopramide)

- g) Muscle relaxants-centrally active including but not limited to

- Flexerilâ (cyclobenzaprine)
- Somaâ (carisoprodol)

- h) Monoamine oxidase inhibitors (MAOI) including but not limited to

- Nardilâ (phenelzine)
- Eldeprylâ (selegiline)
- Parnateâ (tranylcypromine)



**Exclusion Criteria:** The answers for Items 9-31 must be NO to qualify for study.

- i) Parasympatholytics (anticholinergics) including but not limited to
  - Ditropanâ (oxybutynin)
  - Urispasâ (flavoxate)
  - Antivertâ (meclizine)
- j) Antidepressants including but not limited to
  - Prozacâ (fluoxetine)
  - Elavilâ (amitriptyline)
- k) Systemic corticosteroids including but not limited to
  - Depo-medrolâ (methylprednisolone)
- l) Xanthine derivatives including but not limited to
  - Theo-Durâ (theophylline)
- m) Histamine (H<sub>2</sub>) antagonists including but not limited to
  - Tagametâ (cimetidine)
  - Axidâ (nizatidine)
- n) Narcotic Analgesics including but not limited to
  - Darvocet-N 100â , Propacetâ (propoxyphene + acetaminophen)

**Percocet (oxycodone with acetaminophen) and Tylenolâ with codeine #2, #3, #4 (acetaminophen + codeine) ARE allowed in the month prior to enrollment, but are not permitted in the 4 days prior to enrollment.**

- o) Neuroleptics (antipsychotics) including but not limited to
  - Haldolâ (haloperidol)
  - Mellarilâ (thioridazine)

**The use of neuroleptics on an as needed basis is permitted during the month prior to enrollment, but are to be discontinued at least 7 days prior to enrollment.**

- p) Antianxiety agents including but not limited to
  - BuSparâ (buspirone)
  - Libriumâ (chlordiazepoxide)

**Ativanâ (lorazepam) is allowed on an as needed basis in the month prior to enrollment, but is not permitted in the 24 hours prior to enrollment.**

- q) Hypnotics/Sedatives including but not limited to
  - Restorilâ (temazepam)

**Chloral Hydrate is allowed on an as needed basis in the month prior to enrollment, but is not permitted in the 24 hours prior to enrollment.**

- r) Histamine (H<sub>1</sub>) antagonists including but not limited to
  - Benadrylâ (diphenhydramine)
  - Seldaneâ (terfenadine)

**Intermittent use of these antihistamines is permitted during the month prior to enrollment, but is not permitted in the 4 days prior to enrollment.**



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT STUDYID

VISIT  
VISITNUM  
Visit 1  
Page 1 of 14

## PATIENT AND VISIT IDENTIFICATION

Patient initials **Not Entered In Database**  
First \_\_\_\_\_ Middle \_\_\_\_\_ Last \_\_\_\_\_

Visit date **--STDTC --DTC**  
MM / DD / YY

## INFORMED CONSENT

**Not Entered In Database**

Date patient and caregiver signed the consent document **\_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_**  
MM DD YY

## DEMOGRAPHICS

Date of birth **Not Entered In Database**  
MM / DD / YY

**SEX** Sex     F Female     M Male

- RACE** Origin     CA Caucasian (European, Mediterranean, Middle Eastern)  
 AF African Descent (Negro, Black)  
 EA East/Southeast Asian (Burmese, Chinese, Japanese, Korean, Mongolian, Vietnamese)  
 AS Western Asian (Pakistani, Indian Sub-continent)  
 HP Hispanic (Mexican-American, Mexico, Central and South America)  
 O Other (Mixed-racial parentage, American Indian, Eskimo)

## REMINDER

Record the patient's pre-existing conditions on the Pre-existing Conditions and Study Adverse Events page.

Record all medications the patient is currently taking on the Concomitant Medication page.

A physical examination must be performed at this visit. Any clinically significant abnormalities must be listed on the Pre-existing Conditions and Study Adverse Events page.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 1  
Page 2 of 14

## EDUCATION

SCTESTCD

Number of years of education completed

SCORRES

\_\_\_\_\_  
years

## HABITS : SMOKING

INFORMATION NOT OBTAINED  Not Entered In Database

Enter the average current daily use  
**0** = None  
**L** = Less than one (eg, cigar or pipe smoker  
who smokes only 1 or 2x a week)  
**1, 2, 3, etc** = Whole numbers ONLY

Number of cigarettes \_\_\_\_\_ Not Entered In Database

Number of cigars \_\_\_\_\_ Not Entered In Database

Number of pipesful \_\_\_\_\_ Not Entered In Database

Enter the number of years (past or current) patient  
has smoked. If patient has never smoked, enter 0. \_\_\_\_\_ Not Entered In Database  
years

(If the patient has NEVER smoked or is still smoking,  
leave the following question blank.)

Not Entered In Database

Enter the month and year that the patient quit smoking.

\_\_\_\_\_/\_\_\_\_\_  
MM YY

## HABITS : ALCOHOL

INFORMATION NOT OBTAINED  Not Entered In Database

Enter the average current weekly consumption  
**0** = None  
**L** = Less than one  
**1, 2, 3, etc** = Whole numbers ONLY

Number of beers or wine coolers/spritzers \_\_\_\_\_ Not Entered In Database

Number of glasses of wine \_\_\_\_\_ Not Entered In Database

Number of drinks containing distilled spirits \_\_\_\_\_ Not Entered In Database



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 1

Page 3 of 14

## HABITS : CAFFEINE

INFORMATION NOT OBTAINED  Not Entered In Database

Enter the average current daily consumption  
**0** = None  
**L** = Less than one  
**1, 2, 3, etc** = Whole numbers ONLY

Not Entered In Database

Number of cups of coffee

\_\_\_\_\_

Not Entered In Database

Number of cups of tea

\_\_\_\_\_

Not Entered In Database

Number of colas

\_\_\_\_\_



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 1

Page 4 of 14

**MINI-MENTAL STATE**      **QSCAT**

INFORMATION NOT OBTAINED  **Not Entered In Database**

Score      Maximum Score

**QSSCAT**

**Orientation**

- QTESTCD** 1. **QSORRES** (5) What is the (year) (season) (date) (day) (month)?  
**QTESTCD** 2. **QSORRES** (5) Where are we: (state) (county) (town) (hospital) (floor)?

**QSSCAT**

**Registration**

- QTESTCD** 3. **QSORRES** (3) Name 3 objects: 1 second to say each. Then ask the patient all 3 after you have said them. Give 1 point for each correct answer. Then repeat them until he learns all 3. Count trials and record.

**QSSCAT**

**Attention and Calculation**

- QTESTCD** 4. **QSORRES** (5) Serial 7's. 1 point for each correct. Stop after 5 answers.  
Alternatively, spell "world" backwards.

**QSSCAT**

**Recall**

- QTESTCD** 5. **QSORRES** (3) Ask for the 3 objects repeated above. Give 1 point for each correct.

**QSSCAT**

**Language**

- QTESTCD** 6. **QSORRES** (9) Name a pencil, and watch (2 points)  
Repeat the following "No ifs, ands, or buts." (1 point)  
Follow a 3-stage command:  
"Take a paper in your right hand, fold it in half, and put it on the floor" (3 points)

Read and obey the following:  
Close your eyes (1 point)

Write a sentence (1 point)

Copy design (1 point)

(DNDE) **Not Entered In Database**

Total score \_\_\_\_\_

NOTE: Patient must have a score of 10-23 on the MMSE at Visit 1 to be enrolled in this study.

ASSESS level of consciousness along a continuum **Not Entered In Database**

**Alert**      **Drowsy**      **Stupor**      **Coma**



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 1  
Page 5 of 14

**MODIFIED HACHINSKI ISCHEMIC SCORE** QSCAT

INFORMATION NOT OBTAINED  Not Entered In Database

Circle the score that corresponds to the feature being present or absent.

<u>Feature</u>	<u>Present</u>	<u>Absent</u>
<b>QTESTCD</b> 1. Abrupt onset	2 <span style="background-color: #FFFF00; color: red; border: 1px solid black; padding: 2px;">QSORRES</span>	0
<b>QTESTCD</b> 2. Stepwise deterioration	1 <span style="background-color: #FFFF00; color: red; border: 1px solid black; padding: 2px;">QSORRES</span>	0
<b>QTESTCD</b> 3. Fluctuating course	2 <span style="background-color: #FFFF00; color: red; border: 1px solid black; padding: 2px;">QSORRES</span>	0
<b>QTESTCD</b> 4. Nocturnal confusion	1 <span style="background-color: #FFFF00; color: red; border: 1px solid black; padding: 2px;">QSORRES</span>	0
<b>QTESTCD</b> 5. Relative preservation of personality	1 <span style="background-color: #FFFF00; color: red; border: 1px solid black; padding: 2px;">QSORRES</span>	0
<hr/>		
<b>QTESTCD</b> 6. Depression	1 <span style="background-color: #FFFF00; color: red; border: 1px solid black; padding: 2px;">QSORRES</span>	0
<b>QTESTCD</b> 7. Somatic complaints	1 <span style="background-color: #FFFF00; color: red; border: 1px solid black; padding: 2px;">QSORRES</span>	0
<b>QTESTCD</b> 8. Emotional incontinence	1 <span style="background-color: #FFFF00; color: red; border: 1px solid black; padding: 2px;">QSORRES</span>	0
<b>QTESTCD</b> 9. History of hypertension	1 <span style="background-color: #FFFF00; color: red; border: 1px solid black; padding: 2px;">QSORRES</span>	0
<b>QTESTCD</b> 10. History of strokes	2 <span style="background-color: #FFFF00; color: red; border: 1px solid black; padding: 2px;">QSORRES</span>	0
<hr/>		
<b>QTESTCD</b> 11. Evidence of associated atherosclerosis	1 <span style="background-color: #FFFF00; color: red; border: 1px solid black; padding: 2px;">QSORRES</span>	0
<b>QTESTCD</b> 12. Focal neurological symptoms	2 <span style="background-color: #FFFF00; color: red; border: 1px solid black; padding: 2px;">QSORRES</span>	0
<b>QTESTCD</b> 13. Focal neurological signs	2 <span style="background-color: #FFFF00; color: red; border: 1px solid black; padding: 2px;">QSORRES</span>	0

(DNDE) Not Entered In Database

Total Score \_\_\_\_\_

NOTE: Patient must have a score of £4 on the Modified Hachinski Ischemic Scale at Visit 1 to be enrolled in this study.

© Reprinted with permission.  
Arch Neurol 1975;32:632-37.

DS1609  
PRINTED IN USA  
August 22, 1996  
© Eli Lilly and Co.

QS342

Distribution: White and Yellow copies – Sponsor  
Bottom copy - Investigator

COPYRIGHT© 2006 Eli Lilly and Co.



## PATIENT HISTORY : ALZHEIMER'S DISEASE ONSET DATE

MHTERM

Date of onset of the first definite symptoms  
of Alzheimer's Disease

MHSTDTC  
\_\_\_\_ / \_\_\_\_ / \_\_\_\_  
MM DD YY

## CLINICAL FEATURES : ALZHEIMER'S DISEASE

INFORMATION NOT OBTAINED  Not Entered In Database

Does the patient display or has the patient displayed the following clinical features:

1. Extrapyramidal features (masked facies, bradykinesia, slowed rapid alternating movements, flexed posture, gait difficulty) without a resting tremor  Yes  No Not Entered In Database
2. Essential tremor (action or postural)  Yes  No Not Entered In Database
3. Sensitivity to neuroleptics  Yes  No Not Entered In Database
4. Marked deficit of attention and/or fluctuations in level of attention and alertness; confusional episodes  Yes  No Not Entered In Database
5. Visual hallucinations and/or paranoid delusions  Yes  No Not Entered In Database



## EXTRAPYRAMIDAL FINDINGS

INFORMATION NOT OBTAINED  Not Entered In Database

1. Masked facies Not Entered In Database

- 0 None
- 1 Mild
- 2 Moderate
- 3 Severe

2. Rigidity of upper extremity Not Entered In Database

- 0 None
- 1 Mild
- 2 Moderate
- 3 Severe

3. Essential tremor Not Entered In Database

- 0 None
- 1 Mild
- 2 Moderate
- 3 Severe

4. Ambulation Not Entered In Database

How long did it take the patient to walk 25 yards? \_\_\_\_\_  
seconds



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 1

Page 8 of 14

## SIGNIFICANT HISTORICAL DIAGNOSIS

NO SIGNIFICANT HISTORICAL DIAGNOSIS  Not Entered In Database

List each clinically significant (at the discretion of the investigator) historical diagnosis that is  
**NO LONGER PRESENT**. If exact date is unknown, enter the month and year. A year MUST be entered.

MHSPID	Historical Diagnosis COSTART Class Term	Date Recovered/Date of Surgical Procedure		
		MM	DD	YY
0.	MHTERM Not Entered In Database			MHSTDTC
1.				
2.				
3.				
4.				
5.				
6.				
7.				
8.				



## SIGNIFICANT HISTORICAL DIAGNOSIS

List each clinically significant (at the discretion of the investigator) historical diagnosis that is **NO LONGER PRESENT**. If exact date is unknown, enter the month and year. A year MUST be entered.

Historical Diagnosis COSTART Class Term	Date Recovered/Date of Surgical Procedure MM DD YY		
MHTERM			
Not Entered In Database		MHSTDTC	



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 1  
Page 9 of 14

## WEIGHT

VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Measure with shoes off. Round up or down to the nearest tenth kilogram or tenth pound.

Weight VSORRES  kg Kilogram  lb Pound  
VSORRES

## HEIGHT

VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Measure with shoes off. Round up or down to the nearest tenth inch or tenth centimeter.

Height VSORRES  cm Centimeter  in Inch  
VSORRESU

## VITAL SIGNS : HEART RATE AND BLOOD PRESSURE

INFORMATION NOT OBTAINED  Not Entered In Database

NOTE: Blood pressure and pulse must be taken after the patient has been lying down for 5 minutes (supine) and after standing for 1 minute (standing) and 3 minutes.

Position
SU = Supine
ST = Standing

VSTPTNUM

VSPOS

VTESTCD

(DNDE) Reference Time	Timing Code	Position	Heart Rate (bpm)	Blood Pressure (mmHg) Systolic/Diastolic
0. 5 minutes	815	SU	<u>VSORRESU</u> <u>VSORRES</u>	/
1. 1 minute	816	ST		/ <u>VSORRESU</u> <u>VSORRES</u>
2. 3 minutes	817	ST		<u>VTESTCD</u> <u>VSORRESU</u> <u>VSORRES</u>



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 1

Page 10 of 14

## VITAL SIGNS : TEMPERATURE **VSTESTCD**

INFORMATION NOT OBTAINED  **Not Entered In Database**

Temperature **VSORRES**

Unit of measure  <sub>F</sub> Fahrenheit  <sub>C</sub> Centigrade **VSORRESU**

Method **VSLOC**  <sub>PO</sub> Oral       <sub>R</sub> Rectal       <sub>A</sub> Axillary       <sub>E</sub> Ear       <sub>O</sub> Other

## ELECTROCARDIOGRAM

NOT DONE  **Not Entered In Database**

Electrocardiogram date **Not Entered In Database**  
\_\_\_\_ / \_\_\_\_ / \_\_\_\_  
MM DD YY

Electrocardiogram result  <sub>12</sub> Acceptable  <sub>13</sub> Not Acceptable **Not Entered In Database**

NOTE: If abnormality present and clinically relevant, enter the diagnosis or symptom on the Pre-existing Conditions and Study Adverse Events page. Note non-relevant abnormalities in the ECG Comments section below.

## COMMENTS : NON-RELEVANT ECG ABNORMALITIES

NO COMMENTS  **Not Entered In Database**

Print legibly and do not use abbreviations or symbols.

**Not Entered In Database**

---

---

---

---

---

---

---

---

---

---

---

---

---



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 1  
Page 11 of 14

## CHEST X-RAY

NOT DONE  Not Entered In Database

Was the chest x-ray  <sub>1</sub> Taken for this visit  <sub>611</sub> Historical (within the previous 6 months)

Date of chest x-ray  Not Entered In Database  
\_\_\_\_ / \_\_\_\_ / \_\_\_\_  
MM DD YY

Chest x-ray result  <sub>12</sub> Acceptable  <sub>13</sub> Not Acceptable

NOTE: If abnormality present and clinically relevant, enter the diagnosis or symptom on the Pre-existing Conditions and Study Adverse Events page. Note non-relevant abnormalities in the Chest X-ray Comments section below.

## COMMENTS : NON-RELEVANT CHEST X-RAY ABNORMALITIES

NO COMMENTS  Not Entered In Database

Print legibly and do not use abbreviations or symbols.

Not Entered In Database

---

---

---

---

---

---

---

---

---

---

---

---

---



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 1

Page 12 of 14

**PROCEDURE : MRI**

NOT DONE

Not Entered In Database

NOTE: Either a CT scan OR MRI of the brain, which is compatible with Alzheimer's Disease, is required to enter this trial.

Not Entered In Database

Was the MRI  <sub>1</sub> Taken for this visit  <sub>2</sub> Historical (within the previous 12 months)

Date of MRI

Not Entered In Database

\_\_\_\_ / \_\_\_\_ / \_\_\_\_

MM DD YY

NOTE: If abnormality present and clinically relevant, enter the diagnosis or symptom on the Pre-existing Conditions and Study Adverse Events page. Note non-relevant abnormalities in the MRI Comments section below.

**COMMENTS : NON-RELEVANT MRI ABNORMALITIES**

NO COMMENTS  Not Entered In Database

Print legibly and do not use abbreviations or symbols.

Not Entered In Database

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 1  
Page 13 of 14

**PROCEDURE : CT SCAN**

NOT DONE  Not Entered In Database

NOTE: Either a CT scan OR MRI of the brain, which is compatible with Alzheimer's Disease, is required to enter this trial.

Was the CT scan  <sub>1</sub> Taken for this visit  <sub>2</sub> Historical (within the previous 12 months)

Date of CT scan  Not Entered In Database  
\_\_\_\_ / \_\_\_\_ / \_\_\_\_  
MM DD YY

NOTE: If abnormality present and clinically relevant, enter the diagnosis or symptom on the Pre-existing Conditions and Study Adverse Events page. Note non-relevant abnormalities in the CT Scan Comments section below.

**COMMENTS : NON-RELEVANT CT SCAN ABNORMALITIES**

NO COMMENTS  Not Entered In Database

Print legibly and do not use abbreviations or symbols.

Not Entered In Database

---

---

---

---

---

---

---

---

---

---

---

---

---



**COMMENTS : VISIT**

NO COMMENTS  **Not Entered In Database**

Comments should address any clinical report form items that require further explanation. Repeating information from the clinical report form is discouraged.

Comment on all clinically significant lab values that are outside a clinically accepted reference range or clinically significant values that differ importantly from previous values.

If the patient is ending participation in the study at this visit, enter only comments that apply to this visit; then complete the Patient Summary and Study Summary Comments pages.

Print legibly and do not use abbreviations or symbols.

**Not Entered In Database**

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

The information reported for this visit is accurate and complete.

**Not Entered In Database**

**Not Entered In Database**

---

Signature / MM / DD / YY

Signature

MM / DD / YY



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

VISIT  
VISITNUM  
Visit 2  
Page 1 of 3

## PATIENT AND VISIT IDENTIFICATION

Patient initials **Not Entered In Database**  
First \_\_\_\_\_ Middle \_\_\_\_\_ Last \_\_\_\_\_  
  
Visit date **--STDTC --DTC**  
\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_  
MM DD YY

## VITAL SIGNS : HEART RATE AND BLOOD PRESSURE

INFORMATION NOT OBTAINED  **Not Entered In Database**

NOTE: Blood pressure and pulse must be taken after the patient has been lying down for 5 minutes (supine) and after standing for 1 minute (standing) and 3 minutes.

Position
SU = Supine
ST = Standing

**VSTPTNUM**

**VSPOS**

**VTESTCD**

(DNDE) Reference Time	Timing Code	Position	Heart Rate (bpm)	Blood Pressure (mmHg) Systolic/Diastolic
0. 5 minutes	815	SU	<b>VSORRESU</b>	/
1. 1 minute	816	ST	<b>VSORRES</b>	<b>VTESTCD</b> <b>VSORRESU</b>
2. 3 minutes	817	ST	<b>VTESTCD</b> <b>VSORRESU</b>	<b>VSORRES</b>

## REMINDER

On the Pre-existing Conditions and Study Adverse Events page, record new events that occurred since the previous visit and re-evaluate any on-going conditions or events.

On the Concomitant Medication page, record new medications the patient has taken since the previous visit and record a stop date for any medication the patient is no longer taking.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 2  
Page 2 of 3

### VITAL SIGNS : TEMPERATURE **VSTESTCD**

INFORMATION NOT OBTAINED  **Not Entered In Database**

Temperature **VSORRES**.

Unit of measure  F Fahrenheit  C Centigrade **VSORRESU**

Method **VSLOC**  PO Oral  R Rectal  A Axillary  E Ear  O Other

### PROCEDURE : AMBULATORY ECG

NOT DONE  **Not Entered In Database**

Date of ambulatory ECG **Not Entered In Database**  
MM / DD / YY

NOTE: If abnormality present and clinically relevant, enter the diagnosis or symptom on the Pre-existing Conditions and Study Adverse Events page. Note non-relevant abnormalities in the Ambulatory ECG Comments section below.

### COMMENTS : NON-RELEVANT AMBULATORY ECG ABNORMALITIES

NO COMMENTS  **Not Entered In Database**

Print legibly and do not use abbreviations or symbols.

**Not Entered In Database**

---

---

---

---

---

---

---

---

---

---

---

---

---



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 2  
Page 3 of 3

**COMMENTS : VISIT**

NO COMMENTS  **Not Entered In Database**

Comments should address any clinical report form items that require further explanation. Repeating information from the clinical report form is discouraged.

Comment on all clinically significant lab values that are outside a clinically accepted reference range or clinically significant values that differ importantly from previous values.

If the patient is ending participation in the study at this visit, enter only comments that apply to this visit; then complete the Patient Summary and Study Summary Comments pages.

Print legibly and do not use abbreviations or symbols.

**Not Entered In Database**

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

The information reported for this visit is accurate and complete.

**Not Entered In Database**

**Not Entered In Database**

---

Signature

---

MM / DD / YY



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

VISIT  
VISITNUM  
Visit 3  
Page 1 of 7

## PATIENT AND VISIT IDENTIFICATION

Not Entered In Database

Patient initials \_\_\_\_\_  
First \_\_\_\_\_ Middle \_\_\_\_\_ Last \_\_\_\_\_

--STDTC --DTC

Visit date \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_  
MM DD YY

## KIT NUMBER

NONE DISPENSED  Not Entered In Database

Kit number dispensed \_\_\_\_\_

## STUDY DRUG : DAILY PRESCRIBED DOSAGE

For this visit interval, record the number of patches (25-cm<sup>2</sup> and 50-cm<sup>2</sup> patches) that the patient is to wear per day.

Number of 25-cm<sup>2</sup> patches prescribed/day \_\_\_\_\_  
25-cm<sup>2</sup> patches \_\_\_\_\_

Number of 50-cm<sup>2</sup> patches prescribed/day \_\_\_\_\_  
50-cm<sup>2</sup> patches \_\_\_\_\_

## REMINDER

On the Pre-existing Conditions and Study Adverse Events page, record new events that occurred since the previous visit and re-evaluate any on-going conditions or events.

On the Concomitant Medication page, record new medications the patient has taken since the previous visit and record a stop date for any medication the patient is no longer taking.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 3  
Page 2 of 7

**QSCAT**

**ALZHEIMER'S DISEASE ASSESSMENT SCALE : COGNITIVE with ATTENTION/  
CONCENTRATION TASKS**

INFORMATION NOT OBTAINED  **Not Entered In Database**

Clinician's initials \_\_\_\_\_

First \_\_\_\_\_ Middle \_\_\_\_\_ Last \_\_\_\_\_

**Not Entered In Database**

<b>QTESTCD</b>	1. Word Recall Task	(max = 10)	<b>QSORRES</b>
<b>QTESTCD</b>	2. Naming Objects and Fingers (refer to 5 categories in manual)	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	3. Delayed Word Recall	(max = 10)	<b>QSORRES</b>
<b>QTESTCD</b>	4. Commands	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	5. Constructional Praxis	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	6. Ideational Praxis	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	7. Orientation	(max = 8)	<b>QSORRES</b>
<b>QTESTCD</b>	8. Word Recognition	(max = 12)	<b>QSORRES</b>
<b>QTESTCD</b>	9. Attention/Visual Search Task	(max = 40)	<b>QSORRES</b>
<b>QTESTCD</b>	10. Maze Solution	(max = 240)	<b>QSORRES</b> (seconds)
<b>QTESTCD</b>	11. Spoken Language Ability	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	12. Comprehension of Spoken Language	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	13. Word Finding Difficulty in Spontaneous Speech	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	14. Recall of Test Instructions	(max = 5)	<b>QSORRES</b>

© Reprinted with permission.  
*American Journal of Psychiatry* 1984;141:1356-64.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 3  
Page 3 of 7

**NEUROPSYCHIATRIC INVENTORY - REVISED (NPI-X)** QSCAT

INFORMATION NOT OBTAINED  Not Entered In Database

Not Entered In Database  
Clinician's initials \_\_\_\_\_  
First \_\_\_\_\_ Middle \_\_\_\_\_ Last \_\_\_\_\_

The screening question (from worksheet) is asked of the caregiver to determine if the behavioral change is present or absent in the patient. If the answer to the screening question is negative (NO) or if the question is not applicable to the patient, circle the appropriate response (Not Applicable [96] or Absent [0]) and proceed to the next screening question without asking the subquestions to determine frequency, severity, and distress.

	Item	Not		Frequency	Severity	Distress			
		Applicable	Absent			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	A. Delusions	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD	QSORRES	QTESTCD
QSSCAT	B. Hallucinations	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD	QSORRES	QTESTCD
QSSCAT	C. Agitation/Agression	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD	QSORRES	QTESTCD
QSSCAT	D. Depression/ Dysphoria	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD	QSORRES	QTESTCD
QSSCAT	E. Anxiety	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD	QSORRES	QTESTCD
QSSCAT	F. Euphoria/Elation	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD	QSORRES	QTESTCD
QSSCAT	G. Apathy/ Indifference	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD	QSORRES	QTESTCD
QSSCAT	H. Disinhibition	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD	QSORRES	QTESTCD
QSSCAT	I. Irritability/Lability	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD	QSORRES	QTESTCD
QSSCAT	J. Aberrant Motor Behavior	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD	QSORRES	QTESTCD
QSSCAT	K. Night-Time Behavior	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD	QSORRES	QTESTCD
QSSCAT	L. Appetite/Eating Change	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD	QSORRES	QTESTCD

©1994 Jeffrey L. Cummings

DS1609  
PRINTED IN USA  
August 22, 1996  
© Eli Lilly and Co.

QS570

Distribution: White and Yellow copies – Sponsor  
Bottom copy - Investigator

COPYRIGHT© 2006 Eli Lilly and Co.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT


Visit 3  
Page 4 of 7

**DISABILITY ASSESSMENT FOR DEMENTIA (DAD)** **QSCAT**

INFORMATION NOT OBTAINED  Not Entered In Database

Not Entered In Database		
Clinician's initials	_____	_____
First	Middle	Last

During the past two weeks, did the patient without help or reminder:



**QSSCAT**

SCORING: Yes = 1 No = 0 Not Applicable = 96

**HYGIENE**

QTESTCD	1. Undertake to wash himself/herself or to take a bath or a shower			QSORES
QTESTCD	2. Undertake to brush his/her teeth or care for his/her dentures			QSORES
QTESTCD	3. Decide to care for his/her hair (wash and comb)			QSORES
QTESTCD	4. Prepare the water, towels, and soap for washing, taking a bath, or a shower			QSORES
QTESTCD	5. Wash and dry completely all parts of his/her body safely			QSORES
QTESTCD	6. Brush his/her teeth or care for his/her dentures appropriately			QSORES
QTESTCD	7. Care for his/her hair (wash and comb)			QSORES

**DRESSING QSSCAT**

QTESTCD	8. Undertake to dress himself/herself			QSORES
QTESTCD	9. Choose appropriate clothing (with regard to the occasion, neatness, the weather, and color combination)			QSORES
QTESTCD	10. Dress himself/herself in the appropriate order (undergarments, pant/dress, shoes)			QSORES
QTESTCD	11. Dress himself/herself completely			QSORES
QTESTCD	12. Undress himself/herself completely			QSORES

**CONTINENCE QSSCAT**

QTESTCD	13. Decide to use the toilet at appropriate times			QSORES
QTESTCD	14. Use the toilet without "accidents"			QSORES

**EATING QSSCAT**


QTESTCD	15. Decide that he/she needs to eat			QSORES
QTESTCD	16. Choose appropriate utensils and seasonings when eating			QSORES
QTESTCD	17. Eat his/her meals at a normal pace and with appropriate manners			QSORES

**MEAL PREPARATION QSSCAT**

QTESTCD	18. Undertake to prepare a light meal or snack for himself/herself			QSORES
QTESTCD	19. Adequately plan a light meal or snack (ingredients, cookware)			QSORES
QTESTCD	20. Prepare or cook a light meal or a snack safely			QSORES



## DISABILITY ASSESSMENT FOR DEMENTIA (DAD)



**QSSCAT**

SCORING: Yes = 1 No = 0 Not Applicable = 96

### TELEPHONING

QSTESTCD	21. Attempt to telephone someone at a suitable time			QSORRES
QSTESTCD	22. Find and dial a telephone number correctly			QSORRES
QSTESTCD	23. Carry out an appropriate telephone conversation			QSORRES
QSTESTCD	24. Write and convey a telephone message adequately			QSORRES

### GOING ON AN OUTING QSSCAT

QSTESTCD	25. Undertake to go out (walk, visit, shop) at an appropriate time			QSORRES
QSTESTCD	26. Adequately organize an outing with respect to transportation, keys, destination, weather, necessary money, shopping list			QSORRES
QSTESTCD	27. Go out and reach a familiar destination without getting lost			QSORRES
QSTESTCD	28. Safely take the adequate mode of transportation (car, bus, taxi)			QSORRES
QSTESTCD	29. Return from the store with the appropriate items			QSORRES

### FINANCE AND CORRESPONDENCE QSSCAT

QSTESTCD	30. Show an interest in his/her personal affairs such as his/her finances and written correspondence			QSORRES
QSTESTCD	31. Organize his/her finances to pay his/her bills (cheques, bankbook, bills)			QSORRES
QSTESTCD	32. Adequately organize his/her correspondence with respect to stationery, address, stamps			QSORRES
QSTESTCD	33. Handle adequately his/her money (make change)			QSORRES

### MEDICATIONS QSSCAT

QSTESTCD	34. Decide to take his/her medications at the correct time			QSORRES
QSTESTCD	35. Take his/her medications as prescribed (according to the right dosage)			QSORRES

### LEISURE AND HOUSEWORK QSSCAT

QSTESTCD	36. Show an interest in leisure activity(ies)			QSORRES
QSTESTCD	37. Take an interest in household chores that he/she used to perform in the past			QSORRES
QSTESTCD	38. Plan and organize adequately household chores that he/she used to perform in the past			QSORRES
QSTESTCD	39. Complete household chores adequately as he/she used to perform in the past			QSORRES
QSTESTCD	40. Stay safely at home by himself/herself when needed			QSORRES



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 3  
Page 6 of 7

## WEIGHT

VSTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Measure with shoes off. Round up or down to the nearest tenth kilogram or tenth pound.

Weight VSORRES  kg Kilogram  lb Pound  
VSORRESU

## VITAL SIGNS : HEART RATE AND BLOOD PRESSURE

INFORMATION NOT OBTAINED  Not Entered In Database

Position
SU = Supine
ST = Standing

NOTE: Blood pressure and pulse must be taken after the patient has been lying down for 5 minutes (supine) and after standing for 1 minute (standing) and 3 minutes.

VSTPTNUM VSPOS

VSTESTCD

(DNDE) Reference Time	Timing Code	Position	Heart Rate (bpm)	Blood Pressure (mmHg) Systolic/Diastolic
0. 5 minutes	815	SU	VSORRESU VSORRES	/
1. 1 minute	816	ST		/ VSORRESU VSORRES
2. 3 minutes	817	ST		VSORTESTCD VSORRESU / VSORRES

## VITAL SIGNS : TEMPERATURE VSTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Temperature VSORRES

Unit of measure  F Fahrenheit  C Centigrade VSORRESU

Method VSLOC  PO Oral  R Rectal  A Axillary  E Ear  O Other



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 3  
Page 7 of 7

**COMMENTS : VISIT**

NO COMMENTS  **Not Entered In Database**

Comments should address any clinical report form items that require further explanation. Repeating information from the clinical report form is discouraged.

Comment on all clinically significant lab values that are outside a clinically accepted reference range or clinically significant values that differ importantly from previous values.

If the patient is ending participation in the study at this visit, enter only comments that apply to this visit; then complete the Patient Summary and Study Summary Comments pages.

Print legibly and do not use abbreviations or symbols.

**Not Entered In Database**

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

The information reported for this visit is accurate and complete.

**Not Entered In Database**

**Not Entered In Database**

---

Signature

---

---

---

MM / DD / YY



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

VISIT  
VISITNUM  
Visit 3e  
Page 1 of 4

## PATIENT AND VISIT IDENTIFICATION

Patient initials **Not Entered In Database**  
First \_\_\_\_\_ Middle \_\_\_\_\_ Last \_\_\_\_\_  
  
Visit date **-STDTC** **-DTC**  
\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_  
MM DD YY

## STUDY DRUG : COMPLIANCE

INFORMATION NOT OBTAINED  **Not Entered In Database**

Since the previous visit, on how many days was  
the patient unable to complete the therapy? **Not Entered In Database**  
\_\_\_\_\_ days

## STUDY DRUG : DAILY PRESCRIBED DOSAGE

For this visit interval, record the number of patches (25-cm<sup>2</sup> and 50-cm<sup>2</sup> patches)  
that the patient is to wear per day.

Number of 25-cm<sup>2</sup> patches prescribed/day **Not Entered In Database**  
\_\_\_\_\_ 25-cm<sup>2</sup> patches

Number of 50-cm<sup>2</sup> patches prescribed/day **Not Entered In Database**  
\_\_\_\_\_ 50-cm<sup>2</sup> patches

## REMINDER

On the Pre-existing Conditions and Study Adverse Events page, record new  
events that occurred since the previous visit and re-evaluate any on-going  
conditions or events.

On the Concomitant Medication page, record new medications the patient has  
taken since the previous visit and record a stop date for any medication the  
patient is no longer taking.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 3e  
Page 2 of 4

## VITAL SIGNS : HEART RATE AND BLOOD PRESSURE

INFORMATION NOT OBTAINED  Not Entered In Database

Position
SU = Supine
ST = Standing

NOTE: Blood pressure and pulse must be taken after the patient has been lying down for 5 minutes (supine) and after standing for 1 minute (standing) and 3 minutes.

VSTPTNUM

VSPOS

VTESTCD

(DNDE) Reference Time	Timing Code	Position	Heart Rate (bpm)	Blood Pressure (mmHg) Systolic/Diastolic
0. 5 minutes	815	SU	VSORRESU VSORRES	/
1. 1 minute	816	ST		/ VSORRESU VSORRES
2. 3 minutes	817	ST	VTESTCD VSORRESU	/ VSORRES

## VITAL SIGNS : TEMPERATURE VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Temperature VSORRES.

Unit of measure  F Fahrenheit  C Centigrade VSORRESU

Method VSLOC  PO Oral  R Rectal  A Axillary  E Ear  O Other



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 3e  
Page 3 of 4

## PROCEDURE : AMBULATORY ECG

NOT DONE  Not Entered In Database

Date of ambulatory ECG      /  /   
                                  MM      DD      YY

NOTE: If abnormality present and clinically relevant, enter the diagnosis or symptom on the Pre-existing Conditions and Study Adverse Events page. Note non-relevant abnormalities in the Ambulatory ECG Comments section below.

## COMMENTS : NON-RELEVANT AMBULATORY ECG ABNORMALITIES

NO COMMENTS  Not Entered In Database

Print legibly and do not use abbreviations or symbols.

Not Entered In Database

---

---

---

---

---

---

---

---

---

---

---

---

---

---



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 3e  
Page 4 of 4

**COMMENTS : VISIT**

NO COMMENTS  **Not Entered In Database**

Comments should address any clinical report form items that require further explanation. Repeating information from the clinical report form is discouraged.

Comment on all clinically significant lab values that are outside a clinically accepted reference range or clinically significant values that differ importantly from previous values.

If the patient is ending participation in the study at this visit, enter only comments that apply to this visit; then complete the Patient Summary and Study Summary Comments pages.

Print legibly and do not use abbreviations or symbols.

**Not Entered In Database**

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

The information reported for this visit is accurate and complete.

**Not Entered In Database**

**Not Entered In Database**

---

Signature

---

MM / DD / YY



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

VISIT  
VISITNUM  
Visit 4  
Page 1 of 6

## PATIENT AND VISIT IDENTIFICATION

Patient initials Not Entered In Database  
First \_\_\_\_\_ Middle \_\_\_\_\_ Last \_\_\_\_\_  
-STDTC    -DTC  
Visit date \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_  
MM            DD            YY

## STUDY DRUG : COMPLIANCE

INFORMATION NOT OBTAINED  Not Entered In Database

Since the previous visit, on how many days was  
the patient unable to complete the therapy? Not Entered In Database  
\_\_\_\_\_ days

## REMINDER

On the Pre-existing Conditions and Study Adverse Events page, record new events that occurred since the previous visit and re-evaluate any on-going conditions or events.

On the Concomitant Medication page, record new medications the patient has taken since the previous visit and record a stop date for any medication the patient is no longer taking.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 4  
Page 2 of 6

## STUDY DRUG : PATCH ADHERENCE - PREVIOUS THREE DOSES

INFORMATION NOT OBTAINED  Not Entered In Database

For the previous three doses of study drug (patch administration), give the date and the number of hours that a patch was NOT applied (if applicable).

	Date	Number of hours 25-cm <sup>2</sup> patch <u>NOT applied</u>	Number of hours 50-cm <sup>2</sup> patch <u>NOT applied</u>
1. Today's (visit) date	Not Entered In Database ____ / ____ / ____ MM DD YY	Not Entered In Database _____ hours	Not Entered In Database _____ hours
2. Yesterday's date	Not Entered In Database ____ / ____ / ____ MM DD YY	Not Entered In Database _____ hours	Not Entered In Database _____ hours
3. Day before yesterday's date	Not Entered In Database ____ / ____ / ____ MM DD YY	Not Entered In Database _____ hours	Not Entered In Database _____ hours

## STUDY DRUG : DAILY PRESCRIBED DOSAGE

For this visit interval, record the number of patches (25-cm<sup>2</sup> and 50-cm<sup>2</sup> patches) that the patient is to wear per day.

Number of 25-cm<sup>2</sup> patches prescribed/day      Not Entered In Database  
                                                                  25-cm<sup>2</sup> patches

Number of 50-cm<sup>2</sup> patches prescribed/day      Not Entered In Database  
                                                                  50-cm<sup>2</sup> patches



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 4  
Page 3 of 6

**NEUROPSYCHIATRIC INVENTORY - REVISED (NPI-X)** QSCAT

INFORMATION NOT OBTAINED  Not Entered In Database

Clinician's initials	Not Entered In Database		
	First	Middle	Last

The screening question (from worksheet) is asked of the caregiver to determine if the behavioral change is present or absent in the patient. If the answer to the screening question is negative (NO) or if the question is not applicable to the patient, circle the appropriate response (Not Applicable [96] or Absent [0]) and proceed to the next screening question without asking the subquestions to determine frequency, severity, and distress.

	Item	Not		Frequency	Severity	Distress	
		Applicable	Absent			QSORRES	QTESTCD
<b>QSSCAT</b>	<b>QTESTCD</b>			<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>
A.	Delusions	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	<b>QSORRES</b>
<b>QSSCAT</b>	<b>QTESTCD</b>			<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>
B.	Hallucinations	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	<b>QSORRES</b>
<b>QSSCAT</b>	<b>QTESTCD</b>			<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>
C.	Agitation/Agression	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	<b>QSORRES</b>
<b>QSSCAT</b>	<b>QTESTCD</b>			<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>
D.	Depression/ Dysphoria	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	<b>QSORRES</b>
<b>QSSCAT</b>	<b>QTESTCD</b>			<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>
E.	Anxiety	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	<b>QSORRES</b>
<b>QSSCAT</b>	<b>QTESTCD</b>			<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>
F.	Euphoria/Elation	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	<b>QSORRES</b>
<b>QSSCAT</b>	<b>QTESTCD</b>			<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>
G.	Apathy/ Indifference	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	<b>QSORRES</b>
<b>QSSCAT</b>	<b>QTESTCD</b>			<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>
H.	Disinhibition	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	<b>QSORRES</b>
<b>QSSCAT</b>	<b>QTESTCD</b>			<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>
I.	Irritability/Lability	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	<b>QSORRES</b>
<b>QSSCAT</b>	<b>QTESTCD</b>			<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>
J.	Aberrant Motor Behavior	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	<b>QSORRES</b>
<b>QSSCAT</b>	<b>QTESTCD</b>			<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>
K.	Night-Time Behavior	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	<b>QSORRES</b>
<b>QSSCAT</b>	<b>QTESTCD</b>			<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>
L.	Appetite/Eating Change	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	<b>QSORRES</b>

©1994 Jeffrey L. Cummings

DS1609  
PRINTED IN USA  
August 22, 1996  
© Eli Lilly and Co.

QS570

Distribution: White and Yellow copies – Sponsor  
Bottom copy - Investigator

COPYRIGHT© 2006 Eli Lilly and Co.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 4  
Page 4 of 6

## WEIGHT

VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Measure with shoes off. Round up or down to the nearest tenth kilogram or tenth pound.

Weight VSORRES  kg Kilogram  lb Pound  
VSORRES

## VITAL SIGNS : HEART RATE AND BLOOD PRESSURE

INFORMATION NOT OBTAINED  Not Entered In Database

NOTE: Blood pressure and pulse must be taken after the patient has been lying down for 5 minutes (supine) and after standing for 1 minute (standing) and 3 minutes.

VSTPTNUM

VSPOS

VTESTCD

(DNDE) Reference Time	Timing Code	Position	Heart Rate (bpm)	Blood Pressure (mmHg) Systolic/Diastolic
0. 5 minutes	815	SU	VSORRESU VSORRES	/
1. 1 minute	816	ST		/ VSORRESU VSORRES
2. 3 minutes	817	ST		VSTESTCD VSORRESU VSORRES

## VITAL SIGNS : TEMPERATURE VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Temperature VSORRES

Unit of measure  F Fahrenheit  C Centigrade VSORRESU

Method VSLOC  PO Oral  R Rectal  A Axillary  E Ear  O Other



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 4  
Page 5 of 6

## ELECTROCARDIOGRAM

NOT DONE  Not Entered In Database

Electrocardiogram date \_\_\_\_\_ / \_\_\_\_\_ /  
MM DD YY  
Not Entered In Database

Electrocardiogram result  <sub>12</sub> Acceptable  <sub>13</sub> Not Acceptable

NOTE: Any clinically relevant change from Visit 1 (baseline) ECG must be recorded on the Pre-existing Conditions and Adverse Events page. Note non-relevant abnormalities in the ECG Comments section below.

## COMMENTS : NON-RELEVANT ECG ABNORMALITIES

NO COMMENTS  Not Entered In Database

Print legibly and do not use abbreviations or symbols.

Not Entered In Database

---

---

---

---

---

---

---

---

---

---

---

---

---



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 4  
Page 6 of 6

**COMMENTS : VISIT**

NO COMMENTS  Not Entered In Database

Comments should address any clinical report form items that require further explanation. Repeating information from the clinical report form is discouraged.

Comment on all clinically significant lab values that are outside a clinically accepted reference range or clinically significant values that differ importantly from previous values.

If the patient is ending participation in the study at this visit, enter only comments that apply to this visit; then complete the Patient Summary and Study Summary Comments pages.

Print legibly and do not use abbreviations or symbols.

Not Entered In Database

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

The information reported for this visit is accurate and complete.

Not Entered In Database

Not Entered In Database

---

Signature

---

MM / DD / YY



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

VISIT  
VISITNUM  
Visit 5  
Page 1 of 7

## PATIENT AND VISIT IDENTIFICATION

Patient initials **Not Entered In Database**  
First \_\_\_\_\_ Middle \_\_\_\_\_ Last \_\_\_\_\_  
  
Visit date **--STDTC --DTC**  
\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_  
MM DD YY

## STUDY DRUG : COMPLIANCE

INFORMATION NOT OBTAINED  **Not Entered In Database**

Since the previous visit, on how many days was  
the patient unable to complete the therapy?

**Not Entered In Database**

\_\_\_\_\_ days

## REMINDER

On the Pre-existing Conditions and Study Adverse Events page, record new events that occurred since the previous visit and re-evaluate any on-going conditions or events.

On the Concomitant Medication page, record new medications the patient has taken since the previous visit and record a stop date for any medication the patient is no longer taking.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 5  
Page 2 of 7

## STUDY DRUG : PATCH ADHERENCE - PREVIOUS THREE DOSES

INFORMATION NOT OBTAINED  Not Entered In Database

For the previous three doses of study drug (patch administration), give the date and the number of hours that a patch was NOT applied (if applicable).

	Date	Number of hours 25-cm <sup>2</sup> patch <u>NOT applied</u>	Number of hours 50-cm <sup>2</sup> patch <u>NOT applied</u>
1. Today's (visit) date	Not Entered In Database ____ / ____ / ____ MM DD YY	Not Entered In Database _____ hours	Not Entered In Database _____ hours
2. Yesterday's date	Not Entered In Database ____ / ____ / ____ MM DD YY	Not Entered In Database _____ hours	Not Entered In Database _____ hours
3. Day before yesterday's date	Not Entered In Database ____ / ____ / ____ MM DD YY	Not Entered In Database _____ hours	Not Entered In Database _____ hours

## STUDY DRUG : DAILY PRESCRIBED DOSAGE

For this visit interval, record the number of patches (25-cm<sup>2</sup> and 50-cm<sup>2</sup> patches) that the patient is to wear per day.

Number of 25-cm<sup>2</sup> patches prescribed/day  
\_\_\_\_\_

25-cm<sup>2</sup> patches

Number of 50-cm<sup>2</sup> patches prescribed/day  
\_\_\_\_\_

50-cm<sup>2</sup> patches



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 5  
Page 3 of 7

**NEUROPSYCHIATRIC INVENTORY - REVISED (NPI-X)** QSCAT

INFORMATION NOT OBTAINED  Not Entered In Database

Clinician's initials	Not Entered In Database		
	First	Middle	Last

The screening question (from worksheet) is asked of the caregiver to determine if the behavioral change is present or absent in the patient. If the answer to the screening question is negative (NO) or if the question is not applicable to the patient, circle the appropriate response (Not Applicable [96] or Absent [0]) and proceed to the next screening question without asking the subquestions to determine frequency, severity, and distress.

	Item	Not		Frequency	Severity	Distress	
		Applicable	Absent			QTESTCD	QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	A. Delusions	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	B. Hallucinations	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	C. Agitation/Agression	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	D. Depression/ Dysphoria	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	E. Anxiety	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	F. Euphoria/Elation	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	G. Apathy/ Indifference	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	H. Disinhibition	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	I. Irritability/Lability	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	J. Aberrant Motor Behavior	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	K. Night-Time Behavior	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	L. Appetite/Eating Change	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES

©1994 Jeffrey L. Cummings

DS1609  
PRINTED IN USA  
August 22, 1996  
© Eli Lilly and Co.

QS570

Distribution: White and Yellow copies – Sponsor  
Bottom copy - Investigator

COPYRIGHT© 2006 Eli Lilly and Co.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 5  
Page 4 of 7

## WEIGHT

VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Measure with shoes off. Round up or down to the nearest tenth kilogram or tenth pound.

Weight VSORRES  kg Kilogram  lb Pound  
VSORRES

## VITAL SIGNS : HEART RATE AND BLOOD PRESSURE

INFORMATION NOT OBTAINED  Not Entered In Database

NOTE: Blood pressure and pulse must be taken after the patient has been lying down for 5 minutes (supine) and after standing for 1 minute (standing) and 3 minutes.

VSTPTNUM  
VSPOS

(DNDE) Reference Time	Timing VSLOC	Position	Heart Rate (bpm)	Blood Pressure (mmHg) Systolic/Diastolic	VSORRESU
0. 5 minutes	815	SU	VSORRESU VSORRES	/	VTESTCD VSORRESU VSORRES
1. 1 minute	816	ST		/	VSORRESU VSORRES
2. 3 minutes	817	ST		VTESTCD VSORRESU VSORRES	

## VITAL SIGNS : TEMPERATURE VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Temperature VSORRES

Unit of measure  F Fahrenheit  C Centigrade VSORRESU

Method VSLOC  PO Oral  R Rectal  A Axillary  E Ear  O Other



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 5  
Page 5 of 7

## ELECTROCARDIOGRAM

NOT DONE  Not Entered In Database

Electrocardiogram date  /  /   
MM DD YY

Electrocardiogram result  <sub>12</sub> Acceptable  <sub>13</sub> Not Acceptable

NOTE: Any clinically relevant change from Visit 1 (baseline) ECG must be recorded on the Pre-existing Conditions and Adverse Events page. Note non-relevant abnormalities in the ECG Comments section below.

## COMMENTS : NON-RELEVANT ECG ABNORMALITIES

NO COMMENTS  Not Entered In Database

Print legibly and do not use abbreviations or symbols.

Not Entered In Database

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---



## PROCEDURE : AMBULATORY ECG

NOT DONE  Not Entered In Database

Date of ambulatory ECG       Not Entered In Database  
                                  MM / DD / YY

NOTE: If abnormality present and clinically relevant, enter the diagnosis or symptom on the Pre-existing Conditions and Study Adverse Events page. Note non-relevant abnormalities in the Ambulatory ECG Comments section below.

## COMMENTS : NON-RELEVANT AMBULATORY ECG ABNORMALITIES

NO COMMENTS  Not Entered In Database

Print legibly and do not use abbreviations or symbols.

Not Entered In Database

---

---

---

---

---

---

---

---

---

---

---



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 5  
Page 7 of 7

**COMMENTS : VISIT**

NO COMMENTS  **Not Entered In Database**

Comments should address any clinical report form items that require further explanation. Repeating information from the clinical report form is discouraged.

Comment on all clinically significant lab values that are outside a clinically accepted reference range or clinically significant values that differ importantly from previous values.

If the patient is ending participation in the study at this visit, enter only comments that apply to this visit; then complete the Patient Summary and Study Summary Comments pages.

Print legibly and do not use abbreviations or symbols.

**Not Entered In Database**

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

The information reported for this visit is accurate and complete.

**Not Entered In Database**

**Not Entered In Database**

---

Signature

---

MM / DD / YY



## PATIENT AND VISIT IDENTIFICATION

Patient initials **Not Entered In Database**  
First \_\_\_\_\_ Middle \_\_\_\_\_ Last \_\_\_\_\_  
  
Visit date **--STDTC --DTC**  
\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_  
MM DD YY

## STUDY DRUG : COMPLIANCE

INFORMATION NOT OBTAINED  **Not Entered In Database**

Since the previous visit, on how many days was  
the patient unable to complete the therapy? \_\_\_\_\_  
days

## STUDY DRUG : DAILY PRESCRIBED DOSAGE

For this visit interval, record the number of patches (25-cm<sup>2</sup> and 50-cm<sup>2</sup> patches)  
that the patient is to wear per day.

Number of 25-cm<sup>2</sup> patches prescribed/day **Not Entered In Database**  
\_\_\_\_\_  
25-cm<sup>2</sup> patches  
Number of 50-cm<sup>2</sup> patches prescribed/day **Not Entered In Database**  
\_\_\_\_\_  
50-cm<sup>2</sup> patches

## REMINDER

On the Pre-existing Conditions and Study Adverse Events page, record new  
events that occurred since the previous visit and re-evaluate any on-going  
conditions or events.

On the Concomitant Medication page, record new medications the patient has  
taken since the previous visit and record a stop date for any medication the  
patient is no longer taking.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 6  
Page 2 of 3

## VITAL SIGNS : HEART RATE AND BLOOD PRESSURE

INFORMATION NOT OBTAINED  Not Entered In Database

Position
SU = Supine
ST = Standing

NOTE: Blood pressure and pulse must be taken after the patient has been lying down for 5 minutes (supine) and after standing for 1 minute (standing) and 3 minutes.

VSTPTNUM

VSPOS

VTESTCD

(DNDE) Reference Time	Timing Code	Position	Heart Rate (bpm)	Blood Pressure (mmHg) Systolic/Diastolic
0. 5 minutes	815	SU	VSORRESU VSORRES	/
1. 1 minute	816	ST		/ VSORRESU VSORRES
2. 3 minutes	817	ST	VTESTCD VSORRESU VSORRES	

## VITAL SIGNS : TEMPERATURE VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Temperature VSORRES.

Unit of measure  F Fahrenheit  C Centigrade VSORRESU

Method VSLOC  PO Oral  R Rectal  A Axillary  E Ear  O Other



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 6  
Page 3 of 3

**COMMENTS : VISIT**

NO COMMENTS  **Not Entered In Database**

Comments should address any clinical report form items that require further explanation. Repeating information from the clinical report form is discouraged.

Comment on all clinically significant lab values that are outside a clinically accepted reference range or clinically significant values that differ importantly from previous values.

If the patient is ending participation in the study at this visit, enter only comments that apply to this visit; then complete the Patient Summary and Study Summary Comments pages.

Print legibly and do not use abbreviations or symbols.

**Not Entered In Database**

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

The information reported for this visit is accurate and complete.

**Not Entered In Database**

**Not Entered In Database**

---

Signature

---

MM / DD / YY



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

VISIT  
VISITNUM  
Visit 7  
Page 1 of 6

## PATIENT AND VISIT IDENTIFICATION

Patient initials **Not Entered In Database**  

---

First \_\_\_\_\_ Middle \_\_\_\_\_ Last \_\_\_\_\_

Visit date **--STDTC --DTC**  

---

MM / DD / YY

## STUDY DRUG : COMPLIANCE

INFORMATION NOT OBTAINED  **Not Entered In Database**

Since the previous visit, on how many days was the patient unable to complete the therapy? **Not Entered In Database**  

---

days

## REMINDER

On the Pre-existing Conditions and Study Adverse Events page, record new events that occurred since the previous visit and re-evaluate any on-going conditions or events.

On the Concomitant Medication page, record new medications the patient has taken since the previous visit and record a stop date for any medication the patient is no longer taking.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 7  
Page 2 of 6

## STUDY DRUG : PATCH ADHERENCE - PREVIOUS THREE DOSES

INFORMATION NOT OBTAINED  Not Entered In Database

For the previous three doses of study drug (patch administration), give the date and the number of hours that a patch was NOT applied (if applicable).

	Date	Number of hours 25-cm <sup>2</sup> patch <u>NOT applied</u>	Number of hours 50-cm <sup>2</sup> patch <u>NOT applied</u>
1. Today's (visit) date	Not Entered In Database ____ / ____ / ____ MM DD YY	Not Entered In Database _____ hours	Not Entered In Database _____ hours
2. Yesterday's date	Not Entered In Database ____ / ____ / ____ MM DD YY	Not Entered In Database _____ hours	Not Entered In Database _____ hours
3. Day before yesterday's date	Not Entered In Database ____ / ____ / ____ MM DD YY	Not Entered In Database _____ hours	Not Entered In Database _____ hours

## STUDY DRUG : DAILY PRESCRIBED DOSAGE

For this visit interval, record the number of patches (25-cm<sup>2</sup> and 50-cm<sup>2</sup> patches) that the patient is to wear per day.

Number of 25-cm<sup>2</sup> patches prescribed/day      Not Entered In Database  
                                                                      \_\_\_\_\_  
                                                                               25-cm<sup>2</sup> patches

Number of 50-cm<sup>2</sup> patches prescribed/day      Not Entered In Database  
                                                                       \_\_\_\_\_  
                                                                               50-cm<sup>2</sup> patches



Clinical Report Form  
 Safety and Efficacy of the Xanomeline  
 Transdermal Therapeutic System (TTS) in  
 Patients with Mild to Moderate Alzheimer's Disease  
 H2Q-MC-LZZT

Visit 7  
 Page 3 of 6

**NEUROPSYCHIATRIC INVENTORY - REVISED (NPI-X)** QSCAT

INFORMATION NOT OBTAINED  Not Entered In Database

Clinician's initials	Not Entered In Database		
	First	Middle	Last

The screening question (from worksheet) is asked of the caregiver to determine if the behavioral change is present or absent in the patient. If the answer to the screening question is negative (NO) or if the question is not applicable to the patient, circle the appropriate response (Not Applicable [96] or Absent [0]) and proceed to the next screening question without asking the subquestions to determine frequency, severity, and distress.

	Item	Not		Frequency	Severity	Distress					
		Applicable	Absent			QSORRES		QTESTCD		QSORRES	
QSSCAT	QTESTCD					QSORRES	QTESTCD	QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	A. Delusions	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QSORRES	QTESTCD	QSORRES	QTESTCD	QSORRES
QSSCAT	B. Hallucinations	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QSORRES	QTESTCD	QSORRES	QTESTCD	QSORRES
QSSCAT	C. Agitation/Agression	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QSORRES	QTESTCD	QSORRES	QTESTCD	QSORRES
QSSCAT	D. Depression/ Dysphoria	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QSORRES	QTESTCD	QSORRES	QTESTCD	QSORRES
QSSCAT	E. Anxiety	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QSORRES	QTESTCD	QSORRES	QTESTCD	QSORRES
QSSCAT	F. Euphoria/Elation	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QSORRES	QTESTCD	QSORRES	QTESTCD	QSORRES
QSSCAT	G. Apathy/ Indifference	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QSORRES	QTESTCD	QSORRES	QTESTCD	QSORRES
QSSCAT	H. Disinhibition	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QSORRES	QTESTCD	QSORRES	QTESTCD	QSORRES
QSSCAT	I. Irritability/Lability	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QSORRES	QTESTCD	QSORRES	QTESTCD	QSORRES
QSSCAT	J. Aberrant Motor Behavior	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QSORRES	QTESTCD	QSORRES	QTESTCD	QSORRES
QSSCAT	K. Night-Time Behavior	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QSORRES	QTESTCD	QSORRES	QTESTCD	QSORRES
QSSCAT	L. Appetite/Eating Change	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QSORRES	QTESTCD	QSORRES	QTESTCD	QSORRES

©1994 Jeffrey L. Cummings

DS1609  
 PRINTED IN USA  
 August 22, 1996  
 © Eli Lilly and Co.

QS570

Distribution: White and Yellow copies – Sponsor  
 Bottom copy - Investigator

COPYRIGHT© 2006 Eli Lilly and Co.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 7  
Page 4 of 6

## WEIGHT

VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Measure with shoes off. Round up or down to the nearest tenth kilogram or tenth pound.

Weight VSORRES  kg Kilogram  lb Pound  
VSORRES

## VITAL SIGNS : HEART RATE AND BLOOD PRESSURE

INFORMATION NOT OBTAINED  Not Entered In Database

NOTE: Blood pressure and pulse must be taken after the patient has been lying down for 5 minutes (supine) and after standing for 1 minute (standing) and 3 minutes.

VSTPTNUM VSPOS VTESTCD

(DNDE) Reference Time	Timing Code	Position	Heart Rate (bpm)	Blood Pressure (mmHg) Systolic/Diastolic
0. 5 minutes	815	SU	VSORRESU VSORRES	/
1. 1 minute	816	ST		/ VSORRESU VSORRES
2. 3 minutes	817	ST		VSORRESU VSORRES VSORRES

## VITAL SIGNS : TEMPERATURE VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Temperature VSORRES

Unit of measure  F Fahrenheit  C Centigrade VSORRESU

Method VSLOC  PO Oral  R Rectal  A Axillary  E Ear  O Other



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 7  
Page 5 of 6

## ELECTROCARDIOGRAM

NOT DONE  Not Entered In Database

Electrocardiogram date \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_  
MM DD YY

Electrocardiogram result  <sub>12</sub> Acceptable  <sub>13</sub> Not Acceptable

NOTE: Any clinically relevant change from Visit 1 (baseline) ECG must be recorded on the Pre-existing Conditions and Adverse Events page. Note non-relevant abnormalities in the ECG Comments section below.

## COMMENTS : NON-RELEVANT ECG ABNORMALITIES

NO COMMENTS  Not Entered In Database

Print legibly and do not use abbreviations or symbols.

Not Entered In Database Not Entered In Database

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 7  
Page 6 of 6

**COMMENTS : VISIT**

NO COMMENTS  **Not Entered In Database**

Comments should address any clinical report form items that require further explanation. Repeating information from the clinical report form is discouraged.

Comment on all clinically significant lab values that are outside a clinically accepted reference range or clinically significant values that differ importantly from previous values.

If the patient is ending participation in the study at this visit, enter only comments that apply to this visit; then complete the Patient Summary and Study Summary Comments pages.

Print legibly and do not use abbreviations or symbols.

**Not Entered In Database**

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

The information reported for this visit is accurate and complete.

**Not Entered In Database**

**Not Entered In Database**

---

Signature

---

MM / DD / YY



## PATIENT AND VISIT IDENTIFICATION

Patient initials **Not Entered In Database**  
First \_\_\_\_\_ Middle \_\_\_\_\_ Last \_\_\_\_\_  
**--STDTC** **--DTC**  
Visit date \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_  
MM DD YY

## STUDY DRUG : COMPLIANCE

INFORMATION NOT OBTAINED  **Not Entered In Database**

Since the previous visit, on how many days was  
the patient unable to complete the therapy? **Not Entered In Database**  
\_\_\_\_\_ days

## STUDY DRUG : DAILY PRESCRIBED DOSAGE

For this visit interval, record the number of patches (25-cm<sup>2</sup> and 50-cm<sup>2</sup> patches)  
that the patient is to wear per day.

Number of 25-cm<sup>2</sup> patches prescribed/day **Not Entered In Database**  
\_\_\_\_\_  
25-cm<sup>2</sup> patches

Number of 50-cm<sup>2</sup> patches prescribed/day **Not Entered In Database**  
\_\_\_\_\_  
50-cm<sup>2</sup> patches

## REMINDER

On the Pre-existing Conditions and Study Adverse Events page, record new  
events that occurred since the previous visit and re-evaluate any on-going  
conditions or events.

On the Concomitant Medication page, record new medications the patient has  
taken since the previous visit and record a stop date for any medication the  
patient is no longer taking.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 8  
Page 2 of 9

**QSCAT**

**ALZHEIMER'S DISEASE ASSESSMENT SCALE : COGNITIVE with ATTENTION/  
CONCENTRATION TASKS**

INFORMATION NOT OBTAINED  **Not Entered In Database**

Clinician's initials	<b>Not Entered In Database</b>		
	First	Middle	Last

<b>QTESTCD</b>	1. Word Recall Task	(max = 10)	<b>QSORRES</b>
<b>QTESTCD</b>	2. Naming Objects and Fingers (refer to 5 categories in manual)	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	3. Delayed Word Recall	(max = 10)	<b>QSORRES</b>
<b>QTESTCD</b>	4. Commands	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	5. Constructional Praxis	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	6. Ideational Praxis	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	7. Orientation	(max = 8)	<b>QSORRES</b>
<b>QTESTCD</b>	8. Word Recognition	(max = 12)	<b>QSORRES</b>
<b>QTESTCD</b>	9. Attention/Visual Search Task	(max = 40)	<b>QSORRES</b>
<b>QTESTCD</b>	10. Maze Solution	(max = 240)	<b>QSORRES</b> (seconds)
<b>QTESTCD</b>	11. Spoken Language Ability	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	12. Comprehension of Spoken Language	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	13. Word Finding Difficulty in Spontaneous Speech	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	14. Recall of Test Instructions	(max = 5)	<b>QSORRES</b>

© Reprinted with permission.  
*American Journal of Psychiatry* 1984;141:1356-64.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 8  
Page 3 of 9

**CLINICIAN'S INTERVIEW-BASED IMPRESSION OF CHANGE (CIBIC+)**

**QSCAT**

INFORMATION NOT OBTAINED  **Not Entered In Database**

Clinician's initials	<b>Not Entered In Database</b>		
	First	Middle	Last

**QSTESTCD** Check one box to indicate the extent of change, if any, observed since the initial baseline interview.

- QSORRES**
- <sub>1</sub> Marked improvement
  - <sub>2</sub> Moderate improvement
  - <sub>3</sub> Minimal improvement
  - <sub>4</sub> No change
  - <sub>5</sub> Minimal worsening
  - <sub>6</sub> Moderate worsening
  - <sub>7</sub> Marked worsening

The clinical interview-based impression of change scale in this study is from a pilot instrument, the Clinical Global Impression of Change, developed and currently undergoing validity studies by the National Institute on Aging Alzheimer's Disease Study Units Program (1 U01 AG10483; Leon Thal, Principal Investigator), and is in the public domain.



Clinical Report Form  
 Safety and Efficacy of the Xanomeline  
 Transdermal Therapeutic System (TTS) in  
 Patients with Mild to Moderate Alzheimer's Disease  
 H2Q-MC-LZZT

Visit 8  
 Page 4 of 9

**NEUROPSYCHIATRIC INVENTORY - REVISED (NPI-X)** QSCAT

INFORMATION NOT OBTAINED  Not Entered In Database

Clinician's initials	<span style="background-color: #0070C0; color: white; padding: 2px 5px;">Not Entered In Database</span>		
	First	Middle	Last

The screening question (from worksheet) is asked of the caregiver to determine if the behavioral change is present or absent in the patient. If the answer to the screening question is negative (NO) or if the question is not applicable to the patient, circle the appropriate response (Not Applicable [96] or Absent [0]) and proceed to the next screening question without asking the subquestions to determine frequency, severity, and distress.

	Item	Not		Frequency	Severity	Distress		QTESTCD	QSORRES
		Applicable	Absent			QSORRES	QTESTCD		
<b>QSSCAT</b>	<b>QTESTCD</b>								
A.	Delusions	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES	QTESTCD QSORRES	QTESTCD QSORRES
<b>QSSCAT</b>	<b>QTESTCD</b>								
B.	Hallucinations	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES	QTESTCD QSORRES	QTESTCD QSORRES
<b>QSSCAT</b>	<b>QTESTCD</b>								
C.	Agitation/Agression	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES	QTESTCD QSORRES	QTESTCD QSORRES
<b>QSSCAT</b>	<b>QTESTCD</b>								
D.	Depression/ Dysphoria	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES	QTESTCD QSORRES	QTESTCD QSORRES
<b>QSSCAT</b>	<b>QTESTCD</b>								
E.	Anxiety	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES	QTESTCD QSORRES	QTESTCD QSORRES
<b>QSSCAT</b>	<b>QTESTCD</b>								
F.	Euphoria/Elation	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES	QTESTCD QSORRES	QTESTCD QSORRES
<b>QSSCAT</b>	<b>QTESTCD</b>								
G.	Apathy/ Indifference	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES	QTESTCD QSORRES	QTESTCD QSORRES
<b>QSSCAT</b>	<b>QTESTCD</b>								
H.	Disinhibition	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES	QTESTCD QSORRES	QTESTCD QSORRES
<b>QSSCAT</b>	<b>QTESTCD</b>								
I.	Irritability/Lability	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES	QTESTCD QSORRES	QTESTCD QSORRES
<b>QSSCAT</b>	<b>QTESTCD</b>								
J.	Aberrant Motor Behavior	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES	QTESTCD QSORRES	QTESTCD QSORRES
<b>QSSCAT</b>	<b>QTESTCD</b>								
K.	Night-Time Behavior	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES	QTESTCD QSORRES	QTESTCD QSORRES
<b>QSSCAT</b>	<b>QTESTCD</b>								
L.	Appetite/Eating Change	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES	QTESTCD QSORRES	QTESTCD QSORRES

©1994 Jeffrey L. Cummings

DS1609  
 PRINTED IN USA  
 August 22, 1996  
 © Eli Lilly and Co.

QS570

Distribution: White and Yellow copies – Sponsor  
 Bottom copy - Investigator

COPYRIGHT© 2006 Eli Lilly and Co.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT


Visit 8  
Page 5 of 9

**DISABILITY ASSESSMENT FOR DEMENTIA (DAD)** **QSCAT**

INFORMATION NOT OBTAINED  Not Entered In Database

Clinician's initials	Not Entered In Database		
	First	Middle	Last

During the past two weeks, did the patient without help or reminder:



**QSSCAT**

**HYGIENE**

SCORING: Yes = 1 No = 0 Not Applicable = 96

QTESTCD	1. Undertake to wash himself/herself or to take a bath or a shower			QSORES
QTESTCD	2. Undertake to brush his/her teeth or care for his/her dentures			QSORES
QTESTCD	3. Decide to care for his/her hair (wash and comb)			QSORES
QTESTCD	4. Prepare the water, towels, and soap for washing, taking a bath, or a shower			QSORES
QTESTCD	5. Wash and dry completely all parts of his/her body safely			QSORES
QTESTCD	6. Brush his/her teeth or care for his/her dentures appropriately			QSORES
QTESTCD	7. Care for his/her hair (wash and comb)			QSORES

**DRESSING QSSCAT**

QTESTCD	8. Undertake to dress himself/herself			QSORES
QTESTCD	9. Choose appropriate clothing (with regard to the occasion, neatness, the weather, and color combination)			QSORES
QTESTCD	10. Dress himself/herself in the appropriate order (undergarments, pant/dress, shoes)			QSORES
QTESTCD	11. Dress himself/herself completely			QSORES
QTESTCD	12. Undress himself/herself completely			QSORES

**CONTINENCE QSSCAT**

QTESTCD	13. Decide to use the toilet at appropriate times			QSORES
QTESTCD	14. Use the toilet without "accidents"			QSORES

**EATING QSSCAT**


QTESTCD	15. Decide that he/she needs to eat			QSORES
QTESTCD	16. Choose appropriate utensils and seasonings when eating			QSORES
QTESTCD	17. Eat his/her meals at a normal pace and with appropriate manners			QSORES

**MEAL PREPARATION QSSCAT**

QTESTCD	18. Undertake to prepare a light meal or snack for himself/herself			QSORES
QTESTCD	19. Adequately plan a light meal or snack (ingredients, cookware)			QSORES
QTESTCD	20. Prepare or cook a light meal or a snack safely			QSORES



## DISABILITY ASSESSMENT FOR DEMENTIA (DAD)



QSSCAT		SCORING: Yes = 1    No = 0    Not Applicable = 96			
<b>TELEPHONING</b>					
QSTESTCD	21.	Attempt to telephone someone at a suitable time			QSORRES
QSTESTCD	22.	Find and dial a telephone number correctly			QSORRES
QSTESTCD	23.	Carry out an appropriate telephone conversation			QSORRES
QSTESTCD	24.	Write and convey a telephone message adequately			QSORRES
<b>GOING ON AN OUTING</b> QSSCAT					
QSTESTCD	25.	Undertake to go out (walk, visit, shop) at an appropriate time			QSORRES
QSTESTCD	26.	Adequately organize an outing with respect to transportation, keys, destination, weather, necessary money, shopping list			QSORRES
QSTESTCD	27.	Go out and reach a familiar destination without getting lost			QSORRES
QSTESTCD	28.	Safely take the adequate mode of transportation (car, bus, taxi)			QSORRES
QSTESTCD	29.	Return from the store with the appropriate items			QSORRES
<b>FINANCE AND CORRESPONDENCE</b> QSSCAT					
QSTESTCD	30.	Show an interest in his/her personal affairs such as his/her finances and written correspondence			QSORRES
QSTESTCD	31.	Organize his/her finances to pay his/her bills (cheques, bankbook, bills)			QSORRES
QSTESTCD	32.	Adequately organize his/her correspondence with respect to stationery, address, stamps			QSORRES
QSTESTCD	33.	Handle adequately his/her money (make change)			QSORRES
<b>MEDICATIONS</b> QSSCAT					
QSTESTCD	34.	Decide to take his/her medications at the correct time			QSORRES
QSTESTCD	35.	Take his/her medications as prescribed (according to the right dosage)			QSORRES
<b>LEISURE AND HOUSEWORK</b> QSSCAT					
QSTESTCD	36.	Show an interest in leisure activity(ies)			QSORRES
QSTESTCD	37.	Take an interest in household chores that he/she used to perform in the past			QSORRES
QSTESTCD	38.	Plan and organize adequately household chores that he/she used to perform in the past			QSORRES
QSTESTCD	39.	Complete household chores adequately as he/she used to perform in the past			QSORRES
QSTESTCD	40.	Stay safely at home by himself/herself when needed			QSORRES



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 8  
Page 7 of 9

## WEIGHT

VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Measure with shoes off. Round up or down to the nearest tenth kilogram or tenth pound.

Weight VSORRES.  kg Kilogram  lb Pound  
VSORRES

## VITAL SIGNS : HEART RATE AND BLOOD PRESSURE

INFORMATION NOT OBTAINED  Not Entered In Database

Position
SU = Supine
ST = Standing

NOTE: Blood pressure and pulse must be taken after the patient has been lying down for 5 minutes (supine) and after standing for 1 minute (standing) and 3 minutes.

VSTPTNUM

VSPOS

VTESTCD

(DNDE) Reference Time	Timing Code	Position	Heart Rate (bpm)	Blood Pressure (mmHg) Systolic/Diastolic
0. 5 minutes	815	SU	VSORRESU VSORRES	/
1. 1 minute	816	ST		/ VSORRESU VSORRES
2. 3 minutes	817	ST		VSORTESTCD VSORRESU/ VSORRES

## VITAL SIGNS : TEMPERATURE VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Temperature VSORRES.

Unit of measure  F Fahrenheit  C Centigrade VSORRESU

Method VSLOC  PO Oral  R Rectal  A Axillary  E Ear  O Other



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 8  
Page 8 of 9

## ELECTROCARDIOGRAM

NOT DONE  Not Entered In Database

Electrocardiogram date  /  /   
MM DD YY

Electrocardiogram result  <sub>12</sub> Acceptable  <sub>13</sub> Not Acceptable

NOTE: Any clinically relevant change from Visit 1 (baseline) ECG must be recorded on the Pre-existing Conditions and Adverse Events page. Note non-relevant abnormalities in the ECG Comments section below.

## COMMENTS : NON-RELEVANT ECG ABNORMALITIES

NO COMMENTS  Not Entered In Database

Print legibly and do not use abbreviations or symbols.

Not Entered In Database

---

---

---

---

---

---

---

---

---

---

---

---

---



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 8  
Page 9 of 9

**COMMENTS : VISIT**

NO COMMENTS  **Not Entered In Database**

Comments should address any clinical report form items that require further explanation. Repeating information from the clinical report form is discouraged.

Comment on all clinically significant lab values that are outside a clinically accepted reference range or clinically significant values that differ importantly from previous values.

If the patient is ending participation in the study at this visit, enter only comments that apply to this visit; then complete the Patient Summary and Study Summary Comments pages.

Print legibly and do not use abbreviations or symbols.

**Not Entered In Database**

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

The information reported for this visit is accurate and complete.

**Not Entered In Database**

**Not Entered In Database**

---

Signature

---

MM / DD / YY



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

VISIT  
VISITNUM  
Visit 9  
Page 1 of 6

## PATIENT AND VISIT IDENTIFICATION

Patient initials **Not Entered In Database**  
First \_\_\_\_\_ Middle \_\_\_\_\_ Last \_\_\_\_\_  
  
Visit date **-STDTC** **--DTC**  
MM / DD / YY

## STUDY DRUG : COMPLIANCE

INFORMATION NOT OBTAINED  **Not Entered In Database**

Since the previous visit, on how many days was  
the patient unable to complete the therapy?

**Not Entered In Database**  
\_\_\_\_\_ days

## REMINDER

On the Pre-existing Conditions and Study Adverse Events page, record new events that occurred since the previous visit and re-evaluate any on-going conditions or events.

On the Concomitant Medication page, record new medications the patient has taken since the previous visit and record a stop date for any medication the patient is no longer taking.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 9  
Page 2 of 6

## STUDY DRUG : PATCH ADHERENCE - PREVIOUS THREE DOSES

INFORMATION NOT OBTAINED  Not Entered In Database

For the previous three doses of study drug (patch administration), give the date and the number of hours that a patch was NOT applied (if applicable).

	Date	Number of hours 25-cm <sup>2</sup> patch <u>NOT applied</u>	Number of hours 50-cm <sup>2</sup> patch <u>NOT applied</u>
1. Today's (visit) date	Not Entered In Database ____ / ____ / ____ MM DD YY	Not Entered In Database _____ hours	Not Entered In Database _____ hours
2. Yesterday's date	Not Entered In Database ____ / ____ / ____ MM DD YY	Not Entered In Database _____ hours	Not Entered In Database _____ hours
3. Day before yesterday's date	Not Entered In Database ____ / ____ / ____ MM DD YY	Not Entered In Database _____ hours	Not Entered In Database _____ hours

Not Entered In Database

## STUDY DRUG : DAILY PRESCRIBED DOSAGE

For this visit interval, record the number of patches (25-cm<sup>2</sup> and 50-cm<sup>2</sup> patches) that the patient is to wear per day.

Number of 25-cm<sup>2</sup> patches prescribed/day      Not Entered In Database  
\_\_\_\_\_  
25-cm<sup>2</sup> patches

Number of 50-cm<sup>2</sup> patches prescribed/day      Not Entered In Database  
\_\_\_\_\_  
50-cm<sup>2</sup> patches



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 9  
Page 3 of 6

**NEUROPSYCHIATRIC INVENTORY - REVISED (NPI-X)** QSCAT

INFORMATION NOT OBTAINED  Not Entered In Database

Clinician's initials	Not Entered In Database		
	First	Middle	Last

The screening question (from worksheet) is asked of the caregiver to determine if the behavioral change is present or absent in the patient. If the answer to the screening question is negative (NO) or if the question is not applicable to the patient, circle the appropriate response (Not Applicable [96] or Absent [0]) and proceed to the next screening question without asking the subquestions to determine frequency, severity, and distress.

	Item	Not		Frequency	Severity	Distress					
		Applicable	Absent			QSORRES	QTESTCD	QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	QTESTCD										
	A. Delusions	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
QSSCAT	QTESTCD										
	B. Hallucinations	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
QSSCAT	QTESTCD										
	C. Agitation/Agression	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
QSSCAT	QTESTCD										
	D. Depression/ Dysphoria	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
QSSCAT	QTESTCD										
	E. Anxiety	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
QSSCAT	QTESTCD										
	F. Euphoria/Elation	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
QSSCAT	QTESTCD										
	G. Apathy/ Indifference	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
QSSCAT	QTESTCD										
	H. Disinhibition	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
QSSCAT	QTESTCD										
	I. Irritability/Lability	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
QSSCAT	QTESTCD										
	J. Aberrant Motor Behavior	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
QSSCAT	QTESTCD										
	K. Night-Time Behavior	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
QSSCAT	QTESTCD										
	L. Appetite/Eating Change	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				

©1994 Jeffrey L. Cummings

DS1609  
PRINTED IN USA  
August 22, 1996  
© Eli Lilly and Co.

QS570

Distribution: White and Yellow copies – Sponsor  
Bottom copy - Investigator

COPYRIGHT© 2006 Eli Lilly and Co.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 9  
Page 4 of 6

## WEIGHT

VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Measure with shoes off. Round up or down to the nearest tenth kilogram or tenth pound.

Weight VSORRES  kg Kilogram  lb Pound  
VSORRES

## VITAL SIGNS : HEART RATE AND BLOOD PRESSURE

INFORMATION NOT OBTAINED  Not Entered In Database

NOTE: Blood pressure and pulse must be taken after the patient has been lying down for 5 minutes (supine) and after standing for 1 minute (standing) and 3 minutes.

VSTPTNUM

VSPOS

VTESTCD

(DNDE) Reference Time	Timing Code	Position	Heart Rate (bpm)	Blood Pressure (mmHg) Systolic/Diastolic
0. 5 minutes	815	SU	VSORRESU VSORRES	/
1. 1 minute	816	ST		/ VSORRESU
2. 3 minutes	817	ST		VSORRES VSORRESU VSORRES

## VITAL SIGNS : TEMPERATURE VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Temperature VSORRES.

Unit of measure  F Fahrenheit  C Centigrade VSORRESU

Method VSLOC  PO Oral  R Rectal  A Axillary  E Ear  O Other



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 9  
Page 5 of 6

## ELECTROCARDIOGRAM

NOT DONE  Not Entered In Database

Electrocardiogram date \_\_\_\_\_ / \_\_\_\_\_ /  
MM DD YY

Electrocardiogram result  <sub>12</sub> Acceptable  <sub>13</sub> Not Acceptable

NOTE: Any clinically relevant change from Visit 1 (baseline) ECG must be recorded on the Pre-existing Conditions and Adverse Events page. Note non-relevant abnormalities in the ECG Comments section below.

## COMMENTS : NON-RELEVANT ECG ABNORMALITIES

NO COMMENTS  Not Entered In Database

Print legibly and do not use abbreviations or symbols.

Not Entered In Database

---

---

---

---

---

---

---

---

---

---

---

---

---



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 9  
Page 6 of 6

**COMMENTS : VISIT**

NO COMMENTS  **Not Entered In Database**

Comments should address any clinical report form items that require further explanation. Repeating information from the clinical report form is discouraged.

Comment on all clinically significant lab values that are outside a clinically accepted reference range or clinically significant values that differ importantly from previous values.

If the patient is ending participation in the study at this visit, enter only comments that apply to this visit; then complete the Patient Summary and Study Summary Comments pages.

Print legibly and do not use abbreviations or symbols.

**Not Entered In Database**

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

The information reported for this visit is accurate and complete.

**Not Entered In Database**

**Not Entered In Database**

---

Signature

---

MM / DD / YY



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

VISIT

VISITNUM

Visit 10  
Page 1 of 9

## PATIENT AND VISIT IDENTIFICATION

Patient initials **Not Entered In Database**  
First \_\_\_\_\_ Middle \_\_\_\_\_ Last \_\_\_\_\_  
  
Visit date **--STDTC** **--DTC**  
\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_  
MM DD YY

## STUDY DRUG : COMPLIANCE

INFORMATION NOT OBTAINED  **Not Entered In Database**

Since the previous visit, on how many days was  
the patient unable to complete the therapy? **Not Entered In Database**  
\_\_\_\_\_ days

## STUDY DRUG : DAILY PRESCRIBED DOSAGE

For this visit interval, record the number of patches (25-cm<sup>2</sup> and 50-cm<sup>2</sup> patches)  
that the patient is to wear per day.

Number of 25-cm<sup>2</sup> patches prescribed/day **Not Entered In Database**  
\_\_\_\_\_  
25-cm<sup>2</sup> patches

Number of 50-cm<sup>2</sup> patches prescribed/day **Not Entered In Database**  
\_\_\_\_\_  
50-cm<sup>2</sup> patches

## REMINDER

On the Pre-existing Conditions and Study Adverse Events page, record new  
events that occurred since the previous visit and re-evaluate any on-going  
conditions or events.

On the Concomitant Medication page, record new medications the patient has  
taken since the previous visit and record a stop date for any medication the  
patient is no longer taking.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 10  
Page 2 of 9

**QSCAT**

**ALZHEIMER'S DISEASE ASSESSMENT SCALE : COGNITIVE with ATTENTION/  
CONCENTRATION TASKS**

INFORMATION NOT OBTAINED  **Not Entered In Database**

Clinician's initials	<b>Not Entered In Database</b>		
	First	Middle	Last

<b>QTESTCD</b>	1. Word Recall Task	(max = 10)	<b>QSORRES</b>
<b>QTESTCD</b>	2. Naming Objects and Fingers (refer to 5 categories in manual)	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	3. Delayed Word Recall	(max = 10)	<b>QSORRES</b>
<b>QTESTCD</b>	4. Commands	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	5. Constructional Praxis	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	6. Ideational Praxis	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	7. Orientation	(max = 8)	<b>QSORRES</b>
<b>QTESTCD</b>	8. Word Recognition	(max = 12)	<b>QSORRES</b>
<b>QTESTCD</b>	9. Attention/Visual Search Task	(max = 40)	<b>QSORRES</b>
<b>QTESTCD</b>	10. Maze Solution	(max = 240)	<b>QSORRES</b> (seconds)
<b>QTESTCD</b>	11. Spoken Language Ability	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	12. Comprehension of Spoken Language	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	13. Word Finding Difficulty in Spontaneous Speech	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	14. Recall of Test Instructions	(max = 5)	<b>QSORRES</b>

© Reprinted with permission.  
*American Journal of Psychiatry* 1984;141:1356-64.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 10  
Page 3 of 9

**CLINICIAN'S INTERVIEW-BASED IMPRESSION OF CHANGE (CIBIC+)**

**QSCAT**

INFORMATION NOT OBTAINED  **Not Entered In Database**

Clinician's initials	<b>Not Entered In Database</b>		
	First	Middle	Last

**QSTESTCD**

Check one box to indicate the extent of change, if any, observed since the initial baseline interview.

**QSORRES**  <sub>1</sub> Marked improvement

<sub>2</sub> Moderate improvement

<sub>3</sub> Minimal improvement

<sub>4</sub> No change

<sub>5</sub> Minimal worsening

<sub>6</sub> Moderate worsening

<sub>7</sub> Marked worsening

The clinical interview-based impression of change scale in this study is from a pilot instrument, the Clinical Global Impression of Change, developed and currently undergoing validity studies by the National Institute on Aging Alzheimer's Disease Study Units Program (1 U01 AG10483; Leon Thal, Principal Investigator), and is in the public domain.



Clinical Report Form  
 Safety and Efficacy of the Xanomeline  
 Transdermal Therapeutic System (TTS) in  
 Patients with Mild to Moderate Alzheimer's Disease  
 H2Q-MC-LZZT

Visit 10  
 Page 4 of 9

**NEUROPSYCHIATRIC INVENTORY - REVISED (NPI-X)** QSCAT

INFORMATION NOT OBTAINED  Not Entered In Database

Clinician's initials	<b>Not Entered In Database</b>		
	First	Middle	Last

The screening question (from worksheet) is asked of the caregiver to determine if the behavioral change is present or absent in the patient. If the answer to the screening question is negative (NO) or if the question is not applicable to the patient, circle the appropriate response (Not Applicable [96] or Absent [0]) and proceed to the next screening question without asking the subquestions to determine frequency, severity, and distress.

	Item	Not		Frequency	Severity	Distress					
		Applicable	Absent			QSORRES QTESTCD QSORRES QTESTCD QSORRES QTESTCD QSORRES QTESTCD QSORRES					
QSSCAT	QTESTCD					1	2	3	4	5	0
QSSCAT	QTESTCD	A.	Delusions	96	0	1	2	3	4	5	0
QSSCAT	QTESTCD	B.	Hallucinations	96	0	1	2	3	4	5	0
QSSCAT	QTESTCD	C.	Agitation/Agression	96	0	1	2	3	4	5	0
QSSCAT	QTESTCD	D.	Depression/ Dysphoria	96	0	1	2	3	4	5	0
QSSCAT	QTESTCD	E.	Anxiety	96	0	1	2	3	4	5	0
QSSCAT	QTESTCD	F.	Euphoria/Elation	96	0	1	2	3	4	5	0
QSSCAT	QTESTCD	G.	Apathy/ Indifference	96	0	1	2	3	4	5	0
QSSCAT	QTESTCD	H.	Disinhibition	96	0	1	2	3	4	5	0
QSSCAT	QTESTCD	I.	Irritability/Lability	96	0	1	2	3	4	5	0
QSSCAT	QTESTCD	J.	Aberrant Motor Behavior	96	0	1	2	3	4	5	0
QSSCAT	QTESTCD	K.	Night-Time Behavior	96	0	1	2	3	4	5	0
QSSCAT	QTESTCD	L.	Appetite/Eating Change	96	0	1	2	3	4	5	0

©1994 Jeffrey L. Cummings

DS1609  
 PRINTED IN USA  
 August 22, 1996  
 © Eli Lilly and Co.

QS570

Distribution: White and Yellow copies – Sponsor  
 Bottom copy - Investigator

COPYRIGHT© 2006 Eli Lilly and Co.



## DISABILITY ASSESSMENT FOR DEMENTIA (DAD) QSCAT

INFORMATION NOT OBTAINED  Not Entered In Database

Clinician's initials	Not Entered In Database		
	First	Middle	Last

During the past two weeks, did the patient without help or reminder:



### QSSCAT

SCORING: Yes = 1 No = 0 Not Applicable = 96

#### HYGIENE

QTESTCD	1. Undertake to wash himself/herself or to take a bath or a shower			QSORES
QTESTCD	2. Undertake to brush his/her teeth or care for his/her dentures			QSORES
QTESTCD	3. Decide to care for his/her hair (wash and comb)			QSORES
QTESTCD	4. Prepare the water, towels, and soap for washing, taking a bath, or a shower			QSORES
QTESTCD	5. Wash and dry completely all parts of his/her body safely			QSORES
QTESTCD	6. Brush his/her teeth or care for his/her dentures appropriately			QSORES
QTESTCD	7. Care for his/her hair (wash and comb)			QSORES

#### DRESSING QSSCAT

QTESTCD	8. Undertake to dress himself/herself			QSORES
QTESTCD	9. Choose appropriate clothing (with regard to the occasion, neatness, the weather, and color combination)			QSORES
QTESTCD	10. Dress himself/herself in the appropriate order (undergarments, pant/dress, shoes)			QSORES
QTESTCD	11. Dress himself/herself completely			QSORES
QTESTCD	12. Undress himself/herself completely			QSORES

#### CONTINENCE QSSCAT

QTESTCD	13. Decide to use the toilet at appropriate times			QSORES
QTESTCD	14. Use the toilet without "accidents"			QSORES

#### EATING QSSCAT


QTESTCD	15. Decide that he/she needs to eat			QSORES
QTESTCD	16. Choose appropriate utensils and seasonings when eating			QSORES
QTESTCD	17. Eat his/her meals at a normal pace and with appropriate manners			QSORES

#### MEAL PREPARATION QSSCAT

QTESTCD	18. Undertake to prepare a light meal or snack for himself/herself			QSORES
QTESTCD	19. Adequately plan a light meal or snack (ingredients, cookware)			QSORES
QTESTCD	20. Prepare or cook a light meal or a snack safely			QSORES



## DISABILITY ASSESSMENT FOR DEMENTIA (DAD)



	<b>QSSCAT</b>	SCORING: Yes = 1   No = 0   Not Applicable = 96			
<b>TELEPHONING</b>					
<b>QSTESTCD</b>	21. Attempt to telephone someone at a suitable time				QSORRES
<b>QSTESTCD</b>	22. Find and dial a telephone number correctly				QSORRES
<b>QSTESTCD</b>	23. Carry out an appropriate telephone conversation				QSORRES
<b>QSTESTCD</b>	24. Write and convey a telephone message adequately				QSORRES
<b>GOING ON AN OUTING</b> <b>QSSCAT</b>					
<b>QSTESTCD</b>	25. Undertake to go out (walk, visit, shop) at an appropriate time				QSORRES
<b>QSTESTCD</b>	26. Adequately organize an outing with respect to transportation, keys, destination, weather, necessary money, shopping list				QSORRES
<b>QSTESTCD</b>	27. Go out and reach a familiar destination without getting lost				QSORRES
<b>QSTESTCD</b>	28. Safely take the adequate mode of transportation (car, bus, taxi)				QSORRES
<b>QSTESTCD</b>	29. Return from the store with the appropriate items				QSORRES
<b>FINANCE AND CORRESPONDENCE</b> <b>QSSCAT</b>					
<b>QSTESTCD</b>	30. Show an interest in his/her personal affairs such as his/her finances and written correspondence				QSORRES
<b>QSTESTCD</b>	31. Organize his/her finances to pay his/her bills (cheques, bankbook, bills)				QSORRES
<b>QSTESTCD</b>	32. Adequately organize his/her correspondence with respect to stationery, address, stamps				QSORRES
<b>QSTESTCD</b>	33. Handle adequately his/her money (make change)				QSORRES
<b>MEDICATIONS</b> <b>QSSCAT</b>					
<b>QSTESTCD</b>	34. Decide to take his/her medications at the correct time				QSORRES
<b>QSTESTCD</b>	35. Take his/her medications as prescribed (according to the right dosage)				QSORRES
<b>LEISURE AND HOUSEWORK</b> <b>QSSCAT</b>					
<b>QSTESTCD</b>	36. Show an interest in leisure activity(ies)				QSORRES
<b>QSTESTCD</b>	37. Take an interest in household chores that he/she used to perform in the past				QSORRES
<b>QSTESTCD</b>	38. Plan and organize adequately household chores that he/she used to perform in the past				QSORRES
<b>QSTESTCD</b>	39. Complete household chores adequately as he/she used to perform in the past				QSORRES
<b>QSTESTCD</b>	40. Stay safely at home by himself/herself when needed				QSORRES



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 10  
Page 7 of 9

## WEIGHT

VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Measure with shoes off. Round up or down to the nearest tenth kilogram or tenth pound.

Weight VSORRES  kg Kilogram  lb Pound  
VSORRES

## VITAL SIGNS : HEART RATE AND BLOOD PRESSURE

INFORMATION NOT OBTAINED  Not Entered In Database

NOTE: Blood pressure and pulse must be taken after the patient has been lying down for 5 minutes (supine) and after standing for 1 minute (standing) and 3 minutes.

VSTPTNUM VSPCS

VTESTCD

(DNDE) Reference Time	Timing Code	Position	Heart Rate (bpm)	Blood Pressure (mmHg) Systolic/Diastolic
0. 5 minutes	815	SU	VSORRESU VSORRES	/
1. 1 minute	816	ST		/VSORRESU VSORRES
2. 3 minutes	817	ST	VTESTCD VSORRESU VSORRES	/

## VITAL SIGNS : TEMPERATURE VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Temperature VSORRES.

Unit of measure  F Fahrenheit  C Centigrade VSORRESU

Method VSLOC  PO Oral  R Rectal  A Axillary  E Ear  O Other



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 10  
Page 8 of 9

## ELECTROCARDIOGRAM

NOT DONE  Not Entered In Database

Electrocardiogram date  /  /   
MM DD YY

Electrocardiogram result  <sub>12</sub> Acceptable  <sub>13</sub> Not Acceptable

NOTE: Any clinically relevant change from Visit 1 (baseline) ECG must be recorded on the Pre-existing Conditions and Adverse Events page. Note non-relevant abnormalities in the ECG Comments section below.

## COMMENTS : NON-RELEVANT ECG ABNORMALITIES

NO COMMENTS  Not Entered In Database

Print legibly and do not use abbreviations or symbols.

Not Entered In Database

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---



**COMMENTS : VISIT**

NO COMMENTS  Not Entered In Database

Comments should address any clinical report form items that require further explanation. Repeating information from the clinical report form is discouraged.

Comment on all clinically significant lab values that are outside a clinically accepted reference range or clinically significant values that differ importantly from previous values.

If the patient is ending participation in the study at this visit, enter only comments that apply to this visit; then complete the Patient Summary and Study Summary Comments pages.

Print legibly and do not use abbreviations or symbols.

Not Entered In Database

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

The information reported for this visit is accurate and complete.

Not Entered In Database

Not Entered In Database

---

Signature

---

MM / DD / YY



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

VISIT  
VISITNUM  
Visit 11  
Page 1 of 6

## PATIENT AND VISIT IDENTIFICATION

Patient initials **Not Entered In Database**

First \_\_\_\_\_ Middle \_\_\_\_\_ Last \_\_\_\_\_

--STDTC    --DTC

Visit date \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_  
MM            DD            YY

## STUDY DRUG : COMPLIANCE

INFORMATION NOT OBTAINED  **Not Entered In Database**

Since the previous visit, on how many days was  
the patient unable to complete the therapy?

**Not Entered In Database**  
\_\_\_\_\_ days

## REMINDER

On the Pre-existing Conditions and Study Adverse Events page, record new events that occurred since the previous visit and re-evaluate any on-going conditions or events.

On the Concomitant Medication page, record new medications the patient has taken since the previous visit and record a stop date for any medication the patient is no longer taking.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 11  
Page 2 of 6

## STUDY DRUG : PATCH ADHERENCE - PREVIOUS THREE DOSES

INFORMATION NOT OBTAINED  Not Entered In Database

For the previous three doses of study drug (patch administration), give the date and the number of hours that a patch was NOT applied (if applicable).

	Date	Number of hours 25-cm <sup>2</sup> patch <u>NOT applied</u>	Number of hours 50-cm <sup>2</sup> patch <u>NOT applied</u>
1. Today's (visit) date	Not Entered In Database ____ / ____ / ____ MM DD YY	Not Entered In Database _____ hours	Not Entered In Database _____ hours
2. Yesterday's date	Not Entered In Database ____ / ____ / ____ MM DD YY	Not Entered In Database _____ hours	Not Entered In Database _____ hours
3. Day before yesterday's date	Not Entered In Database ____ / ____ / ____ MM DD YY	Not Entered In Database _____ hours	Not Entered In Database _____ hours

## STUDY DRUG : DAILY PRESCRIBED DOSAGE

For this visit interval, record the number of patches (25-cm<sup>2</sup> and 50-cm<sup>2</sup> patches) that the patient is to wear per day.

Number of 25-cm<sup>2</sup> patches prescribed/day \_\_\_\_\_  
25-cm<sup>2</sup> patches

Number of 50-cm<sup>2</sup> patches prescribed/day \_\_\_\_\_  
50-cm<sup>2</sup> patches



Clinical Report Form  
 Safety and Efficacy of the Xanomeline  
 Transdermal Therapeutic System (TTS) in  
 Patients with Mild to Moderate Alzheimer's Disease  
 H2Q-MC-LZZT

Visit 11  
 Page 3 of 6

**NEUROPSYCHIATRIC INVENTORY - REVISED (NPI-X)** QSCAT

INFORMATION NOT OBTAINED  Not Entered In Database

Clinician's initials	Not Entered In Database		
	First	Middle	Last

The screening question (from worksheet) is asked of the caregiver to determine if the behavioral change is present or absent in the patient. If the answer to the screening question is negative (NO) or if the question is not applicable to the patient, circle the appropriate response (Not Applicable [96] or Absent [0]) and proceed to the next screening question without asking the subquestions to determine frequency, severity, and distress.

	Item	Not		Frequency	Severity	Distress	
		Applicable	Absent			QTESTCD	QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	A. Delusions	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	B. Hallucinations	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	C. Agitation/Agression	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	D. Depression/ Dysphoria	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	E. Anxiety	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	F. Euphoria/Elation	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	G. Apathy/ Indifference	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	H. Disinhibition	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	I. Irritability/Lability	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	J. Aberrant Motor Behavior	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	K. Night-Time Behavior	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES
QSSCAT	QTESTCD			QSORRES	QTESTCD	QSORRES	QTESTCD
QSSCAT	L. Appetite/Eating Change	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5	QTESTCD QSORRES

©1994 Jeffrey L. Cummings

DS1609  
 PRINTED IN USA  
 August 22, 1996  
 © Eli Lilly and Co.

QS570

Distribution: White and Yellow copies – Sponsor  
 Bottom copy - Investigator

COPYRIGHT© 2006 Eli Lilly and Co.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 11  
Page 4 of 6

## WEIGHT

VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Measure with shoes off. Round up or down to the nearest tenth kilogram or tenth pound.

Weight VSORRES  kg Kilogram  lb Pound  
VSORRES

## VITAL SIGNS : HEART RATE AND BLOOD PRESSURE

INFORMATION NOT OBTAINED  Not Entered In Database

NOTE: Blood pressure and pulse must be taken after the patient has been lying down for 5 minutes (supine) and after standing for 1 minute (standing) and 3 minutes.

VSTPTNUM VSPOS VTESTCD

(DNDE) Reference Time	Timing Code	Position	Heart Rate (bpm)	Blood Pressure (mmHg) Systolic/Diastolic
0. 5 minutes	815	SU	VSORRESU VSORRES	/
1. 1 minute	816	ST		/ VSORRESU VSORRES
2. 3 minutes	817	ST		VSORRES VSORRESU VSORRES

## VITAL SIGNS : TEMPERATURE VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Temperature VSORRES

Unit of measure  F Fahrenheit  C Centigrade VSORRESU

Method VSLOC  PO Oral  R Rectal  A Axillary  E Ear  O Other



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 11  
Page 5 of 6

## ELECTROCARDIOGRAM

NOT DONE  Not Entered In Database

Electrocardiogram date \_\_\_\_\_ / \_\_\_\_\_ /  
MM DD YY

Electrocardiogram result  <sub>12</sub> Acceptable  <sub>13</sub> Not Acceptable

NOTE: Any clinically relevant change from Visit 1 (baseline) ECG must be recorded on the Pre-existing Conditions and Adverse Events page. Note non-relevant abnormalities in the ECG Comments section below.

## COMMENTS : NON-RELEVANT ECG ABNORMALITIES

NO COMMENTS  Not Entered In Database

Print legibly and do not use abbreviations or symbols.

Not Entered In Database

---

---

---

---

---

---

---

---

---

---

---

---

---



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 11  
Page 6 of 6

**COMMENTS : VISIT**

NO COMMENTS  **Not Entered In Database**

Comments should address any clinical report form items that require further explanation. Repeating information from the clinical report form is discouraged.

Comment on all clinically significant lab values that are outside a clinically accepted reference range or clinically significant values that differ importantly from previous values.

If the patient is ending participation in the study at this visit, enter only comments that apply to this visit; then complete the Patient Summary and Study Summary Comments pages.

Print legibly and do not use abbreviations or symbols.

**Not Entered In Database**

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

The information reported for this visit is accurate and complete.

**Not Entered In Database**

**Not Entered In Database**

---

Signature

---

MM / DD / YY



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

VISIT  
VISITNUM

Telephone Visit Visit 11t  
Page 1 of 2

## PATIENT AND VISIT IDENTIFICATION

Patient initials

Not Entered In Database

First      Middle      Last

--STDTC    --DTC

Visit (telephone) date

\_\_\_\_ / \_\_\_\_ / \_\_\_\_  
MM      DD      YY



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Telephone Visit   Visit 11t  
Page 2 of 2

**NEUROPSYCHIATRIC INVENTORY - REVISED (NPI-X)** QSCAT

INFORMATION NOT OBTAINED  Not Entered In Database

Clinician's initials	<span style="font-size: small;">Not Entered In Database</span>		
	First	Middle	Last

The screening question (from worksheet) is asked of the caregiver to determine if the behavioral change is present or absent in the patient. If the answer to the screening question is negative (NO) or if the question is not applicable to the patient, circle the appropriate response (Not Applicable [96] or Absent [0]) and proceed to the next screening question without asking the subquestions to determine frequency, severity, and distress.

	Item	Not		Frequency	Severity	Distress
		Applicable	Absent			
<b>QSSCAT</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>
A.	Delusions	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5
<b>QSSCAT</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>
B.	Hallucinations	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5
<b>QSSCAT</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>
C.	Agitation/Agression	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5
<b>QSSCAT</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>
D.	Depression/ Dysphoria	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5
<b>QSSCAT</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>
E.	Anxiety	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5
<b>QSSCAT</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>
F.	Euphoria/Elation	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5
<b>QSSCAT</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>
G.	Apathy/ Indifference	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5
<b>QSSCAT</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>
H.	Disinhibition	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5
<b>QSSCAT</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>
I.	Irritability/Lability	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5
<b>QSSCAT</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>
J.	Aberrant Motor Behavior	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5
<b>QSSCAT</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>
K.	Night-Time Behavior	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5
<b>QSSCAT</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>	<b>QTESTCD</b>	<b>QSORRES</b>
L.	Appetite/Eating Change	96	0	1 2 3 4	1 2 3	0 1 2 3 4 5

©1994 Jeffrey L. Cummings

DS1609  
PRINTED IN USA  
August 22, 1996  
© Eli Lilly and Co.

QS570

Distribution: White and Yellow copies – Sponsor  
Bottom copy - Investigator

COPYRIGHT© 2006 Eli Lilly and Co.



## PATIENT AND VISIT IDENTIFICATION

Patient initials **Not Entered In Database**

First \_\_\_\_\_ Middle \_\_\_\_\_ Last \_\_\_\_\_

Visit date **--STDTC --DTC**  
\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_  
MM DD YY

## STUDY DRUG : COMPLIANCE

INFORMATION NOT OBTAINED  **Not Entered In Database**

Since the previous visit, on how many days was the patient unable to complete the therapy? **Not Entered In Database**  
\_\_\_\_\_ days

## STUDY DRUG : DAILY PRESCRIBED DOSAGE

For this visit interval, record the number of patches (25-cm<sup>2</sup> and 50-cm<sup>2</sup> patches) that the patient is to wear per day.

Number of 25-cm<sup>2</sup> patches prescribed/day **Not Entered In Database**  
\_\_\_\_\_ 25-cm<sup>2</sup> patches

Number of 50-cm<sup>2</sup> patches prescribed/day **Not Entered In Database**  
\_\_\_\_\_ 50-cm<sup>2</sup> patches

## REMINDER

On the Pre-existing Conditions and Study Adverse Events page, record new events that occurred since the previous visit and re-evaluate any on-going conditions or events.

On the Concomitant Medication page, record new medications the patient has taken since the previous visit and record a stop date for any medication the patient is no longer taking.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 12  
Page 2 of 9

**QSCAT**

**ALZHEIMER'S DISEASE ASSESSMENT SCALE : COGNITIVE with ATTENTION/  
CONCENTRATION TASKS**

INFORMATION NOT OBTAINED  **Not Entered In Database**

Clinician's initials	<b>Not Entered In Database</b>		
	First	Middle	Last

<b>QTESTCD</b>	1. Word Recall Task	(max = 10)	<b>QSORRES</b>
<b>QTESTCD</b>	2. Naming Objects and Fingers (refer to 5 categories in manual)	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	3. Delayed Word Recall	(max = 10)	<b>QSORRES</b>
<b>QTESTCD</b>	4. Commands	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	5. Constructional Praxis	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	6. Ideational Praxis	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	7. Orientation	(max = 8)	<b>QSORRES</b>
<b>QTESTCD</b>	8. Word Recognition	(max = 12)	<b>QSORRES</b>
<b>QTESTCD</b>	9. Attention/Visual Search Task	(max = 40)	<b>QSORRES</b>
<b>QTESTCD</b>	10. Maze Solution	(max = 240)	<b>QSORRES</b> (seconds)
<b>QTESTCD</b>	11. Spoken Language Ability	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	12. Comprehension of Spoken Language	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	13. Word Finding Difficulty in Spontaneous Speech	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	14. Recall of Test Instructions	(max = 5)	<b>QSORRES</b>

© Reprinted with permission.  
*American Journal of Psychiatry* 1984;141:1356-64.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 12  
Page 3 of 9

**CLINICIAN'S INTERVIEW-BASED IMPRESSION OF CHANGE (CIBIC+)**

**QSCAT**

INFORMATION NOT OBTAINED  **Not Entered In Database**

Clinician's initials	<b>Not Entered In Database</b>		
	First	Middle	Last

**QSTESTCD**

Check one box to indicate the extent of change, if any, observed since the initial baseline interview.

**QSORRES**  <sub>1</sub> Marked improvement

<sub>2</sub> Moderate improvement

<sub>3</sub> Minimal improvement

<sub>4</sub> No change

<sub>5</sub> Minimal worsening

<sub>6</sub> Moderate worsening

<sub>7</sub> Marked worsening

The clinical interview-based impression of change scale in this study is from a pilot instrument, the Clinical Global Impression of Change, developed and currently undergoing validity studies by the National Institute on Aging Alzheimer's Disease Study Units Program (1 U01 AG10483; Leon Thal, Principal Investigator), and is in the public domain.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 12  
Page 4 of 9

**NEUROPSYCHIATRIC INVENTORY - REVISED (NPI-X)** QSCAT

INFORMATION NOT OBTAINED  Not Entered In Database

Clinician's initials	Not Entered In Database		
	First	Middle	Last

The screening question (from worksheet) is asked of the caregiver to determine if the behavioral change is present or absent in the patient. If the answer to the screening question is negative (NO) or if the question is not applicable to the patient, circle the appropriate response (Not Applicable [96] or Absent [0]) and proceed to the next screening question without asking the subquestions to determine frequency, severity, and distress.

	Item	Not		Frequency	Severity	Distress					
		Applicable	Absent			QSORRES		QTESTCD		QSORRES	
QSSCAT	QTESTCD					1	2	3	4	1	2
QSSCAT	QTESTCD	A.	Delusions	96	0					0	1
QSSCAT	QTESTCD	B.	Hallucinations	96	0					1	2
QSSCAT	QTESTCD	C.	Agitation/Agression	96	0					2	3
QSSCAT	QTESTCD	D.	Depression/ Dysphoria	96	0					3	4
QSSCAT	QTESTCD	E.	Anxiety	96	0					4	5
QSSCAT	QTESTCD	F.	Euphoria/Elation	96	0					0	1
QSSCAT	QTESTCD	G.	Apathy/ Indifference	96	0					2	3
QSSCAT	QTESTCD	H.	Disinhibition	96	0					3	4
QSSCAT	QTESTCD	I.	Irritability/Lability	96	0					4	5
QSSCAT	QTESTCD	J.	Aberrant Motor Behavior	96	0					0	1
QSSCAT	QTESTCD	K.	Night-Time Behavior	96	0					2	3
QSSCAT	QTESTCD	L.	Appetite/Eating Change	96	0					3	4

©1994 Jeffrey L. Cummings

DS1609  
PRINTED IN USA  
August 22, 1996  
© Eli Lilly and Co.

QS570

Distribution: White and Yellow copies – Sponsor  
Bottom copy - Investigator

COPYRIGHT© 2006 Eli Lilly and Co.




## DISABILITY ASSESSMENT FOR DEMENTIA (DAD) QSCAT

INFORMATION NOT OBTAINED  Not Entered In Database

Clinician's initials	Not Entered In Database		
	First	Middle	Last

During the past two weeks, did the patient without help or reminder:



### QSSCAT

### HYGIENE

SCORING: Yes = 1 No = 0 Not Applicable = 96

QTESTCD	1. Undertake to wash himself/herself or to take a bath or a shower			QSORES
QTESTCD	2. Undertake to brush his/her teeth or care for his/her dentures			QSORES
QTESTCD	3. Decide to care for his/her hair (wash and comb)			QSORES
QTESTCD	4. Prepare the water, towels, and soap for washing, taking a bath, or a shower			QSORES
QTESTCD	5. Wash and dry completely all parts of his/her body safely			QSORES
QTESTCD	6. Brush his/her teeth or care for his/her dentures appropriately			QSORES
QTESTCD	7. Care for his/her hair (wash and comb)			QSORES

### DRESSING QSSCAT

QTESTCD	8. Undertake to dress himself/herself			QSORES
QTESTCD	9. Choose appropriate clothing (with regard to the occasion, neatness, the weather, and color combination)			QSORES
QTESTCD	10. Dress himself/herself in the appropriate order (undergarments, pant/dress, shoes)			QSORES
QTESTCD	11. Dress himself/herself completely			QSORES
QTESTCD	12. Undress himself/herself completely			QSORES

### CONTINENCE QSSCAT

QTESTCD	13. Decide to use the toilet at appropriate times			QSORES
QTESTCD	14. Use the toilet without "accidents"			QSORES

### EATING QSSCAT


QTESTCD	15. Decide that he/she needs to eat			QSORES
QTESTCD	16. Choose appropriate utensils and seasonings when eating			QSORES
QTESTCD	17. Eat his/her meals at a normal pace and with appropriate manners			QSORES

### MEAL PREPARATION QSSCAT

QTESTCD	18. Undertake to prepare a light meal or snack for himself/herself			QSORES
QTESTCD	19. Adequately plan a light meal or snack (ingredients, cookware)			QSORES
QTESTCD	20. Prepare or cook a light meal or a snack safely			QSORES



## DISABILITY ASSESSMENT FOR DEMENTIA (DAD)



QSSCAT		SCORING: Yes = 1   No = 0   Not Applicable = 96			
<b>TELEPHONING</b>					
QSTESTCD	21.	Attempt to telephone someone at a suitable time			QSORRES
QSTESTCD	22.	Find and dial a telephone number correctly			QSORRES
QSTESTCD	23.	Carry out an appropriate telephone conversation			QSORRES
QSTESTCD	24.	Write and convey a telephone message adequately			QSORRES
<b>GOING ON AN OUTING</b> QSSCAT					
QSTESTCD	25.	Undertake to go out (walk, visit, shop) at an appropriate time			QSORRES
QSTESTCD	26.	Adequately organize an outing with respect to transportation, keys, destination, weather, necessary money, shopping list			QSORRES
QSTESTCD	27.	Go out and reach a familiar destination without getting lost			QSORRES
QSTESTCD	28.	Safely take the adequate mode of transportation (car, bus, taxi)			QSORRES
QSTESTCD	29.	Return from the store with the appropriate items			QSORRES
<b>FINANCE AND CORRESPONDENCE</b> QSSCAT					
QSTESTCD	30.	Show an interest in his/her personal affairs such as his/her finances and written correspondence			QSORRES
QSTESTCD	31.	Organize his/her finances to pay his/her bills (cheques, bankbook, bills)			QSORRES
QSTESTCD	32.	Adequately organize his/her correspondence with respect to stationery, address, stamps			QSORRES
QSTESTCD	33.	Handle adequately his/her money (make change)			QSORRES
<b>MEDICATIONS</b> QSSCAT					
QSTESTCD	34.	Decide to take his/her medications at the correct time			QSORRES
QSTESTCD	35.	Take his/her medications as prescribed (according to the right dosage)			QSORRES
<b>LEISURE AND HOUSEWORK</b> QSSCAT					
QSTESTCD	36.	Show an interest in leisure activity(ies)			QSORRES
QSTESTCD	37.	Take an interest in household chores that he/she used to perform in the past			QSORRES
QSTESTCD	38.	Plan and organize adequately household chores that he/she used to perform in the past			QSORRES
QSTESTCD	39.	Complete household chores adequately as he/she used to perform in the past			QSORRES
QSTESTCD	40.	Stay safely at home by himself/herself when needed			QSORRES



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 12  
Page 7 of 9

## WEIGHT

VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Measure with shoes off. Round up or down to the nearest tenth kilogram or tenth pound.

Weight VSORRES  kg Kilogram  lb Pound  
VSORRES

## VITAL SIGNS : HEART RATE AND BLOOD PRESSURE

INFORMATION NOT OBTAINED  Not Entered In Database

Position
SU = Supine
ST = Standing

NOTE: Blood pressure and pulse must be taken after the patient has been lying down for 5 minutes (supine) and after standing for 1 minute (standing) and 3 minutes.

VSTPTNUM VSPOS

VTESTCD

(DNDE) Reference Time	Timing Code	Position	Heart Rate (bpm)	Blood Pressure (mmHg) Systolic/Diastolic
0. 5 minutes	815	SU	VSORRESU VSORRES	/
1. 1 minute	816	ST		/ VSORRESU VSORRES
2. 3 minutes	817	ST		VSTESTCD VSORRESU/ VSORRES

## VITAL SIGNS : TEMPERATURE VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Temperature VSORRES .

Unit of measure  F Fahrenheit  C Centigrade VSORRESU

Method VSLOC  PO Oral  R Rectal  A Axillary  E Ear  O Other



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 12  
Page 8 of 9

## ELECTROCARDIOGRAM

NOT DONE  Not Entered In Database

Electrocardiogram date \_\_\_\_\_ / \_\_\_\_\_ /  
MM DD YY

Electrocardiogram result  <sub>12</sub> Acceptable  <sub>13</sub> Not Acceptable

NOTE: Any clinically relevant change from Visit 1 (baseline) ECG must be recorded on the Pre-existing Conditions and Adverse Events page. Note non-relevant abnormalities in the ECG Comments section below.

## COMMENTS : NON-RELEVANT ECG ABNORMALITIES

NO COMMENTS  Not Entered In Database

Print legibly and do not use abbreviations or symbols.

Not Entered In Database

---

---

---

---

---

---

---

---

---

---

---

---

---

---



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 12  
Page 9 of 9

**COMMENTS : VISIT**

NO COMMENTS  Not Entered In Database

Comments should address any clinical report form items that require further explanation. Repeating information from the clinical report form is discouraged.

Comment on all clinically significant lab values that are outside a clinically accepted reference range or clinically significant values that differ importantly from previous values.

If the patient is ending participation in the study at this visit, enter only comments that apply to this visit; then complete the Patient Summary and Study Summary Comments pages.

Print legibly and do not use abbreviations or symbols.

Not Entered In Database

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

The information reported for this visit is accurate and complete.

Not Entered In Database

Not Entered In Database

---

Signature

---

MM / DD / YY



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

VISIT  
VISITNUM  
Visit 13  
Page 1 of 9

## PATIENT AND VISIT IDENTIFICATION

Patient initials **Not Entered In Database**  

---

First \_\_\_\_\_ Middle \_\_\_\_\_ Last \_\_\_\_\_

Visit date **-STDTC** **--DTC**  

---

MM / DD / YY

## STUDY DRUG : COMPLIANCE

INFORMATION NOT OBTAINED  **Not Entered In Database**

Since the previous visit, on how many days was the patient unable to complete the therapy? **Not Entered In Database**  

---

days

## REMINDER

On the Pre-existing Conditions and Study Adverse Events page, record new events that occurred since the previous visit and re-evaluate any on-going conditions or events.

On the Concomitant Medication page, record new medications the patient has taken since the previous visit and record a stop date for any medication the patient is no longer taking.

A physical examination must be performed at this visit. Any clinically significant abnormalities must be listed on the Pre-existing Conditions and Study Adverse Events page.



## EXTRAPYRAMIDAL FINDINGS

INFORMATION NOT OBTAINED  Not Entered In Database

1. Masked facies Not Entered In Database

- 0 None
- 1 Mild
- 2 Moderate
- 3 Severe

2. Rigidity of upper extremity Not Entered In Database

- 0 None
- 1 Mild
- 2 Moderate
- 3 Severe

3. Essential tremor Not Entered In Database

- 0 None
- 1 Mild
- 2 Moderate
- 3 Severe

4. Ambulation Not Entered In Database

How long did it take the patient to walk 25 yards? \_\_\_\_\_  
seconds



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 13  
Page 3 of 9

**NEUROPSYCHIATRIC INVENTORY - REVISED (NPI-X)** QSCAT

INFORMATION NOT OBTAINED  Not Entered In Database

Clinician's initials	Not Entered In Database		
	First	Middle	Last

The screening question (from worksheet) is asked of the caregiver to determine if the behavioral change is present or absent in the patient. If the answer to the screening question is negative (NO) or if the question is not applicable to the patient, circle the appropriate response (Not Applicable [96] or Absent [0]) and proceed to the next screening question without asking the subquestions to determine frequency, severity, and distress.

	Item	Not		Frequency	Severity	Distress					
		Applicable	Absent			QSORRES		QTESTCD		QSORRES	
QSSCAT	QTESTCD					1	2	3	4	1	2
QSSCAT	QTESTCD	A.	Delusions	96	0					0	1
QSSCAT	QTESTCD	B.	Hallucinations	96	0					1	2
QSSCAT	QTESTCD	C.	Agitation/Agression	96	0					2	3
QSSCAT	QTESTCD	D.	Depression/ Dysphoria	96	0					3	4
QSSCAT	QTESTCD	E.	Anxiety	96	0					4	5
QSSCAT	QTESTCD	F.	Euphoria/Elation	96	0					0	1
QSSCAT	QTESTCD	G.	Apathy/ Indifference	96	0					2	3
QSSCAT	QTESTCD	H.	Disinhibition	96	0					3	4
QSSCAT	QTESTCD	I.	Irritability/Lability	96	0					4	5
QSSCAT	QTESTCD	J.	Aberrant Motor Behavior	96	0					0	1
QSSCAT	QTESTCD	K.	Night-Time Behavior	96	0					2	3
QSSCAT	QTESTCD	L.	Appetite/Eating Change	96	0					3	4

©1994 Jeffrey L. Cummings

DS1609  
PRINTED IN USA  
August 22, 1996  
© Eli Lilly and Co.

QS570

Distribution: White and Yellow copies – Sponsor  
Bottom copy - Investigator

COPYRIGHT© 2006 Eli Lilly and Co.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 13  
Page 4 of 9

## WEIGHT

VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Measure with shoes off. Round up or down to the nearest tenth kilogram or tenth pound.

Weight VSORRES  kg Kilogram  lb Pound  
VSORRES

## VITAL SIGNS : HEART RATE AND BLOOD PRESSURE

INFORMATION NOT OBTAINED  Not Entered In Database

NOTE: Blood pressure and pulse must be taken after the patient has been lying down for 5 minutes (supine) and after standing for 1 minute (standing) and 3 minutes.

Position
SU = Supine
ST = Standing

VSTPTNUM VSPOS VTESTCD

(DNDE) Reference Time	Timing Code	Position	Heart Rate (bpm)	Blood Pressure (mmHg) Systolic/Diastolic
0. 5 minutes	815	SU	VSORRESU VSORRES	/
1. 1 minute	816	ST		/ VSORRESU VSORRES
2. 3 minutes	817	ST		VSTESTCD VSORRESU/ VSORRES

## VITAL SIGNS : TEMPERATURE VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Temperature VSORRES .

Unit of measure  F Fahrenheit  C Centigrade VSORRESU

Method VSLOC  PO Oral  R Rectal  A Axillary  E Ear  O Other



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 13  
Page 5 of 9

## ELECTROCARDIOGRAM

NOT DONE  Not Entered In Database

Electrocardiogram date \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_  
MM DD YY

Electrocardiogram result  <sub>12</sub> Acceptable  <sub>13</sub> Not Acceptable

NOTE: Any clinically relevant change from Visit 1 (baseline) ECG must be recorded on the Pre-existing Conditions and Adverse Events page. Note non-relevant abnormalities in the ECG Comments section below.

## COMMENTS : NON-RELEVANT ECG ABNORMALITIES

NO COMMENTS  Not Entered In Database

Print legibly and do not use abbreviations or symbols.

Not Entered In Database

---

---

---

---

---

---

---

---

---

---

---

---

---

---



## ACCEPTABILITY : CAREGIVER'S RESPONSE ABOUT THE PATCH

INFORMATION NOT OBTAINED  Not Entered In Database

The following question is to be answered by the caregiver.

Based on the experience of applying and wearing this patch, if the patient were prescribed a drug for Alzheimer's disease and was given the choice of this patch or an oral pill given twice daily (assume that both formulations are equally effective), would you (the caregiver):

Not Entered In Database

- 1 Insist that the patient receive an oral pill
- 2 Prefer that the patient receive an oral pill
- 3 Have no preference (neutral) for an oral or patch formulation
- 4 Prefer that the patient receive a patch
- 5 Insist that the patient receive a patch



## ACCEPTABILITY : CAREGIVER'S RESPONSE ABOUT THE PATCH

INFORMATION NOT OBTAINED  Not Entered In Database

The following questions are intended to be answered by the caregiver and address the patch's design and wearability. Focus only on the act of wearing and removing the transdermal patch. On each scale below, circle one number (do not circle on the scale between numbers) that best describes your feelings about the patch:

1. The appearance of the patch while being worn is acceptable:

Not Entered In Database



2. The size of the patch is acceptable:

Not Entered In Database



3. The patches were durable (eg, did not discolor, tear) while being worn:

Not Entered In Database



## STUDY DRUG THERAPY : DATE OF FINAL DOSE

EXENDTC

Date of final dose of study drug \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_  
MM DD YY



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 13  
Page 8 of 9

## PATIENT SUMMARY

Patient Initials **Not Entered In Database**  
First \_\_\_\_\_ Middle \_\_\_\_\_ Last \_\_\_\_\_

### CHECK ONE PRIMARY REASON FOR ENDING PARTICIPATION IN THE STUDY

DSTERM  <sub>1</sub> Protocol completed

**AESPID**

DSTERM  <sub>3</sub> Adverse event E \_\_\_\_\_

E Code

DSTERM  <sub>4</sub> Death\* E **AESPID**  
E Code

If # 4 is checked, enter date of death.

**DSSTDTC**

Date of Death \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_  
MM DD YY

DSTERM  <sub>8</sub> Lack of efficacy, patient/caregiver perception

DSTERM  <sub>9</sub> Lack of efficacy, physician perception

DSTERM  <sub>11</sub> Unable to contact patient (lost to follow-up)

DSDECOD  <sub>13</sub> Personal conflict or other patient/caregiver decision \_\_\_\_\_ **DSTERM**  
Specify

DSDECOD  <sub>22</sub> Physician decision \_\_\_\_\_ **DSTERM**  
Specify

DSTERM  <sub>14</sub> Protocol entry criteria not met \_\_\_\_\_ **SUPPDS.QVAL**  
Specify (Specify number from entry criteria checklist)

DSTERM  <sub>243</sub> Protocol violation

DSTERM  <sub>18</sub> Sponsor decision (study or patient discontinued by the Sponsor)

\* **Contact the Quintiles Drug Safety Unit immediately in event of death.** Obtain a copy of the autopsy report (if autopsy performed) or hospital discharge summary. Forward to Quintiles Drug Safety Unit as soon as possible. Explain circumstances of the death on the Study Summary Comments page.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 13  
Page 9 of 9

**COMMENTS : STUDY SUMMARY**

NO COMMENTS  **Not Entered In Database**

Repeating information from the clinical report form is discouraged. If the patient is ending participation in the study for any reason other than protocol complete (Reason 1 on Patient Summary page) give a brief description of the circumstances.

Enter comments below. Print legibly and do not use abbreviations or symbols.

**Not Entered In Database**

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

All information reported for this patient is accurate and complete.

**Not Entered In Database**

**Not Entered In Database**

---

Investigator Signature

---

MM / DD / YY



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

VISIT  
VISITNUM  
Visit 201  
Page 1 of 8

## PATIENT AND VISIT IDENTIFICATION

Patient initials **Not Entered In Database**  
First \_\_\_\_\_ Middle \_\_\_\_\_ Last \_\_\_\_\_  
  
Visit date **--STDTC**    **--DTC**  
\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_  
MM DD YY

### REMINDER

On the Pre-existing Conditions and Study Adverse Events page, record new events that occurred since the previous visit and re-evaluate any on-going conditions or events.

On the Concomitant Medication page, record new medications the patient has taken since the previous visit and record a stop date for any medication the patient is no longer taking.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 201  
Page 2 of 8

**QSCAT**

**ALZHEIMER'S DISEASE ASSESSMENT SCALE : COGNITIVE with ATTENTION/  
CONCENTRATION TASKS**

INFORMATION NOT OBTAINED  **Not Entered In Database**

Clinician's initials	<b>Not Entered In Database</b>		
	First	Middle	Last

<b>QTESTCD</b>	1. Word Recall Task	(max = 10)	<b>QSORRES</b>
<b>QTESTCD</b>	2. Naming Objects and Fingers (refer to 5 categories in manual)	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	3. Delayed Word Recall	(max = 10)	<b>QSORRES</b>
<b>QTESTCD</b>	4. Commands	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	5. Constructional Praxis	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	6. Ideational Praxis	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	7. Orientation	(max = 8)	<b>QSORRES</b>
<b>QTESTCD</b>	8. Word Recognition	(max = 12)	<b>QSORRES</b>
<b>QTESTCD</b>	9. Attention/Visual Search Task	(max = 40)	<b>QSORRES</b>
<b>QTESTCD</b>	10. Maze Solution	(max = 240)	<b>QSORRES</b> (seconds)
<b>QTESTCD</b>	11. Spoken Language Ability	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	12. Comprehension of Spoken Language	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	13. Word Finding Difficulty in Spontaneous Speech	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	14. Recall of Test Instructions	(max = 5)	<b>QSORRES</b>

© Reprinted with permission.  
*American Journal of Psychiatry* 1984;141:1356-64.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 201  
Page 3 of 8

**CLINICIAN'S INTERVIEW-BASED IMPRESSION OF CHANGE (CIBIC+)**

**QSCAT**

INFORMATION NOT OBTAINED  **Not Entered In Database**

Clinician's initials	<b>Not Entered In Database</b>		
	First	Middle	Last

**QSTESTCD** Check one box to indicate the extent of change, if any, observed since the initial baseline interview.

**QSORRES**  <sub>1</sub> Marked improvement

<sub>2</sub> Moderate improvement

<sub>3</sub> Minimal improvement

<sub>4</sub> No change

<sub>5</sub> Minimal worsening

<sub>6</sub> Moderate worsening

<sub>7</sub> Marked worsening

The clinical interview-based impression of change scale in this study is from a pilot instrument, the Clinical Global Impression of Change, developed and currently undergoing validity studies by the National Institute on Aging Alzheimer's Disease Study Units Program (1 U01 AG10483; Leon Thal, Principal Investigator), and is in the public domain.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 201  
Page 4 of 8

**NEUROPSYCHIATRIC INVENTORY - REVISED (NPI-X)** QSCAT

INFORMATION NOT OBTAINED  Not Entered In Database

Clinician's initials	<span style="background-color: #0070C0; color: white; padding: 2px 5px;">Not Entered In Database</span>		
	First	Middle	Last

The screening question (from worksheet) is asked of the caregiver to determine if the behavioral change is present or absent in the patient. If the answer to the screening question is negative (NO) or if the question is not applicable to the patient, circle the appropriate response (Not Applicable [96] or Absent [0]) and proceed to the next screening question without asking the subquestions to determine frequency, severity, and distress.

	Item	Not		Frequency	Severity	Distress					
		Applicable	Absent			QSORRES	QTESTCD	QSORRES	QTESTCD	QSORRES	QTESTCD
<b>QSSCAT</b>	<b>QTESTCD</b>										
A.	Delusions	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
<b>QSSCAT</b>	<b>QTESTCD</b>										
B.	Hallucinations	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
<b>QSSCAT</b>	<b>QTESTCD</b>										
C.	Agitation/Agression	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
<b>QSSCAT</b>	<b>QTESTCD</b>										
D.	Depression/ Dysphoria	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
<b>QSSCAT</b>	<b>QTESTCD</b>										
E.	Anxiety	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
<b>QSSCAT</b>	<b>QTESTCD</b>										
F.	Euphoria/Elation	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
<b>QSSCAT</b>	<b>QTESTCD</b>										
G.	Apathy/ Indifference	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
<b>QSSCAT</b>	<b>QTESTCD</b>										
H.	Disinhibition	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
<b>QSSCAT</b>	<b>QTESTCD</b>										
I.	Irritability/Lability	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
<b>QSSCAT</b>	<b>QTESTCD</b>										
J.	Aberrant Motor Behavior	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
<b>QSSCAT</b>	<b>QTESTCD</b>										
K.	Night-Time Behavior	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
<b>QSSCAT</b>	<b>QTESTCD</b>										
L.	Appetite/Eating Change	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				

©1994 Jeffrey L. Cummings

DS1609  
PRINTED IN USA  
August 22, 1996  
© Eli Lilly and Co.

QS570

Distribution: White and Yellow copies – Sponsor  
Bottom copy - Investigator

COPYRIGHT© 2006 Eli Lilly and Co.



## DISABILITY ASSESSMENT FOR DEMENTIA (DAD) QSCAT

INFORMATION NOT OBTAINED  Not Entered In Database

Clinician's initials	Not Entered In Database		
	First	Middle	Last

During the past two weeks, did the patient without help or reminder:



### QSSCAT

SCORING: Yes = 1 No = 0 Not Applicable = 96

#### HYGIENE

QTESTCD	1. Undertake to wash himself/herself or to take a bath or a shower			QSORES
QTESTCD	2. Undertake to brush his/her teeth or care for his/her dentures			QSORES
QTESTCD	3. Decide to care for his/her hair (wash and comb)			QSORES
QTESTCD	4. Prepare the water, towels, and soap for washing, taking a bath, or a shower			QSORES
QTESTCD	5. Wash and dry completely all parts of his/her body safely			QSORES
QTESTCD	6. Brush his/her teeth or care for his/her dentures appropriately			QSORES
QTESTCD	7. Care for his/her hair (wash and comb)			QSORES

#### DRESSING QSSCAT

QTESTCD	8. Undertake to dress himself/herself			QSORES
QTESTCD	9. Choose appropriate clothing (with regard to the occasion, neatness, the weather, and color combination)			QSORES
QTESTCD	10. Dress himself/herself in the appropriate order (undergarments, pant/dress, shoes)			QSORES
QTESTCD	11. Dress himself/herself completely			QSORES
QTESTCD	12. Undress himself/herself completely			QSORES

#### CONTINENCE QSSCAT

QTESTCD	13. Decide to use the toilet at appropriate times			QSORES
QTESTCD	14. Use the toilet without "accidents"			QSORES

#### EATING QSSCAT

QTESTCD	15. Decide that he/she needs to eat			QSORES
QTESTCD	16. Choose appropriate utensils and seasonings when eating			QSORES
QTESTCD	17. Eat his/her meals at a normal pace and with appropriate manners			QSORES

#### MEAL PREPARATION QSSCAT

QTESTCD	18. Undertake to prepare a light meal or snack for himself/herself			QSORES
QTESTCD	19. Adequately plan a light meal or snack (ingredients, cookware)			QSORES
QTESTCD	20. Prepare or cook a light meal or a snack safely			QSORES



## DISABILITY ASSESSMENT FOR DEMENTIA (DAD)



QSSCAT		SCORING: Yes = 1   No = 0   Not Applicable = 96			
<b>TELEPHONING</b>					
QSTESTCD	21.	Attempt to telephone someone at a suitable time			QSORRES
QSTESTCD	22.	Find and dial a telephone number correctly			QSORRES
QSTESTCD	23.	Carry out an appropriate telephone conversation			QSORRES
QSTESTCD	24.	Write and convey a telephone message adequately			QSORRES
<b>GOING ON AN OUTING</b>					
QSTESTCD	25.	Undertake to go out (walk, visit, shop) at an appropriate time			QSORRES
QSTESTCD	26.	Adequately organize an outing with respect to transportation, keys, destination, weather, necessary money, shopping list			QSORRES
QSTESTCD	27.	Go out and reach a familiar destination without getting lost			QSORRES
QSTESTCD	28.	Safely take the adequate mode of transportation (car, bus, taxi)			QSORRES
QSTESTCD	29.	Return from the store with the appropriate items			QSORRES
<b>FINANCE AND CORRESPONDENCE</b>					
QSTESTCD	30.	Show an interest in his/her personal affairs such as his/her finances and written correspondence			QSORRES
QSTESTCD	31.	Organize his/her finances to pay his/her bills (cheques, bankbook, bills)			QSORRES
QSTESTCD	32.	Adequately organize his/her correspondence with respect to stationery, address, stamps			QSORRES
QSTESTCD	33.	Handle adequately his/her money (make change)			QSORRES
<b>MEDICATIONS</b>					
QSTESTCD	34.	Decide to take his/her medications at the correct time			QSORRES
QSTESTCD	35.	Take his/her medications as prescribed (according to the right dosage)			QSORRES
<b>LEISURE AND HOUSEWORK</b>					
QSTESTCD	36.	Show an interest in leisure activity(ies)			QSORRES
QSTESTCD	37.	Take an interest in household chores that he/she used to perform in the past			QSORRES
QSTESTCD	38.	Plan and organize adequately household chores that he/she used to perform in the past			QSORRES
QSTESTCD	39.	Complete household chores adequately as he/she used to perform in the past			QSORRES
QSTESTCD	40.	Stay safely at home by himself/herself when needed			QSORRES



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 201  
Page 7 of 8

## VITAL SIGNS : HEART RATE AND BLOOD PRESSURE

INFORMATION NOT OBTAINED  Not Entered In Database

Position
SU = Supine
ST = Standing

NOTE: Blood pressure and pulse must be taken after the patient has been lying down for 5 minutes (supine) and after standing for 1 minute (standing) and 3 minutes.

VSTPTNUM

VSPOS

VTESTCD

(DNDE) Reference Time	Timing Code	Position	Heart Rate (bpm)	Blood Pressure (mmHg) Systolic/Diastolic
0. 5 minutes	815	SU	<span style="background-color: #FFFF00; border: 1px solid black; padding: 2px;">VSORRESU</span> <span style="background-color: #FFFF00; border: 1px solid black; padding: 2px;">VSORRES</span>	/
1. 1 minute	816	ST		/ <span style="background-color: #FFFF00; border: 1px solid black; padding: 2px;">VSORRESU</span> <span style="background-color: #FFFF00; border: 1px solid black; padding: 2px;">VSORRES</span>
2. 3 minutes	817	ST		<span style="background-color: #FFFF00; border: 1px solid black; padding: 2px;">VTESTCD</span> <span style="background-color: #FFFF00; border: 1px solid black; padding: 2px;">VSORRESU</span> <span style="background-color: #FFFF00; border: 1px solid black; padding: 2px;">VSORRES</span>

## VITAL SIGNS : TEMPERATURE VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Temperature

VSORRES

Unit of measure  <sub>F</sub> Fahrenheit  <sub>C</sub> Centigrade VSORRESU

Method VSLOC  <sub>PO</sub> Oral  <sub>R</sub> Rectal  <sub>A</sub> Axillary  <sub>E</sub> Ear  <sub>O</sub> Other



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Visit 201  
Page 8 of 8

**COMMENTS : STUDY SUMMARY**

NO COMMENTS  **Not Entered In Database**

Repeating information from the clinical report form is discouraged. If the patient is ending participation in the study for any reason other than protocol complete (Reason 1 on Patient Summary page) give a brief description of the circumstances.

Enter comments below. Print legibly and do not use abbreviations or symbols.

**Not Entered In Database**

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

All information reported for this patient is accurate and complete.

**Not Entered In Database**      **Not Entered In Database**

Investigator Signature \_\_\_\_\_ MM / DD / YY



## PATIENT AND VISIT IDENTIFICATION

Patient initials **Not Entered In Database**  
First \_\_\_\_\_ Middle \_\_\_\_\_ Last \_\_\_\_\_  
  
Visit date **-STDTC -DTC**  
\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_  
MM DD YY

### REMINDER

On the Pre-existing Conditions and Study Adverse Events page, record new events that occurred since the previous visit and re-evaluate any on-going conditions or events.

On the Concomitant Medication page, record new medications the patient has taken since the previous visit and record a stop date for any medication the patient is no longer taking.



## ADVERSE EVENT FOLLOW-UP

Not Entered In Database

1. Patient initials \_\_\_\_\_  
First \_\_\_\_\_ Middle \_\_\_\_\_ Last \_\_\_\_\_

AESPID

2. Primary event causing discontinuation \_\_\_\_\_  
(E \_\_\_\_ Code from  
Patient Summary page)

3. Check one PRIMARY reason for ending the ADVERSE EVENT follow-up period

Not Entered In Database

<sub>101</sub> Event resolved

Not Entered In Database

Date resolved \_\_\_\_/\_\_\_\_/\_\_\_\_  
MM DD YY

<sub>102</sub> Laboratory test result returned to acceptable range

<sub>11</sub> Patient is lost to follow-up

<sub>103</sub> Event or condition is stable and not expected to change

<sub>99</sub> Other \_\_\_\_\_

Specify

4. Check one patient outcome

Not Entered In Database

<sub>104</sub> No residual effect

<sub>105</sub> Impairment or disability

<sub>4</sub> Death\*

<sub>99</sub> Other \_\_\_\_\_

Specify

\* **Contact the Quintiles Drug Safety Unit immediately in event of death.** Obtain a copy of the autopsy report (if autopsy performed) or hospital discharge summary. Forward to Lilly as soon as possible. Explain circumstances of the death on the Adverse Event Follow-Up Comments page.



## **COMMENTS : STUDY SUMMARY**

NO COMMENTS  Not Entered In Database

Repeating information from the clinical report form is discouraged. If the patient is ending participation in the study for any reason other than protocol complete (Reason 1 on Patient Summary page) give a brief description of the circumstances.

Enter comments below. Print legibly and do not use abbreviations or symbols.

**Not Entered In Database**

All information reported for this patient is accurate and complete.

Not Entered In Database

---

Investigator Signature \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_  
MM DD YY



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Addendum Study - Early Termination Visit \_\_\_\_\_  
Page 1 of 1

**PROCEDURE : MRSI**

NOT DONE  Not Entered In Database

Date of MRSI      Not Entered In Database  
                        \_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_  
                        MM      DD      YY



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Addendum Study Visit 3  
Page 1 of 1

**PROCEDURE : MRSI**

NOT DONE  Not Entered In Database

Not Entered In Database

Date of MRSI    \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_  
                    MM        DD        YY



## PRE-EXISTING CONDITIONS AND STUDY ADVERSE EVENTS

NO CONDITIONS OR EVENTS

**Not Entered In Database**

- List all pre-existing conditions or symptoms present at entry to study.
- List all clinically relevant abnormalities found on the physical exam, ECG, chest x-ray, or Holter monitor.
- List all events that occur during study.

\*Serious Codes

1 = Fatal
2 = Life-threatening
3 = Permanently disabling
4 = Hospitalization
5 = Congenital anomaly
6 = Cancer
7 = Overdose
8 = Other reason

\* If Event is serious,  
notify the Quintiles Drug  
Safety Unit immediately.

Severity Codes

1 = Mild
2 = Moderate
3 = Severe

Evaluate when  
event stops or at  
end of patient's  
participation in  
study

Code	Description of Condition/Event COSTART Class Term	Onset Date MM DD YY		Serious* during trial?	Severity of Condition/Event Record the onset visit number and maximum severity at that visit. Then record the maximum severity in each subsequent visit <b>ONLY</b> if there is a change in severity.		Relationship to Study Drug <b>AEREL</b>
		Stop Date MM DD YY	Visit Number		Severity	--SEV	
-SPID E01	-TERM <b>Not Entered In Database</b>			<input type="checkbox"/> N No If Yes, enter Serious Code(s) <b>AESEN</b>	Visit Number		1 = None 2 = Remote (Unlikely) 3 = Possible 4 = Probable
E02		-STDTC --ENDTC		<input type="checkbox"/> N No If Yes, enter Serious Code(s)	Visit Number		1 = None 2 = Remote (Unlikely) 3 = Possible 4 = Probable
E03				<input type="checkbox"/> N No If Yes, enter Serious Code(s)	Visit Number		1 = None 2 = Remote (Unlikely) 3 = Possible 4 = Probable
E04				<input type="checkbox"/> N No If Yes, enter Serious Code(s)	Visit Number		1 = None 2 = Remote (Unlikely) 3 = Possible 4 = Probable
E05				<input type="checkbox"/> N No If Yes, enter Serious Code(s)	Visit Number		1 = None 2 = Remote (Unlikely) 3 = Possible 4 = Probable
E06				<input type="checkbox"/> N No If Yes, enter Serious Code(s)	Visit Number		1 = None 2 = Remote (Unlikely) 3 = Possible 4 = Probable
E07				<input type="checkbox"/> N No If Yes, enter Serious Code(s)	Visit Number		1 = None 2 = Remote (Unlikely) 3 = Possible 4 = Probable



## PRE-EXISTING CONDITIONS AND STUDY ADVERSE EVENTS

Continue listing all pre-existing conditions and events that occur during the study.

*Serious Codes	
AESDTH	1 = Fatal
	2 = Life-threatening
AESLIFE	
AESDISAB	3 = Permanently disabling
AESHOSP	4 = Hospitalization
AESCONG	5 = Congenital anomaly
	6 = Cancer
AESCAN	
AESMIE	7 = Overdose
AESOTH	8 = Other reason

\* If Event is serious, notify the Quintiles Drug Safety Unit immediately.

Severity Codes	
1	Mild
2	Moderate
3	Severe

Evaluate when event stops or at end of patient's participation in study

Code	Description of Condition/Event COSTART Class Term	Onset Date MM DD YY		Serious* during trial?	Severity of Condition/Event Record the onset visit number and maximum severity at that visit. Then record the maximum severity in each subsequent visit ONLY if there is a change in severity.		Relationship to Study Drug AEREL
		Stop Date MM DD YY	Visit Number		Severity	AESEV	
-SPID E08	-TERM -DECOD			<input type="checkbox"/> N No If Yes, enter Serious Code(s)	Visit Number		1 = None 2 = Remote (Unlikely) 3 = Possible 4 = Probable
E09		-STDTC		<input type="checkbox"/> N No If Yes, enter Serious Code(s)	Visit Number		1 = None 2 = Remote (Unlikely) 3 = Possible 4 = Probable
E10		-ENDTC		<input type="checkbox"/> N No If Yes, enter Serious Code(s)	Visit Number		1 = None 2 = Remote (Unlikely) 3 = Possible 4 = Probable
E11				<input type="checkbox"/> N No If Yes, enter Serious Code(s)	Visit Number		1 = None 2 = Remote (Unlikely) 3 = Possible 4 = Probable
E12				<input type="checkbox"/> N No If Yes, enter Serious Code(s)	Visit Number		1 = None 2 = Remote (Unlikely) 3 = Possible 4 = Probable
E13				<input type="checkbox"/> N No If Yes, enter Serious Code(s)	Visit Number		1 = None 2 = Remote (Unlikely) 3 = Possible 4 = Probable
E14				<input type="checkbox"/> N No If Yes, enter Serious Code(s)	Visit Number		1 = None 2 = Remote (Unlikely) 3 = Possible 4 = Probable



## Clinical Report Form

Safety and Efficacy of the Xanomeline

Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease

H2Q-MC-LZZT

VISITNUM

Visit

\_\_\_\_\_  
Page 1 \_\_\_\_ of 1

## PRE-EXISTING CONDITIONS AND STUDY ADVERSE EVENTS

Continue listing all pre-existing conditions and events that occur during the study.

*Serious Codes	
AESDTH	1 = Fatal
	2 = Life-threatening
AESLIFE	
AESDISAB	3 = Permanently disabling
AESHOSP	4 = Hospitalization
AESCONG	5 = Congenital anomaly
	6 = Cancer
AESCAN	
AESMIE	7 = Overdose
AESOTH	8 = Other reason

\* If Event is serious,  
notify the Quintiles Drug  
Safety Unit immediately.

Severity Codes	
1	Mild
2	Moderate
3	Severe

Evaluate when event stops or at end of patient's participation in study

Code	Description of Condition/Event  COSTART Class Term	Onset Date MM DD YY		Serious* during trial?	Severity of Condition/Event		Relationship to Study Drug  <b>AEREL</b>
		Stop Date MM DD YY	Visit Number		Severity	AESEV	
-SPID	E_ -TERM -DECOD			<input type="checkbox"/> N If Yes, enter Serious Code(s)			1 = None 2 = Remote (Unlikely) 3 = Possible 4 = Probable
E_		-STDTC		<input type="checkbox"/> N If Yes, enter Serious Code(s)			1 = None 2 = Remote (Unlikely) 3 = Possible 4 = Probable
E_		--ENDTC		<input type="checkbox"/> N If Yes, enter Serious Code(s)			1 = None 2 = Remote (Unlikely) 3 = Possible 4 = Probable
E_				<input type="checkbox"/> N If Yes, enter Serious Code(s)			1 = None 2 = Remote (Unlikely) 3 = Possible 4 = Probable
E_				<input type="checkbox"/> N If Yes, enter Serious Code(s)			1 = None 2 = Remote (Unlikely) 3 = Possible 4 = Probable
E_				<input type="checkbox"/> N If Yes, enter Serious Code(s)			1 = None 2 = Remote (Unlikely) 3 = Possible 4 = Probable
E_				<input type="checkbox"/> N If Yes, enter Serious Code(s)			1 = None 2 = Remote (Unlikely) 3 = Possible 4 = Probable
E_				<input type="checkbox"/> N If Yes, enter Serious Code(s)			1 = None 2 = Remote (Unlikely) 3 = Possible 4 = Probable



Clinical Report Form  
 Safety and Efficacy of the Xanomeline  
 Transdermal Therapeutic System (TTS) in  
 Patients with Mild to Moderate Alzheimer's Disease  
 H2Q-MC-LZZT

VISIT  
 VISITNUM

Visit \_\_\_\_\_  
 Page 1 of 1

## CONCOMITANT MEDICATION

NO CONCOMITANT MEDICATIONS

**Not Entered In Database**

Enter all medications, other than study drug, the patient is taking at **entry** and **during the study**.

### Indication for Use (IFU)

Enter code from patient's Pre-existing Conditions and Study Adverse Events page.

E\_\_ = Pre-Existing Condition or Event (eg, E01)  
 or

X1 = Primary study condition

X2 = Prophylaxis or non-therapeutic use

**CMTRT**

Brand or Trade Name (Use generic if brand or trade name unknown)	CMDOSE Dose	Unit	Fre- quency	Route	Start Date MM DD YY	Stop Date MM DD YY	IFU
0.	CMDOSU	CMDOSFRQ	CMRCUTE				CMINDC
1.					CMSTDTC		CMENDTC
2.							
3.							
4.							
5.							
6.							
7.							
8.							
9.							
10.							
11.							



Clinical Report Form  
 Safety and Efficacy of the Xanomeline  
 Transdermal Therapeutic System (TTS) in  
 Patients with Mild to Moderate Alzheimer's Disease  
 H2Q-MC-LZZT

VISIT  
 VISITNUM

Visit   
 Page 1 a of 1

## CONCOMITANT MEDICATION

Continue entering all medications, other than study drug,  
 the patient is taking at **entry** and **during the study**.

### Indication for Use (IFU)

Enter code from patient's Pre-existing  
 Conditions and Study Adverse Events  
 page.

E\_\_ = Pre-Existing Condition or Event  
 (eg, E01)  
 or

X1 = Primary study condition

X2 = Prophylaxis or non-therapeutic  
 use

### CMTRT

Brand or Trade Name (Use generic if brand or trade name unknown)	CMDOSE Dose	Unit	Fre- quency	Route	Start Date			Stop Date			IFU
					MM	DD	YY	MM	DD	YY	
12.		CMDOSU	CMDOSFRQ	CMRCUTE							CMINDC
13.								CMSTDTC			CMENDTC
14.											
15.											
16.											
17.											
18.											
19.											
20.											
21.											
22.											
23.											



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

VISIT  
VISITNUM

Visit   
Page 1  of 1

## CONCOMITANT MEDICATION

Continue entering all medications, other than study drug, the patient is taking at **entry** and **during the study**.

### Indication for Use (IFU)

Enter code from patient's Pre-existing Conditions and Study Adverse Events page.

E\_\_ = Pre-Existing Condition or Event (eg, E01)  
or

X1 = Primary study condition

X2 = Prophylaxis or non-therapeutic use

**CMTRT**

Brand or Trade Name (Use generic if brand or trade name unknown)	CMDOSE Dose	Unit	Fre- quency	Route	Start Date			Stop Date			IFU
					MM	DD	YY	MM	DD	YY	
											<b>CMINDC</b>



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

DOSING CHANGE Visit \_\_\_\_\_  
Page 1 of 1

**STUDY DRUG DOSE CHANGE : START DATE (12-14 hour patch)**

Not Entered In Database

Start date of the new study drug dosing regimen (12-14 hour patch) \_\_\_\_/\_\_\_\_/\_\_\_\_  
MM DD YY



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

VISIT  
VISITNUM

Early Termination Visit   
Page 1 of 13

## PATIENT AND VISIT IDENTIFICATION

Not Entered In Database

Patient initials \_\_\_\_\_  
First \_\_\_\_\_ Middle \_\_\_\_\_ Last \_\_\_\_\_

-STDTC -DTC

Visit date \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_  
MM DD YY

## STUDY DRUG : COMPLIANCE

INFORMATION NOT OBTAINED  Not Entered In Database

Since the previous visit, on how many days was  
the patient unable to complete the therapy?

\_\_\_\_\_ days

## REMINDER

On the Pre-existing Conditions and Study Adverse Events page, record new events that occurred since the previous visit and re-evaluate any on-going conditions or events.

On the Concomitant Medication page, record new medications the patient has taken since the previous visit and record a stop date for any medication the patient is no longer taking.

A physical examination must be performed at this visit. Any clinically significant abnormalities must be listed on the Pre-existing Conditions and Study Adverse Events page.



## EXTRAPYRAMIDAL FINDINGS

INFORMATION NOT OBTAINED  Not Entered In Database

1. Masked facies Not Entered In Database

- 0 None
- 1 Mild
- 2 Moderate
- 3 Severe

2. Rigidity of upper extremity Not Entered In Database

- 0 None
- 1 Mild
- 2 Moderate
- 3 Severe

3. Essential tremor Not Entered In Database

- 0 None
- 1 Mild
- 2 Moderate
- 3 Severe

4. Ambulation Not Entered In Database

How long did it take the patient to walk 25 yards? \_\_\_\_\_  
seconds



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Early Termination Visit   
Page 3 of 13

**QSCAT**

**ALZHEIMER'S DISEASE ASSESSMENT SCALE : COGNITIVE with ATTENTION/  
CONCENTRATION TASKS**

INFORMATION NOT OBTAINED  **Not Entered In Database**

Clinician's initials	<b>Not Entered In Database</b>		
	First	Middle	Last

<b>QTESTCD</b>	1. Word Recall Task	(max = 10)	<b>QSORRES</b>
<b>QTESTCD</b>	2. Naming Objects and Fingers (refer to 5 categories in manual)	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	3. Delayed Word Recall	(max = 10)	<b>QSORRES</b>
<b>QTESTCD</b>	4. Commands	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	5. Constructional Praxis	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	6. Ideational Praxis	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	7. Orientation	(max = 8)	<b>QSORRES</b>
<b>QTESTCD</b>	8. Word Recognition	(max = 12)	<b>QSORRES</b>
<b>QTESTCD</b>	9. Attention/Visual Search Task	(max = 40)	<b>QSORRES</b>
<b>QTESTCD</b>	10. Maze Solution	(max = 240)	<b>QSORRES</b> (seconds)
<b>QTESTCD</b>	11. Spoken Language Ability	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	12. Comprehension of Spoken Language	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	13. Word Finding Difficulty in Spontaneous Speech	(max = 5)	<b>QSORRES</b>
<b>QTESTCD</b>	14. Recall of Test Instructions	(max = 5)	<b>QSORRES</b>

© Reprinted with permission.  
*American Journal of Psychiatry* 1984;141:1356-64.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Early Termination Visit   
Page 4 of 13

**CLINICIAN'S INTERVIEW-BASED IMPRESSION OF CHANGE (CIBIC+)** **QSCAT**

INFORMATION NOT OBTAINED  **Not Entered In Database**

Clinician's initials	<b>Not Entered In Database</b>		
	First	Middle	Last

**QSTESTCD** Check one box to indicate the extent of change, if any, observed since the initial baseline interview.

- QSORRES**  <sub>1</sub> Marked improvement  
 <sub>2</sub> Moderate improvement  
 <sub>3</sub> Minimal improvement  
 <sub>4</sub> No change  
 <sub>5</sub> Minimal worsening  
 <sub>6</sub> Moderate worsening  
 <sub>7</sub> Marked worsening

The clinical interview-based impression of change scale in this study is from a pilot instrument, the Clinical Global Impression of Change, developed and currently undergoing validity studies by the National Institute on Aging Alzheimer's Disease Study Units Program (1 U01 AG10483; Leon Thal, Principal Investigator), and is in the public domain.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Early Termination Visit   
Page 5 of 13

**NEUROPSYCHIATRIC INVENTORY - REVISED (NPI-X)** QSCAT

INFORMATION NOT OBTAINED  Not Entered In Database

Clinician's initials	<b>Not Entered In Database</b>		
	First	Middle	Last

The screening question (from worksheet) is asked of the caregiver to determine if the behavioral change is present or absent in the patient. If the answer to the screening question is negative (NO) or if the question is not applicable to the patient, circle the appropriate response (Not Applicable [96] or Absent [0]) and proceed to the next screening question without asking the subquestions to determine frequency, severity, and distress.

	Item	Not		Frequency	Severity	Distress					
		Applicable	Absent			QSORRES	QTESTCD	QSORRES	QTESTCD	QSORRES	QTESTCD
<b>QSSCAT</b>	<b>QTESTCD</b>										
A.	Delusions	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
<b>QSSCAT</b>	<b>QTESTCD</b>										
B.	Hallucinations	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
<b>QSSCAT</b>	<b>QTESTCD</b>										
C.	Agitation/Agression	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
<b>QSSCAT</b>	<b>QTESTCD</b>										
D.	Depression/ Dysphoria	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
<b>QSSCAT</b>	<b>QTESTCD</b>										
E.	Anxiety	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
<b>QSSCAT</b>	<b>QTESTCD</b>										
F.	Euphoria/Elation	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
<b>QSSCAT</b>	<b>QTESTCD</b>										
G.	Apathy/ Indifference	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
<b>QSSCAT</b>	<b>QTESTCD</b>										
H.	Disinhibition	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
<b>QSSCAT</b>	<b>QTESTCD</b>										
I.	Irritability/Lability	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
<b>QSSCAT</b>	<b>QTESTCD</b>										
J.	Aberrant Motor Behavior	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
<b>QSSCAT</b>	<b>QTESTCD</b>										
K.	Night-Time Behavior	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				
<b>QSSCAT</b>	<b>QTESTCD</b>										
L.	Appetite/Eating Change	96	0	1 2 3 4	1 2 3	0	1 2 3 4 5				

©1994 Jeffrey L. Cummings

DS1609  
PRINTED IN USA  
August 22, 1996  
© Eli Lilly and Co.

QS570

Distribution: White and Yellow copies – Sponsor  
Bottom copy - Investigator

COPYRIGHT© 2006 Eli Lilly and Co.



## DISABILITY ASSESSMENT FOR DEMENTIA (DAD) QSCAT

INFORMATION NOT OBTAINED  Not Entered In Database

Clinician's initials	Not Entered In Database		
	First	Middle	Last

During the past two weeks, did the patient without help or reminder:



### QSSCAT

SCORING: Yes = 1 No = 0 Not Applicable = 96

#### HYGIENE

<b>QTESTCD</b>	1. Undertake to wash himself/herself or to take a bath or a shower			QSORES
<b>QTESTCD</b>	2. Undertake to brush his/her teeth or care for his/her dentures			QSORES
<b>QTESTCD</b>	3. Decide to care for his/her hair (wash and comb)			QSORES
<b>QTESTCD</b>	4. Prepare the water, towels, and soap for washing, taking a bath, or a shower			QSORES
<b>QTESTCD</b>	5. Wash and dry completely all parts of his/her body safely			QSORES
<b>QTESTCD</b>	6. Brush his/her teeth or care for his/her dentures appropriately			QSORES
<b>QTESTCD</b>	7. Care for his/her hair (wash and comb)			QSORES

#### DRESSING QSSCAT

<b>QTESTCD</b>	8. Undertake to dress himself/herself			QSORES
<b>QTESTCD</b>	9. Choose appropriate clothing (with regard to the occasion, neatness, the weather, and color combination)			QSORES
<b>QTESTCD</b>	10. Dress himself/herself in the appropriate order (undergarments, pant/dress, shoes)			QSORES
<b>QTESTCD</b>	11. Dress himself/herself completely			QSORES
<b>QTESTCD</b>	12. Undress himself/herself completely			QSORES

#### CONTINENCE QSSCAT

<b>QTESTCD</b>	13. Decide to use the toilet at appropriate times			QSORES
<b>QTESTCD</b>	14. Use the toilet without "accidents"			QSORES

#### EATING QSSCAT

<b>QTESTCD</b>	15. Decide that he/she needs to eat			QSORES
<b>QTESTCD</b>	16. Choose appropriate utensils and seasonings when eating			QSORES
<b>QTESTCD</b>	17. Eat his/her meals at a normal pace and with appropriate manners			QSORES

#### MEAL PREPARATION QSSCAT

<b>QTESTCD</b>	18. Undertake to prepare a light meal or snack for himself/herself			QSORES
<b>QTESTCD</b>	19. Adequately plan a light meal or snack (ingredients, cookware)			QSORES
<b>QTESTCD</b>	20. Prepare or cook a light meal or a snack safely			QSORES



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Early Termination Visit   
Page 7 of 13

## DISABILITY ASSESSMENT FOR DEMENTIA (DAD)



**QSSCAT**

SCORING: Yes = 1 No = 0 Not Applicable = 96

### TELEPHONING

QSTESTCD	21. Attempt to telephone someone at a suitable time			QSORRES
QSTESTCD	22. Find and dial a telephone number correctly			QSORRES
QSTESTCD	23. Carry out an appropriate telephone conversation			QSORRES
QSTESTCD	24. Write and convey a telephone message adequately			QSORRES

### GOING ON AN OUTING QSSCAT

QSTESTCD	25. Undertake to go out (walk, visit, shop) at an appropriate time			QSORRES
QSTESTCD	26. Adequately organize an outing with respect to transportation, keys, destination, weather, necessary money, shopping list			QSORRES
QSTESTCD	27. Go out and reach a familiar destination without getting lost			QSORRES
QSTESTCD	28. Safely take the adequate mode of transportation (car, bus, taxi)			QSORRES
QSTESTCD	29. Return from the store with the appropriate items			QSORRES

### FINANCE AND CORRESPONDENCE QSSCAT

QSTESTCD	30. Show an interest in his/her personal affairs such as his/her finances and written correspondence			QSORRES
QSTESTCD	31. Organize his/her finances to pay his/her bills (cheques, bankbook, bills)			QSORRES
QSTESTCD	32. Adequately organize his/her correspondence with respect to stationery, address, stamps			QSORRES
QSTESTCD	33. Handle adequately his/her money (make change)			QSORRES

### MEDICATIONS QSSCAT

QSTESTCD	34. Decide to take his/her medications at the correct time			QSORRES
QSTESTCD	35. Take his/her medications as prescribed (according to the right dosage)			QSORRES

### LEISURE AND HOUSEWORK QSSCAT

QSTESTCD	36. Show an interest in leisure activity(ies)			QSORRES
QSTESTCD	37. Take an interest in household chores that he/she used to perform in the past			QSORRES
QSTESTCD	38. Plan and organize adequately household chores that he/she used to perform in the past			QSORRES
QSTESTCD	39. Complete household chores adequately as he/she used to perform in the past			QSORRES
QSTESTCD	40. Stay safely at home by himself/herself when needed			QSORRES



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Early Termination Visit   
Page 8 of 13

## WEIGHT

VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Measure with shoes off. Round up or down to the nearest tenth kilogram or tenth pound.

Weight VSORRES  Kilogram  Pound  
VSORRES

## VITAL SIGNS : HEART RATE AND BLOOD PRESSURE

INFORMATION NOT OBTAINED  Not Entered In Database

NOTE: Blood pressure and pulse must be taken after the patient has been lying down for 5 minutes (supine) and after standing for 1 minute (standing) and 3 minutes.

Position
SU = Supine
ST = Standing

VSTPTNUM

VSPOS

VTESTCD

(DNDE) Reference Time	Timing Code	Position	Heart Rate (bpm)	Blood Pressure (mmHg) Systolic/Diastolic
0. 5 minutes	815	SU	VSORRESU VSORRES	/
1. 1 minute	816	ST		/ VSORRESU VSORRES
2. 3 minutes	817	ST	VTESTCD VSORRESU VSORRES	/

## VITAL SIGNS : TEMPERATURE VTESTCD

INFORMATION NOT OBTAINED  Not Entered In Database

Temperature VSORRES

Unit of measure  F Fahrenheit  C Centigrade VSORRESU

Method VSLOC  PO Oral  R Rectal  A Axillary  E Ear  O Other



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Early Termination Visit   
Page 9 of 13

## ELECTROCARDIOGRAM

NOT DONE  Not Entered In Database

Electrocardiogram date  /  /   
MM DD YY

Electrocardiogram result  <sub>12</sub> Acceptable  <sub>13</sub> Not Acceptable

NOTE: Any clinically relevant change from Visit 1 (baseline) ECG must be recorded on the Pre-existing Conditions and Adverse Events page. Note non-relevant abnormalities in the ECG Comments section below.

## COMMENTS : NON-RELEVANT ECG ABNORMALITIES

NO COMMENTS  Not Entered In Database

Print legibly and do not use abbreviations or symbols.

Not Entered In Database

---

---

---

---

---

---

---

---

---

---

---

---



## ACCEPTABILITY : CAREGIVER'S RESPONSE ABOUT THE PATCH

INFORMATION NOT OBTAINED  Not Entered In Database

The following question is to be answered by the caregiver.

Based on the experience of applying and wearing this patch, if the patient were prescribed a drug for Alzheimer's disease and was given the choice of this patch or an oral pill given twice daily (assume that both formulations are equally effective), would you (the caregiver):

Not Entered In Database

- 1 Insist that the patient receive an oral pill
- 2 Prefer that the patient receive an oral pill
- 3 Have no preference (neutral) for an oral or patch formulation
- 4 Prefer that the patient receive a patch
- 5 Insist that the patient receive a patch



## ACCEPTABILITY : CAREGIVER'S RESPONSE ABOUT THE PATCH

INFORMATION NOT OBTAINED  Not Entered In Database

The following questions are intended to be answered by the caregiver and address the patch's design and wearability. Focus only on the act of wearing and removing the transdermal patch. On each scale below, circle one number (do not circle on the scale between numbers) that best describes your feelings about the patch:

1. The appearance of the patch while being worn is acceptable:

Not Entered In Database



2. The size of the patch is acceptable:

Not Entered In Database



3. The patches were durable (eg, did not discolor, tear) while being worn:

Not Entered In Database



## STUDY DRUG THERAPY : DATE OF FINAL DOSE

EXENDTC

Date of final dose of study drug           /          /            
          MM    DD    YY



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Early Termination Visit   
Page 12 of 13

## PATIENT SUMMARY

Patient Initials **Not Entered In Database**  
First \_\_\_\_\_ Middle \_\_\_\_\_ Last \_\_\_\_\_

### CHECK ONE PRIMARY REASON FOR ENDING PARTICIPATION IN THE STUDY

DTERM  <sub>1</sub> Protocol completed

DTERM  <sub>3</sub> Adverse event E **AESPID**  
E\_\_ Code

DTERM  <sub>4</sub> Death\* E **AESPID**  
E\_\_ Code

If # 4 is checked, enter date of death.

**DSSTDTC**

Date of Death \_\_\_\_/\_\_\_\_/\_\_\_\_  
MM DD YY

DTERM  <sub>8</sub> Lack of efficacy, patient/caregiver perception

DTERM  <sub>9</sub> Lack of efficacy, physician perception

DTERM  <sub>11</sub> Unable to contact patient (lost to follow-up)

DSDECOD  <sub>13</sub> Personal conflict or other patient/caregiver decision \_\_\_\_\_ **DTERM**  
Specify

DSDECOD  <sub>22</sub> Physician decision \_\_\_\_\_ **DTERM**  
Specify

DTERM  <sub>14</sub> Protocol entry criteria not met \_\_\_\_\_ **SUPPDS.QVAL**  
Specify (Specify number from entry criteria checklist)

DTERM  <sub>243</sub> Protocol violation

DTERM  <sub>18</sub> Sponsor decision (study or patient discontinued by the Sponsor)

\* **Contact the Quintiles Drug Safety Unit immediately in event of death.** Obtain a copy of the autopsy report (if autopsy performed) or hospital discharge summary. Forward to Quintiles Drug Safety Unit as soon as possible. Explain circumstances of the death on the Study Summary Comments page.



Clinical Report Form  
Safety and Efficacy of the Xanomeline  
Transdermal Therapeutic System (TTS) in  
Patients with Mild to Moderate Alzheimer's Disease  
H2Q-MC-LZZT

Early Termination Visit

Page 13 of 13

## COMMENTS : STUDY SUMMARY

NO COMMENTS  Not Entered In Database

Repeating information from the clinical report form is discouraged. If the patient is ending participation in the study for any reason other than protocol complete (Reason 1 on Patient Summary page) give a brief description of the circumstances.

Enter comments below. Print legibly and do not use abbreviations or symbols.

Not Entered In Database

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

All information reported for this patient is accurate and complete.

Not Entered In Database Not Entered In Database

\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_  
Investigator Signature MM DD YY

## Instructions for Administration of the NPI

The purpose of the Neuropsychiatric Inventory (NPI) is to obtain information on the presence of psychopathology in patients with brain disorders. The NPI was developed for application to patients with Alzheimer's disease and other dementias, but it may be useful in the assessment of behavioral changes in other conditions. Twelve behavioral areas are included in the NPI:

Delusions	Apathy
Hallucinations	Disinhibition
Agitation	Irritability
Depression	Aberrant motor behavior
Anxiety	Night-time behaviors
Euphoria	Appetite and eating changes

The NPI is based on responses from an informed caregiver, preferably one living with the patient. If an informed observer is not available, this instrument cannot be used or must be modified. The interview is best conducted with the caregiver in the absence of the patient to facilitate an open discussion of behaviors that may be difficult to describe with the patient present. Several points should be made when you introduce the NPI interview to the caregiver:

- Purpose of the interview
- Ratings - frequency, severity, distress (described below)
- Answers apply to behaviors that are new since the onset of the disease and have been present for the past two weeks or other defined period
- Questions can usually be answered with "yes" or "no" and responses should be brief

When beginning the inventory, say to the caregiver "These questions are designed to evaluate your [husband's/wife's/etc] behavior. They can usually be answered 'yes' or 'no' so please try to be brief in your responses." If the caregiver lapses into elaborate responses that provide little useful information, they may be reminded of the need to be brief. Some of the issues raised with this are very emotionally disturbing to caregivers and the interviewer should reassure the caregiver that they will discuss the problems in more detail after completion of the inventory.

Questions should be asked exactly as written. Clarification should be provided if the caregiver does not understand the question. Acceptable clarifications are restatements of the questions in alternate terms.

The questions pertain to changes in the patient's behavior that have appeared since the onset of the illness. Behaviors that have been present throughout the patient's life and have not changed in the course of the illness are not scored even if they are abnormal (e.g., anxiety, depression). Behaviors that have been present throughout life but have changed since the illness are scored (e.g., the patient has always been apathetic but there has been a notable increase in apathy during the period of inquiry).

The NPI is typically used to assess changes in the patient's behavior that have appeared in a defined period of time (e.g., in the past four weeks or other defined interval). In some studies, the NPI may be used to address changes occurring in response to treatment or that have changed since the last clinic visit. The time frame of the question would then be revised to reflect this interest in recent changes. Emphasize to the caregiver that the questions pertain to behaviors that have appeared or changed since the onset of the illness. For example, the questions might be phrased "Since he/she began treatment with the new medications . . ." or "Since our last interview . . ."

The screening question is asked to determine if the behavioral change is present or absent. If the answer to the screening question is negative, mark NO and proceed to the next screening question without asking the subquestions. If the answer to the screening question is positive or if there are any

uncertainties in the caregiver's response or any inconsistencies between the response and other information known by the clinician (e.g., the caregiver responds negatively to the euphoria screening question but the patient appears euphoric to the clinician), the category is marked YES and is explored in more depth with the subquestions. If the subquestions confirm the screening question, the severity and frequency of the behavior are determined according to the criteria provided with each behavior. When determining frequency and severity, use the behaviors identified by the subquestions as most aberrant. For example, if the caregiver indicates that resistive behavior is particularly problematic when you are asking the subquestions of the agitation section, then use resistive behavior to prompt judgments regarding the frequency and severity of agitation. If two behaviors are very problematic, use the frequency and severity of both behaviors to score the item. For example, if the patient has two or more types of delusions, then use the severity and frequency of all delusional behaviors to phrase the questions regarding severity and frequency.

In some cases, the caregiver will provide a positive response to the screening question and a negative reply to all subquestions. If this happens, ask the caregiver to expand on why they responded affirmatively to the screen. If they provide information relevant to the behavioral domain but in different terms, the behavior should be scored for severity and frequency as usual. If the original affirmative response was erroneous, leading to a failure to endorse any subquestions, then the behavior is changed to "NO" on the screen.

Some sections such as the questions pertaining to appetite are framed so as to capture whether there is an increase or decrease in the behavior (increased or decreased appetite or weight). If the caregiver answer "yes" to the first member of the paired question (such as has the patient's weight decreased?), do not ask the second question (has the patient's weight increased?) since the answer to the second question is contained in the answer to the first. If the caregiver answers "no" to the first member of the pair of questions, then the second question must be asked.

When determining frequency, say to the person being interviewed "Now I want to find out how often these things [define using description of the behaviors they noted as most problematic on the subquestions] occur. Would you say that they occur less than once per week, about once per week, several times per week but not every day, or essentially every day?" Some behaviors, such as apathy eventually become continuously present, and then "are constantly present" can be substituted for "every day." When determining severity, tell the person being interviewed "Now I would like to find out how severe these behaviors are. By severity, I mean how disturbing or disabling they are for the patient. Would you say that [the behaviors] are mild, moderate, or marked?" Additional descriptors are provided in each section that may be used to help the interviewer clarify each grade of severity. In each case, be sure that the caregiver provides you with a definite answer as to the frequency and severity of the behaviors. Do not guess what you think the caregiver would say based on your discussion. We have found it helpful to provide the caregiver with a piece of paper on which is written the frequency and severity descriptions (less than once per week, about once per week, several times per week and daily or continuously for frequency and mild, moderate, and severe for severity) to allow them to visually see the response alternatives. This also saves the examiner from reiterating the alternatives with each question.

In very impaired patients or patients with special medical circumstances, a set of questions may not be applicable. For example, bed-bound patients may exhibit hallucinations or agitation but could not exhibit aberrant motor behavior. If the clinician or the caregiver believes that the questions are inappropriate, then the section should be marked NA (upper right corner of each section), and no further data are not recorded for the section. Likewise, if the clinician feels that the responses are invalid (e.g., the caregiver did not seem to understand the particular set of questions asked), NA should also be marked.

When each domain is completed and the caregiver has completed the frequency and severity rating, you may want to ask the associated caregiver distress question if your protocol includes the distress assessment. To do this, ask the caregiver how much, if any, "emotional or psychological" distress the behavior he or she just discussed causes him or her (the caregiver). The caregiver must rate their own distress on a five point scale from 0 - no distress, 1 - minimal, 2 - mild,

3 - moderate, 4 - moderately severe, 5 - very severe or extreme. The distress scale of this instrument was developed by Daniel Kaufer, M.D.

#### Scoring the NPI

Frequency is rated as:

- 1 - Occasionally - less than once per week
- 2 - Often - about once per week
- 3 - Frequently - several times per week but less than every day
- 4 - Very frequently - daily or essentially continuously present

Severity is rated as:

- 1 - Mild - produce little distress in the patient
- 2 - Moderate - more disturbing to the patient but can be redirected by the caregiver
- 3 - Marked - very disturbing to the patient and difficult to redirect

The score for each domain is: domain score = frequency x severity

Distress is scored as:

- 0 - no distress
- 1 - minimal
- 2 - mild
- 3 - moderate
- 4 - moderately severe
- 5 - very severe to extreme

Thus, for each behavioral domain there are four scores:

- Frequency
- Severity
- Total (frequency x severity)
- Caregiver distress

A total NPI score can be calculated by adding all domain scores together. The distress score is not included in the total NPI score.

#### Instructional Videotape

An instructional videotape demonstrating the use of the NPI is available through the UCLA Alzheimer's Disease Center, Neuropsychiatric Institute, 740 Westwood Plaza, Los Angeles, California, 90024. The cost of the videotape is \$25.00 (subject to change).

#### Reference

Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. *Neurology* 1994; 44: 2308-2314.

Acknowledgments: UCLA Alzheimer's Disease Center, Academic Geriatric Resource Program, UCLA Center on Aging and the Irving and Helga Cooper Geriatric Research Award.

**A. Delusions**

Does the patient have beliefs that you know are not true? For example, insisting that people are trying to harm him/her or steal from him/her. Has he/she said that family members are not who they say they are or that the house is not their home? I'm not asking about mere suspiciousness; I am interested if the patient is convinced that these things are happening to him/her.

NO (If no, proceed to the next screening question)      YES (If yes, proceed to subquestions).

1. Does the patient believe that he/she is in danger - that others are planning to hurt him/her? \_\_\_\_\_
2. Does the patient believe that others are stealing from him/her? \_\_\_\_\_
3. Does patient believe that his/her spouse is having an affair? \_\_\_\_\_
4. Does patient believe that unwelcome guests are living in his/her house? \_\_\_\_\_
5. Does the patient believe that his/her spouse or others are not who they claim to be? \_\_\_\_\_
6. Does the patient believe that his/her house is not his/her home? \_\_\_\_\_
7. Does the patient believe that family members plan to abandon him/her? \_\_\_\_\_
8. Does the patient believe that television or magazine figures are actually present in the home? [Does he/she try to talk or interact with them?] \_\_\_\_\_
9. Does the he/she believe any other unusual things that I haven't asked about? \_\_\_\_\_

If the screening question is confirmed, determine the frequency and severity of the delusions.

**Frequency:**

1. Occasionally - less than once per week.
2. Often - about once per week.
3. Frequently - several times per week but less than every day.
4. Very frequently - once or more per day.

**Severity:**

1. Mild - delusions present but seem harmless and produce little distress in the patient.
2. Moderate - delusions are distressing and disruptive.
3. Marked - delusions are very disruptive and are a major source of behavioral disruption. [If PRN medications are prescribed, their use signals that the delusions are of marked severity.]

**Distress:**

How emotionally distressing do you find this behavior:

0. Not at all
1. Minimally
2. Mildly
3. Moderately
4. Severely
5. Very severely or extremely

**B. Hallucinations**

Does the patient have hallucinations such as false visions or voices? Does he/she seem to see, hear or experience things that are not present? By this question we do not mean just mistaken beliefs such as stating that someone who has died is still alive; rather we are asking if the patient actually has abnormal experiences of sound, or visions.

NO (If no, proceed to the next screening question)      YES (If yes, proceed to subquestions).

1. Does the patient describe hearing voices or act as if he/she hears voices? \_\_\_\_\_
2. Does the patient talk to people who are not there? \_\_\_\_\_
3. Does the patient describe seeing things not seen by others or behave as if he/she is seeing things not seen by others (people, animals, lights, etc)? \_\_\_\_\_
4. Does the patient report smelling odors not smelled by others? \_\_\_\_\_
5. Does the patient describe feeling things on his/her skin or otherwise appear to be feeling things crawling or touching him/her? \_\_\_\_\_
6. Does the patient describe tastes that are without any known cause? \_\_\_\_\_
7. Does the patient describe any other unusual sensory experiences? \_\_\_\_\_

If the screening question is confirmed, determine the frequency and severity of the hallucinations.

- Frequency:    1. Occasionally - less than once per week.  
                      2. Often - about once per week.  
                      3. Frequently - several times per week but less than every day.  
                      4. Very frequently - once or more per day.
- Severity:     1. Mild - hallucinations present but seem harmless and produce little distress in the patient.  
                      2. Moderate - hallucinations are distressing and disruptive to the patient.  
                      3. Marked - hallucinations are very disruptive and are a major source of behavioral disturbance. PRN medications may be required to control them.
- Distress:      How emotionally distressing do you find this behavior:  
                      0. Not at all  
                      1. Minimally  
                      2. Mildly  
                      3. Moderately  
                      4. Severely  
                      5. Very severely or extremely

**C. Agitation/Aggression**

Does the patient have periods when he/she refuses to cooperate or won't let people help him/her? Is he/she hard to handle?

NO (If no, proceed to the next screening question)      YES (If yes, proceed to subquestions).

1. Does the patient get upset with those trying to care for him/her or resist activities such as bathing or changing clothes? \_\_\_\_\_
2. Is the patient stubborn, having to have things his/her way? \_\_\_\_\_
3. Is the patient uncooperative, resistive to help from others? \_\_\_\_\_
4. Does the patient have any other behaviors that make him hard to handle? \_\_\_\_\_
5. Does the patient shout or curse angrily? \_\_\_\_\_
6. Does the patient slam doors, kick furniture, throw things? \_\_\_\_\_
7. Does the patient attempt to hurt or hit others? \_\_\_\_\_
8. Does the patient have any other aggressive or agitated behaviors? \_\_\_\_\_

If the screening question is confirmed, determine the frequency and severity of the agitation.

- Frequency:
1. Occasionally - less than once per week.
  2. Often - about once per week.
  3. Frequently - several times per week but less than every day.
  4. Very frequently - once or more per day.

- Severity:
1. Mild - behavior is disruptive but can be managed with redirection or reassurance.
  2. Moderate - behaviors disruptive and difficult to redirect or control.
  3. Marked - agitation is very disruptive and a major source of difficulty; there may be a threat of personal harm. Medications are often required.

- Distress: How emotionally distressing do you find this behavior:
0. Not at all
  1. Minimally
  2. Mildly
  3. Moderately
  4. Severely
  5. Very severely or extremely

**D. Depression/Dysphoria**

Does the patient seem sad or depressed? Does he/she say that he/she feels sad or depressed?

NO (If no, proceed to the next screening question)      YES (If yes, proceed to subquestions).

1. Does the patient have periods of tearfulness or sobbing that seem to indicate sadness? \_\_\_\_\_
2. Does the patient say or act as if he/she is sad or in low spirits? \_\_\_\_\_
3. Does the patient put him/herself down or say the he/she feels like a failure? \_\_\_\_\_
4. Does the patient say that he/she is a bad person or deserves to be punished? \_\_\_\_\_
5. Does the patient seem very discouraged or say that he/she has no future? \_\_\_\_\_
6. Does the patient say he/she is a burden to the family or that the family would be better off without him/her? \_\_\_\_\_
7. Does the patient express a wish for death or talk about killing him/herself? \_\_\_\_\_
8. Does the patient show any other signs of depression or sadness? \_\_\_\_\_

If the screening question is confirmed, determine the frequency and severity of the depression.

- Frequency:
1. Occasionally - less than once per week.
  2. Often - about once per week.
  3. Frequently - several times per week but less than every day.
  4. Very frequently - once or more per day.

- Severity:
1. Mild - depression is distressing but usually responds to redirection or reassurance.
  2. Moderate - depression is distressing, depressive symptoms are spontaneously voiced by the patient and difficult to alleviate.
  3. Marked - depression is very distressing and a major source of suffering for the patient.

- Distress: How emotionally distressing do you find this behavior:
0. Not at all
  1. Minimally
  2. Mildly
  3. Moderately
  4. Severely
  5. Very severely or extremely

**E. Anxiety**

Is the patient very nervous, worried, or frightened for no apparent reason? Does he/she seem very tense or fidgety? Is the patient afraid to be apart from you?

NO (If no, proceed to the next screening question)      YES (If yes, proceed to subquestions).

1. Does the patient say that he/she is worried about planned events? \_\_\_\_\_
2. Does the patient have periods of feeling shaky, unable to relax, or feeling excessively tense? \_\_\_\_\_
3. Does the patient have periods of [or complain of] shortness of breath, gasping, or sighing for no apparent reason other than nervousness? \_\_\_\_\_
4. Does the patient complain of butterflies in his/her stomach, or of racing or pounding of the heart in association with nervousness? [Symptoms not explained by ill health] \_\_\_\_\_
5. Does the patient avoid certain places or situations that make him/her more nervous such as riding in the car, meeting with friends, or being in crowds? \_\_\_\_\_
6. Does the patient become nervous and upset when separated from you [or his/her caregiver]? [Does he/she cling to you to keep from being separated?] \_\_\_\_\_
7. Does the patient show any other signs of anxiety? \_\_\_\_\_

If the screening question is confirmed, determine the frequency and severity of the anxiety.

- Frequency:
1. Occasionally - less than once per week.
  2. Often - about once per week.
  3. Frequently - several times per week but less than every day.
  4. Very frequently - once or more per day.

- Severity:
1. Mild - anxiety is distressing but usually responds to redirection or reassurance.
  2. Moderate - anxiety is distressing, anxiety symptoms are spontaneously voiced by the patient and difficult to alleviate.
  3. Marked - anxiety is very distressing and a major source of suffering for the patient.

- Distress: How emotionally distressing do you find this behavior:
0. Not at all
  1. Minimally
  2. Mildly
  3. Moderately
  4. Severely
  5. Very severely or extremely

**F. Elation/Euphoria**

Does the patient seem too cheerful or too happy for no reason? I don't mean the normal happiness that comes from seeing friends, receiving presents, or spending time with family members. I am asking if the patient has a persistent and abnormally good mood or finds humor where others do not.

NO (If no, proceed to the next screening question)      YES (If yes, proceed to subquestions).

1. Does the patient appear to feel too good or to be too happy, different from his/her usual self? \_\_\_\_\_
2. Does the patient find humor and laugh at things that others do not find funny? \_\_\_\_\_
3. Does the patient seem to have a childish sense of humor with a tendency to giggle or laugh inappropriately (such as when something unfortunate happens to others)? \_\_\_\_\_
4. Does the patient tell jokes or make remarks that have little humor for others but seem funny to him/her? \_\_\_\_\_
5. Does he/she play childish pranks such as pinching or playing "keep away" for the fun of it? \_\_\_\_\_
6. Does the patient "talk big" or claim to have more abilities or wealth than is true? \_\_\_\_\_
7. Does the patient show any other signs of feeling too good or being too happy? \_\_\_\_\_

If the screening question is confirmed, determine the frequency and severity of the elation/euphoria.

- Frequency:
1. Occasionally - less than once per week.
  2. Often - about once per week.
  3. Frequently - several times per week but less than every day.
  4. Very frequently - once or more per day.
- Severity:
1. Mild - elation is notable to friends and family but is not disruptive.
  2. Moderate - elation is notably abnormal.
  3. Marked - elation is very pronounced; patient is euphoric and finds nearly everything to be humorous.
- Distress: How emotionally distressing do you find this behavior:
0. Not at all
  1. Minimally
  2. Mildly
  3. Moderately
  4. Severely
  5. Very severely or extremely

**G. Apathy/Indifference**

Has the patient lost interest in the world around him/her? Has he/she lost interest in doing things or lack motivation for starting new activities? Is he/she more difficult to engage in conversation or in doing chores? Is the patient apathetic or indifferent?

NO (If no, proceed to the next screening question)      YES (If yes, proceed to subquestions).

1. Does the patient seem less spontaneous and less active than usual? \_\_\_\_\_
2. Is the patient less likely to initiate a conversation? \_\_\_\_\_
3. Is the patient less affectionate or lacking in emotions when compared to his/her usual self? \_\_\_\_\_
4. Does the patient contribute less to household chores? \_\_\_\_\_
5. Does the patient seem less interested in the activities and plans of others? \_\_\_\_\_
6. Has the patient lost interest in friends and family members? \_\_\_\_\_
7. Is the patient less enthusiastic about his/her usual interests? \_\_\_\_\_
8. Does the patient show any other signs that he/she doesn't care about doing new things? \_\_\_\_\_

If the screening question is confirmed, determine the frequency and severity of the apathy/indifference.

Frequency:    1. Occasionally - less than once per week.

2. Often - about once per week.

3. Frequently - several times per week but less than every day.

4. Very frequently - once or more per day.

Severity:    1. Mild - apathy is notable but produces little interference with daily routines; only mildly different from patient's usual behavior; patient responds to suggestions to engage in activities.

2. Moderate - apathy is very evident; may be overcome by the caregiver with coaxing and encouragement; responds spontaneously only to powerful events such as visits from close relatives or family members.

3. Marked - apathy is very evident and usually fails to respond to any encouragement or external events.

Distress:    How emotionally distressing do you find this behavior:

0. Not at all

1. Minimally

2. Mildly

3. Moderately

4. Severely

5. Very severely or extremely

**H. Disinhibition**

Does the patient seem to act impulsively without thinking? Does he/she do or say things that are not usually done or said in public? Does he/she do things that are embarrassing to you or others?

NO (If no, proceed to the next screening question)      YES (If yes, proceed to subquestions).

1. Does the patient act impulsively without appearing to consider the consequences? \_\_\_\_\_
2. Does the patient talk to total strangers as if he/she knew them? \_\_\_\_\_
3. Does the patient say things to people that are insensitive or hurt their feelings? \_\_\_\_\_
4. Does the patient say crude things or make sexual remarks that they would not usually have said? \_\_\_\_\_
5. Does the patient talk openly about very personal or private matters not usually discussed in public? \_\_\_\_\_
6. Does the patient take liberties or touch or hug others in way that is out of character for him/her? \_\_\_\_\_
7. Does the patient show any other signs of loss of control of his/her impulses? \_\_\_\_\_

If the screening question is confirmed, determine the frequency and severity of the disinhibition.

- Frequency:      1. Occasionally - less than once per week.  
                        2. Often - about once per week.  
                        3. Frequently - several times per week but less than every day.  
                        4. Very frequently - once or more per day.
- Severity:      1. Mild - disinhibition is notable but usually responds to redirection and guidance.  
                        2. Moderate - disinhibition is very evident and difficult to overcome by the caregiver.  
                        3. Marked - disinhibition usually fails to respond to any intervention by the caregiver, and is a source of embarrassment or social distress.
- Distress:      How emotionally distressing do you find this behavior:  
                        0. Not at all  
                        1. Minimally  
                        2. Mildly  
                        3. Moderately  
                        4. Severely  
                        5. Very severely or extremely

**I. Irritability/Lability**

Does the patient get irritated and easily disturbed? Are his/her moods very changeable? Is he/she abnormally impatient? We do not mean frustration over memory loss or inability to perform usual tasks; we are interested to know if the patient has abnormal irritability, impatience, or rapid emotional changes different from his/her usual self.

NO (If no, proceed to the next screening question)      YES (If yes, proceed to subquestions).

1. Does the patient have a bad temper, flying "off the handle" easily over little things? \_\_\_\_\_
2. Does the patient rapidly change moods from one to another, being fine one minute and angry the next? \_\_\_\_\_
3. Does the patient have sudden flashes of anger? \_\_\_\_\_
4. Is the patient impatient, having trouble coping with delays or waiting for planned activities? \_\_\_\_\_
5. Is the patient cranky and irritable? \_\_\_\_\_
6. Is the patient argumentative and difficult to get along with? \_\_\_\_\_
7. Does the patient show any other signs of irritability? \_\_\_\_\_

If the screening question is confirmed, determine the frequency and severity of the irritability/lability.

- Frequency:
1. Occasionally - less than once per week.
  2. Often - about once per week.
  3. Frequently - several times per week but less than every day.
  4. Very frequently - once or more per day.
- Severity:
1. Mild - irritability or lability is notable but usually responds to redirection and reassurance.
  2. Moderate - irritability and lability are very evident and difficult to overcome by the caregiver.
  3. Marked - irritability and lability are very evident, they usually fail to respond to any intervention by the caregiver, and they are a major source of distress.
- Distress: How emotionally distressing do you find this behavior:
0. Not at all
  1. Minimally
  2. Mildly
  3. Moderately
  4. Severely
  5. Very severely or extremely

**J. Aberrant Motor Behavior**

Does the patient pace, do things over and over such as opening closets or drawers, or repeatedly pick at things or wind string or threads?

NO (If no, proceed to the next screening question)      YES (If yes, proceed to subquestions).

1. Does the patient pace around the house without apparent purpose? \_\_\_\_\_
2. Does the patient rummage around opening and unpacking drawers or closets? \_\_\_\_\_
3. Does the patient repeatedly put on and take off clothing? \_\_\_\_\_
4. Does the patient have repetitive activities or "habits" that he/she performs over and over? \_\_\_\_\_
5. Does the patient engage in repetitive activities such as handling buttons, picking wrapping string, etc? \_\_\_\_\_
6. Does the patient fidget excessively, seem unable to sit still, or bounce his/her feet or tap his/her fingers a lot? \_\_\_\_\_
7. Does the patient do any other activities over and over? \_\_\_\_\_

If the screening question is confirmed, determine the frequency and severity of the aberrant motor activity:

- Frequency:
1. Occasionally - less than once per week.
  2. Often - about once per week.
  3. Frequently - several times per week but less than every day.
  4. Very frequently - once or more per day.

- Severity:
1. Mild - abnormal motor activity is notable but produce little interference with daily routines.
  2. Moderate - abnormal motor activity is very evident; can be overcome by the caregiver.
  3. Marked - abnormal motor activity is very evident, it usually fails to respond to any intervention by the caregiver and is a major source of distress.

- Distress: How emotionally distressing do you find this behavior:
0. Not at all
  1. Minimally
  2. Mildly
  3. Moderately
  4. Severely
  5. Very severely or extremely

**K. Sleep**

Does the patient have difficulty sleeping (do not count as present if the patient simply gets up once or twice per night only to go to the bathroom and falls back asleep immediately)? Is he/she up at night? Does he/she wander at night, get dressed, or disturb your sleep?

NO (If no, proceed to the next screening question)      YES (If yes, proceed to subquestions).

1. Does the patient have difficulty falling asleep? \_\_\_\_\_
2. Does the patient get up during the night (do not count if the patient gets up once or twice per night only to go to the bathroom and falls back asleep immediately)? \_\_\_\_\_
3. Does the patient wander, pace, or get involved in inappropriate activities at night? \_\_\_\_\_
4. Does the patient awaken you during the night? \_\_\_\_\_
5. Does the patient awaken at night, dress, and plan to go out thinking that it is morning and time to start the day? \_\_\_\_\_
6. Does the patient awaken too early in the morning (earlier than was his/her habit)? \_\_\_\_\_
7. Does the patient sleep excessively during the day? \_\_\_\_\_
8. Does the patient have any other night-time behaviors that bother you that we haven't talked about? \_\_\_\_\_

If the screening question is confirmed, determine the frequency and severity of the night-time behavior disturbance.

Frequency:    1. Occasionally - less than once per week.

2. Often - about once per week.

3. Frequently - several times per week but less than every day.

4. Very frequently - once or more per day.

Severity:    1. Mild - night-time behaviors occur but they are not particularly disruptive.

2. Moderate - night-time behaviors occur and disturb the patient and the sleep of the caregiver; more than one type of night-time behavior may be present.

3. Marked - night-time behaviors occur; several types of night-time behaviors may be present; the patient is very distressed during the night and the caregiver's sleep is markedly disturbed.

Distress:    How emotionally distressing do you find this behavior:

0. Not at all

1. Minimally

2. Mildly

3. Moderately

4. Severely

5. Very severely or extremely

**L. Appetite and eating disorders**

Has he/she had any change in appetite, weight, or eating habits (count as NA if the patient is incapacitated and has to be fed)? Has there been any change in type of food he/she prefers?

NO (If no, proceed to the next screening question)      YES (If yes, proceed to subquestions).

1. Has he/she had a loss of appetite? \_\_\_\_\_
2. Has he/she had an increase in appetite? \_\_\_\_\_
3. Has he/she had a loss of weight? \_\_\_\_\_
4. Has he/she gained weight? \_\_\_\_\_
5. Has he/she had a change in eating behavior such as putting too much food in his/her mouth at once? \_\_\_\_\_
6. Has he/she had a change in the kind of food he/she likes such as eating too many sweets or other specific types of food? \_\_\_\_\_
7. Has he/she developed eating behaviors such as eating exactly the same types of food each day or eating the food in exactly the same order? \_\_\_\_\_
8. Have there been any other changes in appetite or eating that I haven't asked about? \_\_\_\_\_

If the screening question is confirmed, determine the frequency and severity of the changes in eating habits or appetite.

Frequency:    1. Occasionally - less than once per week.

2. Often - about once per week.

3. Frequently - several times per week but less than every day.

4. Very frequently - once or more per day.

Severity:    1. Mild - changes in appetite or eating are present but have not led to changes in weight and are not disturbing

2. Moderate - changes in appetite or eating are present and cause minor fluctuations in weight.

3. Marked - obvious changes in appetite or eating are present and cause fluctuations in weight, are embarrassing, or otherwise disturb the patient.

Distress:    How emotionally distressing do you find this behavior:

0. Not at all

1. Minimally

2. Mildly

3. Moderately

4. Severely

5. Very severely or extremely



WORKSHEET (DNDE)  
H2Q-MC-LZZT

Investigator No. \_\_\_\_\_

Patient No. \_\_\_\_\_

Visit \_\_\_\_\_

**DISABILITY ASSESSMENT FOR DEMENTIA (DAD)** **QSCAT**

INFORMATION NOT OBTAINED  **Not Entered In Database**

Clinician's initials	<b>Not Entered In Database</b>		
	First	Middle	Last

During the past two weeks, did the patient without help or reminder:



**QSSCAT**

**HYGIENE**

SCORING: Yes = 1    No = 0    Not Applicable = 96

<b>QTESTCD</b>	1. Undertake to wash himself/herself or to take a bath or a shower			<b>QSORES</b>
<b>QTESTCD</b>	2. Undertake to brush his/her teeth or care for his/her dentures			<b>QSORES</b>
<b>QTESTCD</b>	3. Decide to care for his/her hair (wash and comb)			<b>QSORES</b>
<b>QTESTCD</b>	4. Prepare the water, towels, and soap for washing, taking a bath, or a shower			<b>QSORES</b>
<b>QTESTCD</b>	5. Wash and dry completely all parts of his/her body safely			<b>QSORES</b>
<b>QTESTCD</b>	6. Brush his/her teeth or care for his/her dentures appropriately			<b>QSORES</b>
<b>QTESTCD</b>	7. Care for his/her hair (wash and comb)			<b>QSORES</b>

**DRESSING QSSCAT**

<b>QTESTCD</b>	8. Undertake to dress himself/herself			<b>QSORES</b>
<b>QTESTCD</b>	9. Choose appropriate clothing (with regard to the occasion, neatness, the weather, and color combination)			<b>QSORES</b>
<b>QTESTCD</b>	10. Dress himself/herself in the appropriate order (undergarments, pant/dress, shoes)			<b>QSORES</b>
<b>QTESTCD</b>	11. Dress himself/herself completely			<b>QSORES</b>
<b>QTESTCD</b>	12. Undress himself/herself completely			<b>QSORES</b>

**CONTINENCE QSSCAT**

<b>QTESTCD</b>	13. Decide to use the toilet at appropriate times			<b>QSORES</b>
<b>QTESTCD</b>	14. Use the toilet without "accidents"			<b>QSORES</b>

**EATING QSSCAT**


<b>QTESTCD</b>	15. Decide that he/she needs to eat			<b>QSORES</b>
<b>QTESTCD</b>	16. Choose appropriate utensils and seasonings when eating			<b>QSORES</b>
<b>QTESTCD</b>	17. Eat his/her meals at a normal pace and with appropriate manners			<b>QSORES</b>

**MEAL PREPARATION QSSCAT**

<b>QTESTCD</b>	18. Undertake to prepare a light meal or snack for himself/herself			<b>QSORES</b>
<b>QTESTCD</b>	19. Adequately plan a light meal or snack (ingredients, cookware)			<b>QSORES</b>
<b>QTESTCD</b>	20. Prepare or cook a light meal or a snack safely			<b>QSORES</b>



## DISABILITY ASSESSMENT FOR DEMENTIA (DAD)



**QSSCAT**

SCORING: Yes = 1 No = 0 Not Applicable = 96

### TELEPHONING

QSTESTCD	21. Attempt to telephone someone at a suitable time			QSORRES
QSTESTCD	22. Find and dial a telephone number correctly			QSORRES
QSTESTCD	23. Carry out an appropriate telephone conversation			QSORRES
QSTESTCD	24. Write and convey a telephone message adequately			QSORRES

### GOING ON AN OUTING QSSCAT

QSTESTCD	25. Undertake to go out (walk, visit, shop) at an appropriate time			QSORRES
QSTESTCD	26. Adequately organize an outing with respect to transportation, keys, destination, weather, necessary money, shopping list			QSORRES
QSTESTCD	27. Go out and reach a familiar destination without getting lost			QSORRES
QSTESTCD	28. Safely take the adequate mode of transportation (car, bus, taxi)			QSORRES
QSTESTCD	29. Return from the store with the appropriate items			QSORRES

### FINANCE AND CORRESPONDENCE QSSCAT

QSTESTCD	30. Show an interest in his/her personal affairs such as his/her finances and written correspondence			QSORRES
QSTESTCD	31. Organize his/her finances to pay his/her bills (cheques, bankbook, bills)			QSORRES
QSTESTCD	32. Adequately organize his/her correspondence with respect to stationery, address, stamps			QSORRES
QSTESTCD	33. Handle adequately his/her money (make change)			QSORRES

### MEDICATIONS QSSCAT

QSTESTCD	34. Decide to take his/her medications at the correct time			QSORRES
QSTESTCD	35. Take his/her medications as prescribed (according to the right dosage)			QSORRES

### LEISURE AND HOUSEWORK QSSCAT

QSTESTCD	36. Show an interest in leisure activity(ies)			QSORRES
QSTESTCD	37. Take an interest in household chores that he/she used to perform in the past			QSORRES
QSTESTCD	38. Plan and organize adequately household chores that he/she used to perform in the past			QSORRES
QSTESTCD	39. Complete household chores adequately as he/she used to perform in the past			QSORRES
QSTESTCD	40. Stay safely at home by himself/herself when needed			QSORRES